"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2020/076432 A1,025-263-697-033-701,2020-04-16,2020,US 2019/0049086 W,2019-08-30,US 201862742636 P,2018-10-08,METHODS OF TREATING CANCER WITH PI3K ALPHA INHIBITORS AND METFORMIN,Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K alpha inhibitor.,GENENTECH INC;;HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/025-263-697-033-701,Patent Application,yes,11,5,6,21,0,A61K31/443;;A61K31/4196;;A61K31/553;;A61K31/5375;;A61K31/4745;;A61K31/519;;A61K31/155;;A61K31/5545;;A61P35/00;;A61K31/138;;A61K31/155;;A61K31/337;;A61K31/4196;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4745;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/553;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068,A61K31/155;;A61K31/4196;;A61K31/443;;A61K31/4745;;A61K31/519;;A61K31/5375;;A61K31/553;;A61P35/00,,57,40,099-503-735-766-530;;069-792-512-589-392;;019-263-055-899-581;;002-934-245-685-573;;092-590-870-651-035;;072-042-364-654-214;;050-150-428-597-125;;003-946-692-466-975;;034-378-623-472-45X;;006-745-483-805-14X;;052-073-293-082-752;;046-250-525-927-062;;025-295-991-710-124;;089-130-690-847-828;;061-588-066-879-517;;025-190-866-898-825;;024-396-408-046-85X;;004-149-001-086-485;;007-364-858-655-289;;018-148-915-769-649;;102-071-695-047-127;;030-305-617-236-503;;118-095-502-371-121;;136-644-029-934-559;;065-828-666-135-904;;139-834-687-932-420;;024-538-700-794-450;;133-639-506-733-798;;076-103-754-280-950;;045-642-295-269-469;;059-639-473-600-881;;015-487-968-291-068;;001-411-609-455-826;;130-381-690-753-005;;119-661-255-332-247;;022-512-214-575-772;;002-679-024-004-230;;094-205-582-709-510;;071-152-338-969-707;;038-563-467-493-522,30051890;;pmc6197057;;10.1038/s41586-018-0343-4;;12040186;;10.1126/science.296.5573.1655;;17613433;;10.1016/j.ccr.2007.05.008;;10.1074/jbc.274.13.8347;;10085060;;11282020;;10.1242/jcs.114.8.1439;;21376230;;10.1016/j.cell.2011.02.013;;22358332;;10.1038/nrm3290;;0001707345;;1707345;;10.1016/0092-8674(91)90411-q;;10.1016/0092-8674(95)90195-7;;8521499;;pmc2831175;;10.2174/156800908786733504;;19075596;;18794884;;10.1038/onc.2008.245;;pmc3398461;;15254419;;10.4161/cbt.3.8.994;;10.1126/science.1096502;;15016963;;10.1158/1078-0432.ccr-06-2466;;17473209;;10.1158/1078-0432.ccr-04-2402;;16033851;;pmc4498279;;26059289;;10.1007/s40265-015-0416-8;;pmc3410405;;22778315;;10.1200/jco.2011.39.7356;;12177098;;10.1200/jco.2002.10.058;;10.1002/jps.2600660104;;833720;;10.1016/0378-5173(86)90055-4;;6382953;;10.1016/0065-2571(84)90007-4;;pmc1828746;;17332758;;10.1038/msb4100116;;10.1158/1538-7445.sabcs17-pd4-14;;10.1016/j.mce.2005.04.008;;15950373;;10.2165/11204810-000000000-00000;;21319872;;10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.3.co;2-y;;10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6;;10951345;;15117982;;10.1200/jco.2004.02.112;;10.1016/s1043-321x(09)79195-7;;19704066;;10.1200/jco.2008.21.1136;;24369047;;10.1517/14656566.2014.870555;;10.1016/s1470-2045(14)71159-3;;10.3410/f.725283758.793525555;;25524798;;26030518;;10.1056/nejmoa1505270;;2149502;;10.1016/0960-0760(90)90460-3;;12113048;;10.1586/14737140.2.3.249;;8476755;;10.1016/0960-0760(93)90245-r;;10.1016/j.diabres.2014.03.005;;24731476;;10.1056/nejmct0707092;;18172174;;pmc2732169;;19502540;;10.2337/dc09-0258;;pmc5022149;;27571249;;10.1038/nutd.2016.37;;26947331;;10.1016/s1470-2045(15)00613-0;;10.3410/f.726198033.793559052,"HOPKINS BENJAMIN D ET AL: ""Suppression of insulin feedback enhances the efficacy of PI3K inhibitors"", NATURE, MACMILLAN JOURNALS LTD., ETC.|, LONDON, vol. 560, no. 7719, 4 July 2018 (2018-07-04), pages 499 - 503, XP036579402, ISSN: 0028-0836, [retrieved on 20180704], DOI: 10.1038/S41586-018-0343-4;;CANTLEY LC, SCIENCE, vol. 296, no. 5573, 2002, pages 1655 - 1657;;GUERTIN DA ET AL., CANCER CELL, vol. 12, 2007, pages 9 - 22;;RAMEH ET AL., J. DIOL CHEM., vol. 274, 1999, pages 8347 - 8350;;CANTRELL DA, J CELL SCI, vol. 114, 2001, pages 1439 - 1445;;HANAHAN D ET AL., CELL, vol. 144, 2011, pages 646 - 674;;VANHAESEBROECK B ET AL., NOT REV MOL CELL BIOL, vol. 13, 2012, pages 195 - 203;;OTSU ET AL., CELL, vol. 65, 1991, pages 91 - 104;;MILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;RAMEH ET AL., CELL, vol. 83, 1995, pages 821 - 30;;VOLINIA ET AL., ONCOGENE, 1992;;GUSTIN J,P ET AL., CURR CANCER DRUG TARGETS, vol. 8, 2008, pages 733 - 740;;YUAN TL, ONCOGENE, vol. 27, 2008, pages 5497 - 5510;;COURTNEY KD ET AL., J CLIN ONCOL, vol. 28, 2010, pages 4594 - 4600;;BACHMAN KE ET AL., CANCER BIOL THER, vol. 3, 2004, pages 772 - 5;;SAMUELS Y ET AL., SCIENCE, vol. 304, 2004, pages 554;;SABNIS G ET AL., CLIN CANCER RES, vol. 13, 2007, pages 2751 - 2757;;BOULAY A ET AL., CLIN CANCER RES, vol. 11, 2005, pages 5319 - 5328;;CANCER RES, vol. 73, no. 8, 2013;;HOSTALEK U ET AL., DRUGS, vol. 75, 2015, pages 1071 - 1094;;BUSAIDY NL ET AL., J CLIN ONCOL, vol. 30, 2012, pages 29 19 - 2928;;OSBORNE CK ET AL., J CLIN ONCOL, vol. 20, 2002, pages 3386 - 3395;;S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 19;;P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 217;;ANDERSON ET AL.: ""The Practice of Medicinal Chemistry"", 1996, ACADEMIC PRESS;;UPTON ET AL., CANCER, vol. 75, 1995, pages 2132;;CHOUTALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;CHOUTALALAY: ""New Avenues in Developmental Cancer Chemotherapy"", 1987, ACADEMIC PRESS;;LEHAR ET AL., MOLECULAR SYSTEMS BIOLOGY, vol. 3, 2007, pages 80;;BRAUN, M. ET AL.: ""Discovery of GDC-0077: A highly selective inhibitor of PDK-alpha that induces degradation of mutant-p 11 0 alpha protein"", ABSTRACTS OF PAPERS. 254TH ACS NATIONAL MEETING EXPOSITION, 20 August 2017 (2017-08-20);;GARLAND, K. ET AL.: ""Discovery of novel class of alpha selective PI3K inhibitors"", ABSTRACTS OF PAPERS, 254TH ACS NATIONAL MEETING & EXPOSITION, 20 August 2017 (2017-08-20);;HONG, R. ET AL.: ""GDC-0077 is a selective PI3K alpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care. therapies"", 2017 SAN ANTONIO BREAST CANCER SYMPOSIUM, 5 December 2017 (2017-12-05);;EDGAR, K. ET AL.: ""Preclinical characterization of GDC-0077, a specific PBK alpha inhibitor in early clinical development"", CANCER RESEARCH, vol. 77, no. 13, July 2017 (2017-07-01);;CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 11 97160-78-3;;KANSRA, MOL CELL EN OCRINOL, vol. 239, no. 1 -2, 2005, pages 27 - 36;;FLEMMING, BREAST CANCER RES TREAT., vol. 15, no. 2, 2009, pages 255 - 68;;VALACHIS ET AL., CRIT REV ONCOL HEMATOL., vol. 73, no. 3, 2010, pages 220 - 7;;CROXTALL, DRUGS, vol. 71, no. 3, 2011, pages 363 - 380;;HOWELL ET AL., CANCER, vol. 89, 2000, pages 817 - 25;;HOWELL ET AL., J CLIN ONCOL, vol. 22, 2004, pages 1605 - 1613;;CHIA ET AL., J CLIN OIRCOL, vol. 26, 2008, pages 1664 - 1670;;ROBERTSON ET AL., CLIN ONCOL, vol. 27, 2009, pages 4530 - 4535;;FINN ET AL., BREAST CANCER RESEARCH: BCR, vol. 11, no. 5, 2009, pages 77;;ROCCA ET AL., EXPERT OPIN PHARMACOTHER, vol. 15, no. 3, 2014, pages 407 - 20;;FINN ET AL., LANCET ONCOL, vol. 16, 2015, pages 25 - 35;;TURNER ET AL., N ENGL J MED, vol. 373, 2015, pages 209 - 19;;FINN ET AL., J CLIN ONCOL, vol. 34, 2016;;CRISTOFANILLI ET AL., LANCER ONCOL, vol. 17, 2016, pages 425 - 39;;BHATNAGAR ET AL., J. STEROID BIOCHEM. AND MOL. BIOL., vol. 37, 1990, pages 1021;;GOSS, P.E.SMITH, R.E., EXPERT REV. ANTICANCER 1HER., vol. 2, 2002, pages 249 - 260;;LANG ET AL., THE JOURNAL OFSTCROID BIOCHCM. AND MOL. BIOL, vol. 44, no. 4-6, 1993, pages 421 - 8;;DUNNING, T. ET AL., DIABETES RES CLIN PRAEL., vol. 103, 2014, pages 538 - 540;;WERNER, Β.A. ET AL., J. CHEM. SOC., vol. 121, 1922, pages 1790 - 1794;;NESTLER, J.E., NEW ENG. JOUR. MED., vol. 358, 2008, pages 47 - 54;;PARK, M.H. ET AL., DIABETES CARE, vol. 32, 2009, pages 1743 - 1745;;VAN PER AA, M. ET AL., NUTRITION & DIABETES, vol. 6, 2016, pages e228;;CRISTOFANILLI M ET AL., LANCET ONCOL, vol. 17, 2016, pages 425 - 439",PENDING
2,WO,A1,WO 2020/023297 A1,030-354-909-220-029,2020-01-30,2020,US 2019/0042539 W,2019-07-19,US 201862702197 P;;US 201862742636 P,2018-07-23,"METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",GENENTECH INC;;HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/030-354-909-220-029,Patent Application,yes,10,5,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,57,44,069-792-512-589-392;;019-263-055-899-581;;002-934-245-685-573;;092-590-870-651-035;;072-042-364-654-214;;050-150-428-597-125;;003-946-692-466-975;;015-505-100-135-710;;034-378-623-472-45X;;006-745-483-805-14X;;052-073-293-082-752;;046-250-525-927-062;;025-295-991-710-124;;089-130-690-847-828;;061-588-066-879-517;;025-190-866-898-825;;024-396-408-046-85X;;004-149-001-086-485;;007-364-858-655-289;;018-148-915-769-649;;028-204-249-222-137;;030-305-617-236-503;;118-095-502-371-121;;136-644-029-934-559;;023-284-842-868-888;;127-409-121-363-262;;065-828-666-135-904;;139-834-687-932-420;;024-538-700-794-450;;133-639-506-733-798;;076-103-754-280-950;;102-609-792-060-763;;045-642-295-269-469;;059-639-473-600-881;;015-487-968-291-068;;001-411-609-455-826;;130-381-690-753-005;;119-661-255-332-247;;022-512-214-575-772;;024-396-408-046-85X;;043-819-929-046-661;;002-679-024-004-230;;094-205-582-709-510;;071-152-338-969-707,12040186;;10.1126/science.296.5573.1655;;17613433;;10.1016/j.ccr.2007.05.008;;10.1074/jbc.274.13.8347;;10085060;;11282020;;10.1242/jcs.114.8.1439;;21376230;;10.1016/j.cell.2011.02.013;;22358332;;10.1038/nrm3290;;0001707345;;1707345;;10.1016/0092-8674(91)90411-q;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(95)90195-7;;8521499;;pmc2831175;;10.2174/156800908786733504;;19075596;;18794884;;10.1038/onc.2008.245;;pmc3398461;;15254419;;10.4161/cbt.3.8.994;;10.1126/science.1096502;;15016963;;10.1158/1078-0432.ccr-06-2466;;17473209;;10.1158/1078-0432.ccr-04-2402;;16033851;;pmc4498279;;26059289;;10.1007/s40265-015-0416-8;;pmc3410405;;22778315;;10.1200/jco.2011.39.7356;;12177098;;10.1200/jco.2002.10.058;;10.1002/jps.2600660104;;833720;;10.1016/0378-5173(86)90055-4;;7697604;;10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u;;pmc1828746;;17332758;;10.1038/msb4100116;;10.1158/1538-7445.sabcs17-pd4-14;;10.1016/j.mce.2005.04.008;;15950373;;18683044;;10.1007/s10549-008-0137-8;;19369092;;10.1016/j.critrevonc.2009.03.006;;10.2165/11204810-000000000-00000;;21319872;;10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.3.co;2-y;;10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6;;10951345;;15117982;;10.1200/jco.2004.02.112;;10.1016/s1043-321x(09)79195-7;;19704066;;10.1200/jco.2008.21.1136;;pmc2790859;;19874578;;10.1186/bcr2419;;24369047;;10.1517/14656566.2014.870555;;10.1016/s1470-2045(14)71159-3;;10.3410/f.725283758.793525555;;25524798;;26030518;;10.1056/nejmoa1505270;;2149502;;10.1016/0960-0760(90)90460-3;;12113048;;10.1586/14737140.2.3.249;;8476755;;10.1016/0960-0760(93)90245-r;;10.1016/j.diabres.2014.03.005;;24731476;;pmc3410405;;22778315;;10.1200/jco.2011.39.7356;;10.1039/ct9222101790;;10.1056/nejmct0707092;;18172174;;pmc2732169;;19502540;;10.2337/dc09-0258;;pmc5022149;;27571249;;10.1038/nutd.2016.37,"CANTLEY LC, SCIENCE, vol. 296, no. 5573, 2002, pages 1655 - 1657;;GUERTIN DA ET AL., CANCER CELL, vol. 12, 2007, pages 9 - 22;;RAMEH ET AL., J. BIOL CHEM., vol. 274, 1999, pages 8347 - 8350;;CANTRELL DA, J CELL SCI, vol. 114, 2001, pages 1439 1445;;HANAHAN D ET AL., CELL, vol. 144, 2011, pages 646 - 674;;VANHAESEBROECK B ET AL., NAT REV MOL CELL BIOL, vol. 13, 2012, pages 195 - 203;;OTSU ET AL., CELL, vol. 65, 1991, pages 91 - 104;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;RAMEH ET AL., CELL, vol. 83, 1995, pages 821 - 30;;VOLINIA ET AL., ONCOGENE, 1992;;GUSTIN J,P ET AL., CURRR CANCER DRUG TARGETS, vol. 8, 2008, pages 733 - 740;;YUAN TL, ONCOGENE, vol. 27, 2008, pages 5497 - 5510;;COURTNEY KD ET AL., J CLIN ONCOL, vol. 28, 2010, pages 4594 - 4600;;BACHMAN KE ET AL., CANCER BIOL THER, vol. 3, 2004, pages 772 - 5;;SAMUELS Y ET AL., SCIENCE, vol. 304, 2004, pages 554;;SABNIS G ET AL., CLIN CANCER RES, vol. 13, 2007, pages 2751 - 2757;;BOULAY A ET AL., CLIN CANCER RES, vol. 11, 2005, pages 5319 - 5328;;JURIC D ET AL.: ""Proceedings of the 104th Annual Meeting of the American Association for Cancer Research"", 6 April 2013, AACR;;CANCER RES, vol. 73, no. 8, 2013;;HOSTALEK U ET AL., DRUGS, vol. 75, 2015, pages 1071 94 - 1094;;BUSAIDY ET AL., J CTIN ONCOL, vol. 30, 2012, pages 2919 - 28;;OSBORNE CK ET AL., J CLIN ONCOL, vol. 20, 2002, pages 3386 95 - 3395;;S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 19;;P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 217;;ANDERSON ET AL.: ""The Practice of Medicinal Chemistry"", 1996, ACADEMIC PRESS;;LIPTON ET AL., CANCER, vol. 75, 1995, pages 2132;;CHOUTALALAY, ADV. ENZYME REGAL., vol. 22, 1984, pages 27 - 55;;CHOUTALALAY: ""New Avenues in Developmental Cancer Chemotherapy"", 1987, ACADEMIC PRESS;;LEHAR ET AL., MOLECULAR SYSTEMS BIOLOGY, vol. 3, 2007, pages 80;;BRAUN, M. ET AL.: ""Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-pl 10 alpha protein"", ABSTRACTS OF PAPERS, 254TH ACS NATIONAL MEETING & EXPOSITION, WASHINGTON, DC, USA, 20 August 2017 (2017-08-20);;GARLAND, K. ET AL.: ""Discovery of novel class of alpha selective PI3K inhibitors"", ABSTRACTS OF PAPERS, 254TH ACS NATIONAL MEETING & EXPOSITION, WASHINGTON, DC, USA, 20 August 2017 (2017-08-20);;HONG, R. ET AL.: ""GDC-0077 is a selective PI3K alpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies"", 2017 SAN ANTONIO BREAST CANCER SYMPOSIUM, 5 December 2017 (2017-12-05);;EDGAR, K. ET AL.: ""Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development"", CANCER RESEARCH, vol. 77, no. 13, July 2017 (2017-07-01);;CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 2060571-02-8;;KANSRA, MOL CELL ENDOCRINOL, vol. 239, no. 1-2, 2005, pages 27 - 36;;FLEMMING ET AL., BREAST CANCER RES TREAT., vol. 115, no. 2, May 2009 (2009-05-01), pages 255 - 68;;VALACHIS ET AL., CRIT REV ONCOL HEMATOL., vol. 73, no. 3, March 2010 (2010-03-01), pages 220 - 7;;CROXTALL, DRUGS, vol. 71, no. 3, 2011, pages 363 - 380;;HOWELL ET AL., CANCER, vol. 89, 2000, pages 817 - 25;;HOWELL ET AL., J CLIN ONCOL, vol. 22, 2004, pages 1605 - 1613;;CHIA ET AL., J CLIN ONCOL, vol. 26, 2008, pages 1664 - 1670;;ROBERTSON ET AL., J CLIN ONCOL, vol. 27, 2009, pages 4530 - 4535;;FINN ET AL., BREAST CANCER RESEARCH : BCR, vol. 11, no. 5, 2009, pages R77;;ROCCA ET AL., EXPERT OPIN PHARMACOTHER, vol. 15, no. 3, 2014, pages 407 - 20;;FINN ET AL., LANCET ONCOL, vol. 16, 2015, pages 25 - 35;;TURNER ET AL., N ENGL J MED, vol. 373, 2015, pages 209 - 19;;FINN ET AL., J CFIN ONCOL, vol. 34, 2016;;CRISTOFANILLI M ET AL., LANCET ONCOL, vol. 17, 2016, pages 425 39 - 439;;BHATNAGAR ET AL., J. STEROID BIOCHEM. AND MOL. BIOL., vol. 37, 1990, pages 1021;;GOSS, P.E.SMITH, RE., EXPERT REV. ANTICANCER THER., vol. 2, 2002, pages 249 - 260;;LANG ET AL., THE JOURNAL OF STEROID BIOCHEM. AND MOL. BIOT., vol. 44, no. 4-6, 1993, pages 421 - 8;;DUNNING, T. ET AL., DIABETES RES CLIN PRACT., vol. 103, 2014, pages 538 - 540;;BUSAIDY NL ET AL., J CLIN ONCOL, vol. 30, 2012, pages 2919 - 2928;;WERNER, E.A. ET AL., J. CHEM. SOC., vol. 121, 1922, pages 1790 - 1794;;NESTLER, J.E., NEW ENG. JOUR. MED., vol. 358, 2008, pages 47 - 54;;PARK, M.H. ET AL., DIABETES CARE, vol. 32, 2009, pages 1743 - 1745;;VAN DER AA, M., NUTRITION & DIABETES, vol. 6, 2016, pages e228",PENDING
3,MX,A,MX 2021000847 A,032-793-566-274-97X,2021-03-26,2021,MX 2021000847 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,"METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077.","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/032-793-566-274-97X,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
4,TW,A,TW 202027736 A,106-880-437-844-786,2020-08-01,2020,TW 108131438 A,2019-08-30,US 201862742636 P,2018-10-08,Methods of treating cancer with PI3K alpha inhibitors and metformin,Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K alpha inhibitor.,HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/106-880-437-844-786,Patent of Addition,no,0,0,6,21,0,A61K31/443;;A61K31/4196;;A61K31/553;;A61K31/5375;;A61K31/4745;;A61K31/519;;A61K31/155;;A61K31/5545;;A61P35/00;;A61K31/138;;A61K31/155;;A61K31/337;;A61K31/4196;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4745;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/553;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068,A61K31/155;;A61K31/4196;;A61K31/443;;A61K31/4745;;A61K31/519;;A61K31/5375;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
5,EP,A4,EP 3826634 A4,081-166-947-370-716,2022-05-04,2022,EP 19840929 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1 ALPHA INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,,FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/081-166-947-370-716,Search Report,no,0,0,9,13,0,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/5377;;A61K31/138;;A61K31/337;;A61K31/357;;A61K31/44;;A61K31/513;;A61K31/555;;A61K31/675;;A61K31/704;;A61K45/06;;A61P35/00;;A61P35/04,,4,2,052-795-108-943-640;;024-122-650-998-682,29480818;;10.1172/jci95873;;pmc5873887;;10.3233/bd-2010-0307;;pmc3532890;;21778573,"ZHAO NA ET AL: ""Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer"", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 4, 2 April 2018 (2018-04-02), GB, pages 1283 - 1299, XP055904300, ISSN: 0021-9738, Retrieved from the Internet <URL:https://dm5migu4zj3pb.cloudfront.net/manuscripts/95000/95873/cache/95873.2-20201218131632-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf> DOI: 10.1172/JCI95873;;CHAVEZ K J ET AL: ""Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer"", INTERNET CITATION, 1 January 2010 (2010-01-01), pages 1 - 17, XP002712389, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532890/> [retrieved on 20130916];;SUSAN E. LOGUE ET AL: ""Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy"", NATURE COMMUNICATIONS, vol. 9, no. 3267, 15 August 2018 (2018-08-15), pages 1 - 14, XP055663186, DOI: 10.1038/s41467-018-05763-8;;See also references of WO 2020020155A1",PENDING
6,AU,A8,AU 2019/310335 A8,012-906-054-495-018,2021-03-04,2021,AU 2019/310335 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,"Methods of treating cancer with PI3K inhibitor, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/012-906-054-495-018,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
7,US,A1,US 2021/0260069 A1,074-876-123-771-085,2021-08-26,2021,US 201917261413 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1a INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,FOSUN ORINOVE PHARMATECH INC (2020-12-28),https://lens.org/074-876-123-771-085,Patent Application,yes,0,0,9,13,15,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/5377;;A61K31/4412;;A61K45/06;;A61P35/04,,0,0,,,,PENDING
8,EP,A1,EP 3863618 A1,159-566-663-288-017,2021-08-18,2021,EP 19773226 A,2019-08-30,US 201862742636 P;;US 2019/0049086 W,2018-10-08,METHODS OF TREATING CANCER WITH PI3K ALPHA INHIBITORS AND METFORMIN,,HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/159-566-663-288-017,Patent Application,yes,0,0,6,21,0,A61K31/443;;A61K31/4196;;A61K31/553;;A61K31/5375;;A61K31/4745;;A61K31/519;;A61K31/155;;A61K31/5545;;A61P35/00;;A61K31/138;;A61K31/155;;A61K31/337;;A61K31/4196;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4745;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/553;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068,A61K31/155;;A61K31/4196;;A61K31/443;;A61K31/4745;;A61K31/519;;A61K31/5375;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
9,CN,A,CN 113164457 A,171-752-037-564-727,2021-07-23,2021,CN 201980063917 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1[ALPHA] INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,"Provided are a pharmaceutical combination comprising an IRE1[alpha] inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/171-752-037-564-727,Patent Application,no,0,0,9,13,0,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/436;;A61K31/4433;;A61P35/00,,0,0,,,,PENDING
10,BR,A2,BR 112021001233 A2,180-599-216-185-800,2021-04-20,2021,BR 112021001233 A,2019-07-19,US 2019/0042539 W;;US 201862702197 P;;US 201862742636 P,2018-07-23,"método para tratar câncer em um paciente, uso de uma quantidade terapeuticamente eficaz de gdc-0077 e quantidade terapeuticamente eficaz de gdc-0077","são descritos neste documento métodos para tratar pacientes com câncer mutante pik3ca por administração de metformina e um inibidor de pi3k, gdc-0077.",HOFFMANN LA ROCHE,JENNIFER SCHUTZMAN;;STEPHANIE JOO;;SUSAN GREENE,,https://lens.org/180-599-216-185-800,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
11,CA,A1,CA 3106731 A1,108-227-342-832-951,2020-01-30,2020,CA 3106731 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1A INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,"Provided are a pharmaceutical combination comprising an IRE1a inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/108-227-342-832-951,Patent Application,no,0,0,9,13,15,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/436;;A61K31/4433;;A61P35/00,,0,0,,,,PENDING
12,WO,A1,WO 2020/019107 A1,186-725-067-856-836,2020-01-30,2020,CN 2018096613 W,2018-07-23,CN 2018096613 W,2018-07-23,IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/186-725-067-856-836,Patent Application,yes,5,1,1,13,15,A61K31/436;;A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/7072;;A61K31/44;;A61K31/337;;A61K31/138;;A61K31/553;;A61K31/167;;A61K31/69;;A61K31/506;;A61K31/502;;A61K31/7068;;A61K31/395,A61K31/436;;A61K31/4433;;A61P35/00,,1,1,121-600-012-531-455,26517687;;pmc4747362;;10.18632/oncotarget.5827,"MING J. ET AL.: ""A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1"", ONCOTARGET, vol. 6, no. 38, 1 December 2015 (2015-12-01), pages 40692 - 40703, XP055557077",PENDING
13,KR,A,KR 20210036374 A,074-540-786-336-333,2021-04-02,2021,KR 20217004949 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,암 치료를 위한 암 치료제와 조합된 IRE1α 억제제,"암성 종양의 치료를 위한 IRE1α 억제제 및 하나 이상의 추가의 암 치료제를 포함하는 약제학적 병용물, 이를 포함하는 약제학적 조성물 및 이를 사용하여 암성 종양을 치료하는 방법이 제공된다.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/074-540-786-336-333,Patent Application,no,0,0,9,13,30,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/5377;;A61K31/138;;A61K31/4196;;A61K31/4412;;A61K31/675;;A61K31/704;;A61K45/06;;A61P35/00,,0,0,,,,PENDING
14,AU,A1,AU 2018/447495 A1,162-214-081-506-159,2021-06-17,2021,AU 2018/447495 A,2018-11-02,CN 2018113783 W,2018-11-02,IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/162-214-081-506-159,Patent Application,no,0,0,3,13,0,A61P35/00;;A61K45/06;;A61K31/37;;A61K31/5377;;A61K31/553;;A61K31/506;;A61K31/44;;A61K31/167;;A61K31/337;;A61K31/7068;;A61K31/5377;;A61K45/06;;A61P35/00;;A61K2300/00,A61K31/436;;A61K31/4433;;A61P35/00,,0,0,,,,PENDING
15,WO,A1,WO 2020/087522 A1,102-503-269-799-189,2020-05-07,2020,CN 2018113783 W,2018-11-02,CN 2018113783 W,2018-11-02,IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/102-503-269-799-189,Patent Application,yes,5,0,3,13,15,A61K31/5377;;A61K45/06;;A61K31/167;;A61K31/337;;A61K31/37;;A61K31/44;;A61K31/506;;A61K31/5377;;A61K31/553;;A61K31/7068;;A61K45/06;;A61K2300/00;;A61P35/00;;A61P35/00,A61K31/436;;A61K31/4433;;A61P35/00,,1,1,121-600-012-531-455,26517687;;pmc4747362;;10.18632/oncotarget.5827,"MING J. ET AL.: ""A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1"", ONCOTARGET, vol. 6, no. 38, 19 October 2015 (2015-10-19), pages 40692 - 40703, XP055557077, DOI: 10.18632/oncotarget.5827",PENDING
16,AU,A1,AU 2019/311031 A1,163-069-070-197-360,2021-03-18,2021,AU 2019/311031 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/163-069-070-197-360,Patent Application,no,0,0,9,13,0,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/436;;A61K31/4433;;A61P35/00,,0,0,,,,PENDING
17,US,A1,US 2021/0322426 A1,017-819-685-598-300,2021-10-21,2021,US 202117223105 A,2021-04-06,US 202117223105 A;;US 2019/0049086 W;;US 201862742636 P,2018-10-08,METHODS OF TREATING CANCER WITH PI3K ALPHA INHIBITORS AND METFORMIN,Described herein are methods of treating PIK 3 CA-mutant cancer patients by administering metformin and a PI 3 K alpha inhibitor.,GENENTECH INC,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/017-819-685-598-300,Patent Application,yes,0,2,6,21,0,A61K31/443;;A61K31/4196;;A61K31/553;;A61K31/5375;;A61K31/4745;;A61K31/519;;A61K31/155;;A61K31/5545;;A61P35/00;;A61K31/138;;A61K31/155;;A61K31/337;;A61K31/4196;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4745;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/553;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068,A61K31/5377;;A61K31/138;;A61K31/155;;A61K31/337;;A61K31/395;;A61K31/4196;;A61K31/427;;A61K31/437;;A61K31/4439;;A61K31/444;;A61K31/4745;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/553;;A61K31/565;;A61K31/675;;A61K31/704;;A61K31/7068;;A61P35/00,,0,0,,,,PENDING
18,WO,A1,WO 2020/020155 A1,157-538-741-551-976,2020-01-30,2020,CN 2019097291 W,2019-07-23,CN 2018096613 W;;CN 2018113783 W,2018-07-23,IRE1α INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,"Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/157-538-741-551-976,Patent Application,yes,5,1,9,13,15,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/4433;;A61K31/436;;A61P35/00,,2,1,121-600-012-531-455,26517687;;pmc4747362;;10.18632/oncotarget.5827,"MING J . ET AL.: ""A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1"", ONCOTARGET, vol. 6, no. 38, 19 October 2015 (2015-10-19), pages 40692 - 40703, XP055557077, DOI: 10.18632/oncotarget.5827;;See also references of EP 3826634A4",PENDING
19,EP,A1,EP 3826634 A1,007-871-512-247-807,2021-06-02,2021,EP 19840929 A,2019-07-23,CN 2018096613 W;;CN 2018113783 W;;CN 2019097291 W,2018-07-23,IRE1 ALPHA INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT,,FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/007-871-512-247-807,Patent Application,yes,0,0,9,13,15,A61P35/00;;A61K45/06;;A61K31/5377;;A61K31/44;;A61K31/357;;A61K31/704;;A61K31/675;;A61K31/513;;A61K31/555;;A61K31/337;;A61K31/138;;A61P35/04;;A61K31/5377;;A61K31/675;;A61K31/337;;A61K31/513;;A61K31/555;;A61K31/704;;A61K31/4196;;A61K31/138;;A61K31/4412;;A61K45/06;;A61P35/00;;A61K2300/00;;A61P35/04;;A61K31/4412;;A61K31/5377;;A61K45/06,A61K31/436;;A61K31/4433;;A61P35/00,,0,0,,,,PENDING
20,AU,A1,AU 2019/310335 A1,071-185-921-377-873,2021-02-11,2021,AU 2019/310335 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,"Methods of treating cancer with PI3K inhibitor, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/071-185-921-377-873,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
21,KR,A,KR 20210087972 A,139-192-235-379-319,2021-07-13,2021,KR 20217016757 A,2018-11-02,CN 2018113783 W,2018-11-02,암 치료를 위한 암 치료제와 병용된 IRE1α 억제제,"암성 종양의 치료를 위한 IRE1α 억제제 및 하나 이상의 추가 암 치료제를 포함하는 약제학적 병용물, 이를 포함하는 약제학적 조성물 및 이를 사용하여 암성 종양을 치료하는 방법이 제공된다.",FOSUN ORINOVE PHARMATECH INC,ZENG QINGPING;;PATTERSON JOHN;;GREENE STEPHANIE,,https://lens.org/139-192-235-379-319,Patent Application,no,0,0,3,13,0,A61K31/5377;;A61K45/06;;A61K31/167;;A61K31/337;;A61K31/37;;A61K31/44;;A61K31/506;;A61K31/5377;;A61K31/553;;A61K31/7068;;A61K45/06;;A61K2300/00;;A61P35/00;;A61P35/00,A61K31/5377;;A61K45/06;;A61P35/00,,0,0,,,,DISCONTINUED
22,KR,A,KR 20210035211 A,008-127-973-141-758,2021-03-31,2021,KR 20217004206 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,PI3K 저해제인 GDC-0077로 암을 치료하는 방법,"메트포르민 및 PI3K 저해제, GDC-0077을 투여함으로써 PIK3CA-돌연변이체 암 환자를 치료하는 방법이 본원에서 설명된다.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/008-127-973-141-758,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/553;;A61K31/155;;A61K45/06;;A61P35/00;;C07D498/04,,0,0,,,,PENDING
23,EP,A1,EP 3826622 A1,029-817-251-901-110,2021-06-02,2021,EP 19749914 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,"METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077",,HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/029-817-251-901-110,Patent Application,yes,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
24,US,A1,US 2021/0252013 A1,039-036-813-407-896,2021-08-19,2021,US 202117156381 A,2021-01-22,US 202117156381 A;;US 2019/0042539 W;;US 201862742636 P;;US 201862702197 P,2018-07-23,"METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",GENENTECH INC,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/039-036-813-407-896,Patent Application,yes,1,2,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/553;;A61K31/519;;A61K31/565;;A61K45/06;;A61P35/00,,2,1,029-790-561-261-211,pmc4943382;;10.1634/theoncologist.2015-0248;;27151652,"Khan et al. (The Oncologist 2016; 21:855–860);;Leone et al. (Advances in Nutrition and Cancer 159; pp 355–376, 2014).",PENDING
25,CA,A1,CA 3106273 A1,067-290-946-138-051,2020-01-30,2020,CA 3106273 A,2019-07-19,US 201862702197 P;;US 201862742636 P;;US 2019/0042539 W,2018-07-23,"METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/067-290-946-138-051,Patent Application,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/155;;A61K31/553;;A61P35/00,,0,0,,,,PENDING
26,TW,A,TW 202011966 A,194-110-677-416-431,2020-04-01,2020,TW 108125627 A,2019-07-19,US 201862702197 P;;US 201862742636 P,2018-07-23,"Methods of treating cancer with PI3K inhibitor, GDC-0077","Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K inhibitor, GDC-0077.",HOFFMANN LA ROCHE,GREENE SUSAN;;JOO STEPHANIE;;SCHUTZMAN JENNIFER,,https://lens.org/194-110-677-416-431,Patent of Addition,no,0,0,15,21,0,A61K31/553;;A61K31/155;;A61P35/00;;A61K31/155;;A61K31/553;;A61P35/00;;A61K31/553;;A61K31/155;;A61K31/519;;A61K31/565;;A61K31/4196;;A61K45/06;;A61P35/00;;C07D498/04;;A61P35/00;;A61K31/519;;A61K31/553;;A61K31/565;;A61K45/06,A61K31/553;;A61P35/00,,0,0,,,,PENDING
27,FR,B1,FR 2814167 B1,158-834-672-502-857,2002-11-08,2002,FR 0011769 A,2000-09-15,FR 0011769 A,2000-09-15,PREPARATION DE LA CAMPTOTHECINE ET DE SES DERIVES,,AVENTIS PHARMA SA,LEUE STEPHANIE;;GARCON STEPHANIE;;GREENE ANDREW;;GENISSON YVES;;LEON PATRICK,,https://lens.org/158-834-672-502-857,Granted Patent,no,0,0,4,6,0,A61P35/00;;C07D215/227;;C07C69/734;;C07D215/18;;C07D309/32;;C07D405/12;;C07D471/04;;C07F7/1804,A61P35/00;;C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22;;C07F7/18,,0,0,,,,EXPIRED
28,FR,A1,FR 2814167 A1,115-103-909-575-386,2002-03-22,2002,FR 0011769 A,2000-09-15,FR 0011769 A,2000-09-15,PREPARATION DE LA CAMPTOTHECINE ET DE SES DERIVES,"<P>La présente invention concerne un nouveau procédé de préparation de la camptothécine et de ses dérivés par synthèse convergente à partir d'un dérivé de la 3-aminométhyl quinoléine et de l'acide 5-hydroxy 5-éthyl 6-oxo 5, 6-dihydro pyrane carboxylique ainsi que les intermédiaires obtenus.</P>",AVENTIS PHARMA SA,LEUE STEPHANIE;;GARCON STEPHANIE;;GREENE ANDREW;;GENISSON YVES;;LEON PATRICK,,https://lens.org/115-103-909-575-386,Patent Application,no,1,0,4,6,0,A61P35/00;;C07D215/227;;C07C69/734;;C07D215/18;;C07D309/32;;C07D405/12;;C07D471/04;;C07F7/1804,A61P35/00;;C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22;;C07F7/18,,2,2,102-681-698-066-495;;042-846-977-709-543,10.1016/s0960-894x(01)80589-8;;10993348;;10.1021/jo0003448,"PEEL, M.R. ET AL.: ""The synthesis and evaluation of flexible analogues of the topoisomerase I inhibitor, camptothecin"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 23, 1994, OXFORD, GB, pages 2753 - 58, XP001015518, ISSN: 0960-894X;;MEKOUAR, KHALID ET AL: ""New Pyridone Approach: Total Synthesis of Mappicine Ketone (Nothapodytine B)"", J. ORG. CHEM. (2000), 65(17), 5212-5215, XP002173673",EXPIRED
29,FR,B1,FR 2794123 B1,072-452-534-827-125,2001-07-27,2001,FR 9906757 A,1999-05-28,FR 9906757 A,1999-05-28,PREPARATION DE DERIVES DE LA CAMPTOTHECINE ET DE LA NOTHAPODYTINE,"The invention concerns the preparation of nothapodytine or camptothecin derivatives which consists in causing 4-ethyl 2methyl hepta-2,4-dienoic acid act on a 3-aminomethyl 2-bromo quinoline derivative (III) wherein R1 and R2 are H or R1 is a halogen atom or alkyl, R2 is a O-CO-X radical as defined for the camptothecin derivatives; or R1 and R2 are defined for the known camptothecin derivatives or represent protected radicals or radicals easily convertible into the radicals R1 and R2, to obtain the quinoline derivative (IV); adding to the resulting quinoline derivative (2-methoxy carbonyl vinyl) tributyltin in the presence of a complex of palladium and triphenylarsin to obtain the quinoline derivative (V); cyclizing the resulting quinoline derivative to obtain the tetracyclic derivative (VI); then in subjecting said derivative to an ozonolysis followed by treatment with dimethyl sulphide to obtain the tetracyclic derivative (VII); saponification followed by decarboxylation in oxidising conditions of the resulting tetracyclic derivative to obtain the nothopodytine derivative (VIII); then optionally transforming the resulting derivative into a camptothecin derivative or into a mappicine derivative.",AVENTIS PHARMA SA,MEKOUAR KHALID;;GENISSON YVES;;LEUE STEPHANIE;;GREENE ANDREW E,,https://lens.org/072-452-534-827-125,Granted Patent,no,0,0,16,17,0,C07D471/14;;C07D471/14,C07B61/00;;C07D471/14;;C07D491/22,,0,0,,,,EXPIRED
30,FR,A1,FR 2794123 A1,178-192-005-361-142,2000-12-01,2000,FR 9906757 A,1999-05-28,FR 9906757 A,1999-05-28,PREPARATION DE DERIVES DE LA CAMPTOTHECINE ET DE LA NOTHAPODYTINE,"The invention concerns the preparation of nothapodytine or camptothecin derivatives which consists in causing 4-ethyl 2methyl hepta-2,4-dienoic acid act on a 3-aminomethyl 2-bromo quinoline derivative (III) wherein R1 and R2 are H or R1 is a halogen atom or alkyl, R2 is a O-CO-X radical as defined for the camptothecin derivatives; or R1 and R2 are defined for the known camptothecin derivatives or represent protected radicals or radicals easily convertible into the radicals R1 and R2, to obtain the quinoline derivative (IV); adding to the resulting quinoline derivative (2-methoxy carbonyl vinyl) tributyltin in the presence of a complex of palladium and triphenylarsin to obtain the quinoline derivative (V); cyclizing the resulting quinoline derivative to obtain the tetracyclic derivative (VI); then in subjecting said derivative to an ozonolysis followed by treatment with dimethyl sulphide to obtain the tetracyclic derivative (VII); saponification followed by decarboxylation in oxidising conditions of the resulting tetracyclic derivative to obtain the nothopodytine derivative (VIII); then optionally transforming the resulting derivative into a camptothecin derivative or into a mappicine derivative.",AVENTIS PHARMA SA,MEKOUAR KHALID;;GENISSON YVES;;LEUE STEPHANIE;;GREENE ANDREW E,,https://lens.org/178-192-005-361-142,Patent Application,no,0,0,16,17,0,C07D471/14;;C07D471/14,C07B61/00;;C07D471/14;;C07D491/22,,2,2,015-979-023-044-683;;136-174-965-308-207,10.1021/jo961698v;;10.1021/ja973007y,"D.L. COMINS ET AL.: ""Concise synthesis of mappicine ketone and (+-)mappicine"", JOURNAL OF ORGANIC CHEMISTRY., vol. 61, no. 26, 1996, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 9623 - 24, XP002129454, ISSN: 0022-3263;;D.L. BOGER ET AL.: ""Total synthesis of nothapodytine B and (-)mappicine"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 120, no. 6, 1998, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US, pages 1218 - 22, XP002129455, ISSN: 0002-7863",EXPIRED
31,AU,A1,AU 2008/200847 A1,061-823-010-019-013,2008-05-29,2008,AU 2008/200847 A,2008-02-15,AU 2002/344234 A;;AU 2008/200847 A,2002-05-31,Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy,,MIRAVANT PHARM INC,ROBINSON BYRON C;;GREENE STEPHANIE;;RYCHNOVSKY STEV;;LEITCH IAN M,,https://lens.org/061-823-010-019-013,Patent Application,no,0,1,1,1,0,,C07D487/22;;A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,DISCONTINUED
32,US,A1,US 2003/0105069 A1,077-253-282-764-104,2003-06-05,2003,US 15900502 A,2002-05-31,US 15900502 A;;US 29534501 P,2001-05-31,Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy,"
   Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease. 
",ROBINSON BYRON C.;;LEITCH IAN M.;;GREENE STEPHANIE;;RYCHNOVSKY STEVE,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEVE,MIRAVANT PHARMACEUTICALS INC (2002-07-24),https://lens.org/077-253-282-764-104,Patent Application,yes,0,40,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;C07D487/22;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,514/185;;X51441;;X604 2;;424/9.61,0,0,,,,EXPIRED
33,US,A1,US 2005/0137180 A1,153-674-300-970-287,2005-06-23,2005,US 96584904 A,2004-10-18,US 96584904 A;;US 15900502 A;;US 29534501 P,2001-05-31,Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy,"Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.",MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEVE,,https://lens.org/153-674-300-970-287,Patent Application,yes,10,71,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,A61K31/555;;A61K41/00;;C07D487/22;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,514/185;;540/145,0,0,,,,DISCONTINUED
34,AU,B2,AU 2002/344234 B2,114-672-869-894-086,2007-11-08,2007,AU 2002/344234 A,2002-05-31,US 29534501 P;;US 0217180 W,2001-05-31,Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy,,MIRAVANT PHARM INC,LEITCH IAN M;;GREENE STEPHANIE;;ROBINSON BYRON C;;RYCHNOVSKY STEV,,https://lens.org/114-672-869-894-086,Granted Patent,no,2,0,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,C07D487/22;;A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,EXPIRED
35,EP,A4,EP 1401506 A4,159-292-922-941-485,2005-02-16,2005,EP 02744204 A,2002-05-31,US 0217180 W;;US 29534501 P,2001-05-31,METALLOTETRAPYRROLIC PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY,,MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEV,,https://lens.org/159-292-922-941-485,Search Report,no,10,0,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,C07D487/22;;A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,DISCONTINUED
36,US,B2,US 6827926 B2,016-680-566-103-440,2004-12-07,2004,US 15900502 A,2002-05-31,US 15900502 A;;US 29534501 P,2001-05-31,Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy,"
    Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease. 
",MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEVE,MIRAVANT PHARMACEUTICALS INC (2002-07-24),https://lens.org/016-680-566-103-440,Granted Patent,yes,9,75,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,A61K31/555;;A61K41/00;;C07D487/22;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,424/9.1;;424/9.362;;424/9.42;;424/9.5;;424/9.61;;514/185;;540/145,16,8,003-942-614-798-159;;144-830-044-805-498;;135-777-089-936-647;;000-921-697-874-820;;051-536-440-591-584;;095-156-635-535-285;;001-137-712-940-353;;069-619-130-707-454,4042296;;10.1161/01.cir.72.5.1081;;10.1016/s0040-4039(00)80313-5;;10.1016/b978-0-12-220101-1.50017-2;;10.1001/jama.285.16.2069;;11311078;;10.1001/jama.285.16.2069-jmn0425-4-1;;10.1016/s0040-4020(01)90371-0;;2146991;;10.1161/01.cir.82.6.2190;;10.1161/01.cir.96.6.1944;;9323085;;10.1016/0735-1097(92)90119-8;;1634687,"Alfonso R. Gennaro, Remington's Pharmaceutical Sciences, 18 Mack Publishing Co., Table of Contents (1990).;;Bonnie H. Weiner, M.D., et al., Comparison Of Pathologic And Angiographic Findings In A Porcine Preparation Of Coronary Atherosclerosis, 72 Circulation 1081-1086 (1985).;;Christopher J. Byrne, et al., A Facile Porphyrin Esterification/Etherification Procedure, 29 Tetrahedron Letters 1421-1424 (1988).;;Johann Walter Buchler, The Porphyrins, I Academic Press, Chapter 10, 389-483 (1978).;;K.M. Kadish, et al., meso-Azaporphyrins and Their Analogues, 2 The Porphyrin Handbook, Chapter 13, 301-360 (2000).;;K.M. Kadish, et al., Synthesis and Organic Chemistry, 1 The Porphyrin Handbook Chapters 1-3 , Table of Contents (2000).;;Kevin M. Smith, Porphyrins and Metalloporphyrins, Elsevier Scientific Publishing Co., Chapter 19, 777 (1975).;;Mike Mitka, Stent + Radiation No Sure Cure for Stenosis, 285 Journal of the American Medical Association (2001).;;R. Grigg., et al., The Cyclisation of 1-Bromo-19-methyl- and 1, 19-Dimethyl-1, 19-dideoxy-biladiene-ac Dihydrobromides, J. Chem. Soc. (C) 176-182 (1969).;;Ravindra K. Pandey, et al., Syntheses of Water-Soluble Cationic Porphyrins and Chlorins, 48 Tetrahedron 7591-7600 (1992).;;Raymond Bonnett, et al., The Bromination and Iodination of Porphyrins, J. Chem. Res (S), 138-139 (1990).;;Robert S. Schwartz, et al., Restenosis After Balloon Angioplasty: A Practical Proliferative Model In the Porcine Coronary Arteries, 82 Circulation 2190-2200 (1990).;;Ron Waksman, MD., et al., Effect of Intravascular Irradiation on Cell Proliferation, Apoptosis and Vascular Remodeling After Balloon Overstretch Injury of Porcine Coronary Arteries, 96 Circulation 1944-1952 (1997).;;Simon T. Belt, et al., Transient Photochemistry of (eta<5>-Cyclopentadieny)bis(ethane)rhodium, 18 J. Chem. Soc., Chem. Commun., 1347-1348 (1987).;;Steven P. Karas, et al., Coronary Intimal Proliferation After Balloon Injury And Stenting In Swine: An Animal Model Of Restenosis, 20 J.Am.C. Cardiology 467-474 (1992).;;Theodora W. Greene, et al., Protective Groups in Organic Synthesis, 2 A Wiley-Interscience Publication, Table of Contents (1991).",EXPIRED
37,WO,A2,WO 2002/096366 A2,123-492-780-600-588,2002-12-05,2002,US 0217180 W,2002-05-31,US 29534501 P,2001-05-31,METALLOTETRAPYRROLIC PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY,"Metallotetrapyrrolic compounds having photherapeutics properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.",MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEV,,https://lens.org/123-492-780-600-588,Patent Application,yes,0,0,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,A61K31/555;;C07D487/22;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,PENDING
38,CA,A1,CA 2448562 A1,166-197-020-444-760,2002-12-05,2002,CA 2448562 A,2002-05-31,US 29534501 P;;US 0217180 W,2001-05-31,METALLOTETRAPYRROLIC PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY,"Metallotetrapyrrolic compounds having photherapeutics properties useful in photodetection and phototherapy of target issues, particularly porphyrins an d azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.",MIRAVANT PHARM INC,RYCHNOVSKY STEV;;GREENE STEPHANIE;;ROBINSON BYRON C;;LEITCH IAN M,,https://lens.org/166-197-020-444-760,Patent Application,no,0,0,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,C07D487/22;;A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,DISCONTINUED
39,US,A1,US 2023/0398568 A1,083-567-933-373-772,2023-12-14,2023,US 202318458245 A,2023-08-30,US 202318458245 A;;US 202016787115 A;;US 202016787129 A;;US 202318183604 A,2020-02-11,METHODS FOR FORMING LIQUID MANAGEMENT PATTERNS ON A SURFACE OF A STRUCTURE OF A VEHICLE,"A method includes printing one or more features on a surface of a structure of an aircraft, and providing, by the one or more features, one or more liquid management patterns. The printing can includes controlling, by a control unit, a printer to form the one or more features on the surface of the structure. The method can also include curing the one or more features with ultraviolet (UV) light.",BOEING CO,DREXLER JASON;;GREENE EDWARD RYAN;;METTING STEPHANIE IRIS;;WANG XIAOXI,THE BOEING COMPANY (2023-08-18),https://lens.org/083-567-933-373-772,Patent Application,yes,0,0,1,5,0,Y02T50/40;;B64C1/067;;B05D1/02;;B64F5/00;;B05D3/067,B05D3/06;;B05D1/02;;B64F5/00,,0,0,,,,PENDING
40,EP,A2,EP 1401506 A2,170-126-093-686-249,2004-03-31,2004,EP 02744204 A,2002-05-31,US 0217180 W;;US 29534501 P,2001-05-31,METALLOTETRAPYRROLIC PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY,,MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEV,,https://lens.org/170-126-093-686-249,Patent Application,yes,0,1,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,C07D487/22;;A61K31/555;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,DISCONTINUED
41,WO,A3,WO 2002/096366 A3,069-206-596-660-963,2003-03-20,2003,US 0217180 W,2002-05-31,US 29534501 P,2001-05-31,METALLOTETRAPYRROLIC PHOTOSENSITIZING AGENTS FOR USE IN PHOTODYNAMIC THERAPY,"Metallotetrapyrrolic compounds having photherapeutics properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.",MIRAVANT PHARM INC,ROBINSON BYRON C;;LEITCH IAN M;;GREENE STEPHANIE;;RYCHNOVSKY STEV,,https://lens.org/069-206-596-660-963,Search Report,yes,4,0,10,10,0,A61K49/0036;;A61K41/0071;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61K49/0036;;A61K41/0071,A61K31/555;;C07D487/22;;A61K41/00;;A61K49/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P17/00;;A61P17/02;;A61P17/04;;A61P19/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P41/00,,0,0,,,,PENDING
42,WO,A1,WO 2002/022618 A1,156-080-528-100-836,2002-03-21,2002,FR 0102840 W,2001-09-13,FR 0011769 A,2000-09-15,METHOD FOR PREPARING CAMPTOTHECIN AND ITS DERIVATIVES,"The invention concerns a novel method for preparing camptothecin and its derivatives by convergent synthesis from a 3-aminomethyl quinoline derivative and 5-hydroxy 5-ethyl 6-oxo 5,6-dihydro pyran carboxylic acid and the resulting intermediates.",AVENTIS PHARMA SA,LEUE STEFANIE;;GARCON STEPHANIE;;GREENE ANDREW-ELLIOT;;GENISSON YVES;;LEON PATRICK,,https://lens.org/156-080-528-100-836,Patent Application,yes,1,22,4,6,0,A61P35/00;;C07D215/227;;C07C69/734;;C07D215/18;;C07D309/32;;C07D405/12;;C07D471/04;;C07F7/1804,A61P35/00;;C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22;;C07F7/18,,2,2,102-681-698-066-495;;042-846-977-709-543,10.1016/s0960-894x(01)80589-8;;10993348;;10.1021/jo0003448,"PEEL, M.R. ET AL.: ""The synthesis and evaluation of flexible analogues of the topoisomerase I inhibitor, camptothecin"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 23, 1994, OXFORD, GB, pages 2753 - 58, XP001015518, ISSN: 0960-894X;;MEKOUAR, KHALID ET AL: ""New Pyridone Approach: Total Synthesis of Mappicine Ketone (Nothapodytine B)"", J. ORG. CHEM. (2000), 65(17), 5212-5215, XP002173673",PENDING
43,ES,T3,ES 2205808 T3,030-916-519-782-124,2004-05-01,2004,ES 99917540 T,1999-04-15,US 7150998 A,1998-05-01,PIGMENTO DE RECUBRIMIENTO PARA IMPRESION POR CHORRO DE TINTA.,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/030-916-519-782-124,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
44,CZ,A3,CZ 20004036 A3,033-454-782-768-624,2002-02-13,2002,CZ 20004036 A,1999-04-15,US 7150998 A,1998-05-01,Coating pigment preparation for ink jet printing,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MONINI AHMED;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/033-454-782-768-624,Patent Application,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,PENDING
45,AU,A,AU 1999/035635 A,082-676-670-791-150,1999-11-23,1999,AU 1999/035635 A,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,Coating pigment for ink-jet printing,,ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/082-676-670-791-150,Patent Application,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
46,BR,B1,BR 9910165 B1,142-444-216-276-943,2009-01-13,2009,BR 9910165 A,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,composição de pigmento para revestimento.,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/142-444-216-276-943,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/00;;B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
47,PT,E,PT 1079977 E,009-440-452-208-344,2004-01-30,2004,PT 99917540 T,1999-04-15,US 7150998 A,1998-05-01,PIGMENTO DE REVESTIMENTO PARA IMPRESSAO A JACTO DE TINTA,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/009-440-452-208-344,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
48,US,A1,US 2022/0241566 A1,111-124-302-993-861,2022-08-04,2022,US 202017611606 A,2020-05-29,US 202017611606 A;;US 201962853778 P;;US 2020/0035072 W,2019-05-29,VENTRICULOAMNIOTIC SHUNT FOR FETAL AQUEDUCTAL STENOSIS,"The invention relates to an in-utero ventriculoamniotic shunting device that includes a composite shunt tube composed of polymer material, e.g., silicone-based material, and metallic wire, having a bend or curve formed in the length of the shunt tube, with one or more anchors composed of super-elastic wire or mesh, e.g., shape memory alloy wire or mesh structures, attached to the shunt tube, and a one-way passive valve composed of a thin polymer membrane. The anchors are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve is effective to prevent the backflow of amniotic fluid.",UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,CHUN YOUNG JAE;;EMERY STEPHEN P;;GREENE STEPHANIE;;SUKINIK JOSEPH RAFFAEL,UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2020-08-08),https://lens.org/111-124-302-993-861,Patent Application,yes,0,0,2,2,0,A61M27/006;;A61M2205/0266;;A61M2205/3344;;A61M2039/244;;A61M2039/242;;A61M27/006;;A61M2205/0266;;A61M2207/00;;B05D1/18,A61M27/00;;B05D1/18,,0,0,,,,PENDING
49,AU,B2,AU 760107 B2,085-601-361-982-255,2003-05-08,2003,AU 1999/035635 A,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,Coating pigment for ink-jet printing,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/085-601-361-982-255,Granted Patent,no,3,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
50,MY,A,MY 118570 A,128-185-442-049-799,2004-12-31,2004,MY PI9901702 A,1999-04-29,US 7150998 A,1998-05-01,COATING PIGMENT FOR INK-JET PRINTING,"A COATING PIGMENT COMPOSITION COMPRISING A HYDROUS CLAY, A CAUSTIC LEACHED CALCINED CLAY, AND A POROUS MINERAL PROVIDES A COATING HAVING EXCELLENT BALANCE OF COLOR INTENSITY AND COLOR DEFINITION CHARACTERISTICS WHEN PRINTED ON BY MULTICOLORED INKS. THE PIGMENT OF THIS INVENTION OFFER A LOW COST ALTERNATIVE TO CONVENTIONAL SILICA-BASED COATING IN ADDITION TO OTHER DESIRABLE BENEFITS SUCH AS IMPROVED RHEOLOGY, LES REQUIRED COAT WEIGHT, AND HIGHER COATING SOLIDS COMPARED TO CONVENTIONAL SILICA COATINGS.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/128-185-442-049-799,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,C09C1/28;;B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
51,WO,A1,WO 2020/243394 A1,172-297-464-781-683,2020-12-03,2020,US 2020/0035072 W,2020-05-29,US 201962853778 P,2019-05-29,VENTRICULOAMNIOTIC SHUNT FOR FETAL AQUEDUCTAL STENOSIS,"The invention relates to an in-utero ventriculoamniotic shunting device that includes a composite shunt tube composed of polymer material, e.g ., silicone-based material, and metallic wire, having a bend or curve formed in the length of the shunt tube, with one or more anchors composed of super-elastic wire or mesh, e.g ., shape memory alloy wire or mesh structures, attached to the shunt tube, and a one-way passive valve composed of a thin polymer membrane. The anchors are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve is effective to prevent the backflow of amniotic fluid.",UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,CHUN YOUNG JAE;;EMERY STEPHEN P;;GREENE STEPHANIE;;SUKINIK JOSEPH RAFFAEL,,https://lens.org/172-297-464-781-683,Patent Application,yes,5,1,2,2,0,A61M27/006;;A61M2205/0266;;A61M2205/3344;;A61M2039/244;;A61M2039/242;;A61M27/006;;A61M2205/0266;;A61M2207/00;;B05D1/18,A61M25/10;;A61M27/00;;A61M39/24,,0,0,,,,PENDING
52,EP,B1,EP 1079977 B1,183-688-717-247-727,2003-08-27,2003,EP 99917540 A,1999-04-15,US 9908278 W;;US 7150998 A,1998-05-01,COATING PIGMENT FOR INK-JET PRINTING,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/183-688-717-247-727,Granted Patent,yes,3,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
53,US,B2,US 6486320 B2,188-545-270-344-048,2002-11-26,2002,US 95150501 A,2001-09-14,US 95150501 A;;FR 0011769 A;;US 24008000 P,2000-09-15,Preparation of camptothecin and of its derivatives,"
    The present invention relates to a novel process for preparation of camptothecin and of its derivatives by convergent synthesis starting from a 3-(aminomethyl)quinoline derivative and 5-hydroxy-5-ethyl-6-oxo-5,6-dihydropyrancarboxylic acid and to the intermediates obtained. 
",AVENTIS PHARMA SA,LEUE STEFANIE;;GARCON STEPHANIE;;GREENE ANDREW-ELLIOT;;GENISSON YVES;;LEON PATRICK,PFIZER ENTERPRISES SARL (2006-12-22);;PFIZER INC (2004-09-01);;AVENTIS PHARMA S.A (2001-07-12),https://lens.org/188-545-270-344-048,Granted Patent,yes,24,1,2,6,0,C07C69/734;;C07D215/18;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D215/227;;C07D309/32;;C07D405/12;;C07C69/734;;C07D471/04;;C07D215/18,C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22,546/48;;84/157;;84/175,12,5,151-576-624-351-253;;051-088-907-115-869;;095-980-359-013-338;;046-554-491-210-022;;075-783-870-770-979,10.1016/s0040-4020(97)00365-7;;10.1248/cpb.39.1446;;1934165;;1806276;;10.1248/cpb.39.2574;;10.1248/cpb.39.3183;;1814610;;8993496;;10.1111/j.1749-6632.1996.tb26372.x,"Abstract: Japio No. 00965715 for JP 57-116015.;;Abstract: Japio No. 00965774 for JP 57-116074.;;Abstract: Japio No. 01293588 for JP 59-5188.;;Abstract: Japio No. 01541290 for JP 60-19790.;;Abstract: Japio No. 02948687 for JP 1-246287.;;Abstract: Japio No. 02952177 for JP 1-249777.;;Abstract: Derwent No. 01984-110813/198418 for JP 59-051289.;;M. A. Ciufolini and F. Roschangar, ""Practical Total Synthsis of (+)-Camptothecin: The Full Story,"" Tetrahedron, 53(32):11049-11060 (1997).;;S. Sawada, S. Okajima, R. Aiyama, K. Nokata, T. Furuta, T. Yokokura, E. Sugino, K. Yamaguchi, and T. Miyasaka, ""Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-Hydroxycamptohecin,"" Chem. Pharm. Bull., 39(6): 1446-1454 (1991).;;S. Sawada, K. Nokata, T. Furuta, T. Yokokura, and T. Miyasaka, ""Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins,"" Chem. Pharm. Bull., 39(10):2574-2580 (1991).;;S. Sawada, S. Matsuoka, K. Nokata, H. Nagata, T. Furuta, T. Yokokura, and T. Miyasaka, ""Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7,10-Disubstituted Camptothecins,"" Chem. Pharm. Bull., 39(12): 3183-3188 (1991).;;S. Sawada and T. Yokokura, ""The Camptothecins From Discovery to the Patient: Synthesis of CPT-11 (Irinotecan Hydrochloride Trihydrate),"" Annals of the New York Academy of Sciences, 803:13-28 (1996).",EXPIRED
54,BR,A,BR 9910165 A,046-966-323-954-824,2001-01-09,2001,BR 9910165 A,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,Pigmento de revestimento para impressão a jato de tinta,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,MOINI AHMAD;;LONDO MICHAEL G;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/046-966-323-954-824,Patent Application,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
55,AU,A,AU 2001/093907 A,052-856-972-979-423,2002-03-26,2002,AU 2001/093907 A,2001-09-13,FR 0011769 A;;FR 0102840 W,2000-09-15,Method for preparing camptothecin and its derivatives,,AVENTIS PHARMA SA,LEUE STEFANIE;;GARCON STEPHANIE;;GREENE ANDREW-ELLIOT;;GENISSON YVES;;LEON PATRICK,,https://lens.org/052-856-972-979-423,Patent Application,no,0,0,4,6,0,A61P35/00;;C07D215/227;;C07C69/734;;C07D215/18;;C07D309/32;;C07D405/12;;C07D471/04;;C07F7/1804,A61P35/00;;C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22;;C07F7/18,,0,0,,,,PENDING
56,EP,A1,EP 1079977 A1,093-436-953-631-25X,2001-03-07,2001,EP 99917540 A,1999-04-15,US 9908278 W;;US 7150998 A,1998-05-01,COATING PIGMENT FOR INK-JET PRINTING,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/093-436-953-631-25X,Patent Application,yes,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
57,US,A,US 5997625 A,009-505-050-746-03X,1999-12-07,1999,US 7150998 A,1998-05-01,US 7150998 A,1998-05-01,Coating pigment for ink-jet printing,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,BASF CORPORATION (2010-04-01);;BASF CATALYSTS LLC (2006-08-01);;ENGELHARD CORPORATION (1998-06-26),https://lens.org/009-505-050-746-03X,Granted Patent,yes,10,39,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,106/486;;106/412;;106/468;;106/470,0,0,,,,EXPIRED
58,WO,A1,WO 1999/056965 A1,028-500-347-791-663,1999-11-11,1999,US 9908278 W,1999-04-15,US 7150998 A,1998-05-01,COATING PIGMENT FOR INK-JET PRINTING,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/028-500-347-791-663,Patent Application,yes,3,4,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,PATENTED
59,DK,T3,DK 1079977 T3,197-167-095-710-522,2003-12-01,2003,DK 99917540 T,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,Overtrækspigment til ink-jettrykning,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/197-167-095-710-522,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,EXPIRED
60,US,A1,US 2002/0045756 A1,052-060-899-643-996,2002-04-18,2002,US 95150501 A,2001-09-14,US 95150501 A;;FR 0011769 A;;US 24008000 P,2000-09-15,Preparation of camptothecin and of its derivatives,"
   The present invention relates to a novel process for preparation of camptothecin and of its derivatives by convergent synthesis starting from a 3-(aminomethyl)quinoline derivative and 5-hydroxy-5-ethyl-6-oxo-5,6-dihydropyrancarboxylic acid and to the intermediates obtained. 
",AVENTIS PHARMA SA,LEUE STEFANIE;;GARCON STEPHANIE;;GREENE ANDREW-ELLIOT;;GENISSON YVES;;LEON PATRICK,PFIZER ENTERPRISES SARL (2006-12-22);;PFIZER INC (2004-09-01);;AVENTIS PHARMA S.A (2001-07-12),https://lens.org/052-060-899-643-996,Patent Application,yes,0,12,2,6,0,C07C69/734;;C07D215/18;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D215/227;;C07D309/32;;C07D405/12;;C07C69/734;;C07D471/04;;C07D215/18,C07C69/734;;C07D215/18;;C07D215/22;;C07D215/227;;C07D309/32;;C07D405/12;;C07D471/04;;C07D491/22,546/48;;546/159,0,0,,,,EXPIRED
61,AT,T1,AT E248070 T1,108-311-446-935-834,2003-09-15,2003,AT 99917540 T,1999-04-15,US 7150998 A;;US 9908278 W,1998-05-01,COATING-PIGMENT FÜR INK-JET DRUCKVERFAHREN,"A coating pigment composition comprising a hydrous clay, a caustic leached calcined clay, and a porous mineral provides a coating having excellent balance of color intensity and color definition characteristics when printed on by multicolored inks. The pigments of this invention offer a low cost alternative to conventional silica-based coatings in addition to affording other desirable benefits such as improved rheology, less required coat weights, and higher coating solids compared to conventional silica coatings.",ENGELHARD CORP,LONDO MICHAEL G;;MOINI AHMAD;;GIBBS MITCHELL R;;GREENE STEPHANIE F,,https://lens.org/108-311-446-935-834,Granted Patent,no,0,0,19,19,0,B41M5/5218;;C01P2002/70;;C01P2004/32;;C01P2004/51;;C01P2004/61;;C01P2004/62;;C01P2006/12;;C01P2006/14;;C01P2006/16;;C01P2006/22;;C01P2006/60;;C01P2006/80;;C09C1/42;;D21H19/40;;B41M5/5218;;C01P2004/61;;C01P2006/14;;C01P2004/62;;C01P2004/32;;C01P2006/80;;C01P2006/60;;C01P2002/70;;C09C1/42;;C01P2004/51;;C01P2006/16;;C01P2006/22;;C01P2006/12;;D21H19/40,B41M5/52;;C09C1/42;;D21H19/40,,0,0,,,,PENDING
62,US,A1,US 2018/0296810 A1,068-705-957-200-816,2018-10-18,2018,US 201615765723 A,2016-10-13,US 201615765723 A;;US 201562241281 P;;US 2016/0056751 W,2015-10-14,A NOVEL LOW-PROFILE VENTRICULOAMNIOTIC SHUNT FOR FETAL AQUEDUCTAL STENOSIS,"The invention relates to an in-utero ventriculoamniotic shunting device that includes a shunt tube ( 26 ) composed of polymer composite and having metallic wire embedded therein, one or more anchors ( 30 ) composed of superelastic wire, e.g., thermal shape-set nitinol structures, that are mechanically attached to an exterior surface of the shunt tube ( 26 ), and a one-way passive valve ( 32 ) composed of a thin polymer membrane. The anchors ( 30 ) are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve ( 32 ) is effective to prevent the backflow of amniotic fluid ( 23 ).",UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,CHEN YANFEI;;CHUN YOUNG JAE;;EMERY STEPHEN;;GU XINZHU;;WAGNER WILLIAM;;GREENE STEPHANIE,UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2018-09-14),https://lens.org/068-705-957-200-816,Patent Application,yes,0,4,3,3,0,A61M27/006;;A61M27/006;;A61B5/031;;A61B5/031;;A61B5/055;;A61B5/055;;A61B5/4362;;A61B5/4362;;A61L31/128;;A61L31/128;;A61M25/00;;A61M25/00;;A61M27/00;;A61M27/00;;A61M39/24;;A61M2205/0266;;A61M2207/00,A61M27/00;;A61B5/00;;A61B5/03;;A61L31/12;;A61M39/24,,0,0,,,,ACTIVE
63,WO,A1,WO 2017/066389 A1,133-302-367-370-363,2017-04-20,2017,US 2016/0056751 W,2016-10-13,US 201562241281 P,2015-10-14,A NOVEL LOW-PROFILE VENTRICULOAMNIOTIC SHUNT FOR FETAL AQUEDUCTAL STENOSIS,"The invention relates to an in-utero ventriculoamniotic shunting device that includes a shunt tube (26) composed of polymer composite and having metallic wire embedded therein, one or more anchors (30) composed of superelastic wire, e.g., thermal shape-set nitinol structures, that are mechanically attached to an exterior surface of the shunt tube (26), and a one-way passive valve (32) composed of a thin polymer membrane. The anchors (30) are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve (32) is effective to prevent the backflow of amniotic fluid (23).",UNIV OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,CHEN YANFEI;;CHUN YOUNG JAE;;EMERY STEPHEN;;GU XINZHU;;WAGNER WILLIAM;;GREENE STEPHANIE,,https://lens.org/133-302-367-370-363,Patent Application,yes,5,0,3,3,0,A61M27/006;;A61M27/006;;A61B5/031;;A61B5/031;;A61B5/055;;A61B5/055;;A61B5/4362;;A61B5/4362;;A61L31/128;;A61L31/128;;A61M25/00;;A61M25/00;;A61M27/00;;A61M27/00;;A61M39/24;;A61M2205/0266;;A61M2207/00,A61M27/00;;A61B5/055;;A61L31/02;;A61L31/12;;A61M25/00,,0,0,,,,PENDING
64,US,B2,US 10744308 B2,112-114-092-276-73X,2020-08-18,2020,US 201615765723 A,2016-10-13,US 201615765723 A;;US 201562241281 P;;US 2016/0056751 W,2015-10-14,Low-profile ventriculoamniotic shunt for fetal aqueductal stenosis,"The invention relates to an in-utero ventriculoamniotic shunting device that includes a shunt tube ( 26 ) composed of polymer composite and having metallic wire embedded therein, one or more anchors ( 30 ) composed of superelastic wire, e.g., thermal shape-set nitinol structures, that are mechanically attached to an exterior surface of the shunt tube ( 26 ), and a one-way passive valve ( 32 ) composed of a thin polymer membrane. The anchors ( 30 ) are effective to prevent migration and dislodgement of the shunting device following its deployment, and the valve ( 32 ) is effective to prevent the backflow of amniotic fluid ( 23 ).",UNIV OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION;;UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION,CHEN YANFEI;;CHUN YOUNG JAE;;EMERY STEPHEN;;GU XINZHU;;WAGNER WILLIAM;;GREENE STEPHANIE,UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2018-09-14),https://lens.org/112-114-092-276-73X,Granted Patent,yes,5,0,3,3,0,A61M27/006;;A61M27/006;;A61B5/031;;A61B5/031;;A61B5/055;;A61B5/055;;A61B5/4362;;A61B5/4362;;A61L31/128;;A61L31/128;;A61M25/00;;A61M25/00;;A61M27/00;;A61M27/00;;A61M39/24;;A61M2205/0266;;A61M2207/00,A61M27/00;;A61B5/00;;A61B5/03;;A61B5/055;;A61L31/12;;A61M25/00;;A61M39/24,,0,0,,,,ACTIVE
65,CN,A,CN 101453988 A,066-472-114-237-111,2009-06-10,2009,CN 200780013424 A,2007-04-16,US 74488206 P,2006-04-14,Glucagon-like peptide 1(glp-1) pharmaceutical formulations,"A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,STEPHANIE GREENE;;DAVID BRANDT;;COHAVA GELBER;;MARK KING;;WENDELL CHEATHAM WAYMAN;;KEITH OBERG;;MARY FARIS,,https://lens.org/066-472-114-237-111,Patent Application,no,0,3,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16,,0,0,,,,DISCONTINUED
66,WO,A1,WO 2009/158649 A1,127-408-989-018-792,2009-12-30,2009,US 2009/0048915 W,2009-06-26,US 7609808 P;;US 9554808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC;;GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,,https://lens.org/127-408-989-018-792,Patent Application,yes,2,58,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/64,,3,3,018-625-854-727-523;;031-195-957-275-914;;124-051-595-355-739,16982418;;10.1016/j.neuron.2006.08.027;;10.1080/15216540600735974;;17002984;;18165356;;10.1096/fj.07-9973com,"SEBURN KEVIN L ET AL: ""An active dominant mutation of Glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model"", NEURON, vol. 51, no. 6, September 2006 (2006-09-01), pages 715 - 726, XP002551146, ISSN: 0896-6273;;PARK SANG GYU ET AL: ""Do aminoacyl-tRNA synthetases have biological functions other than in protein biosynthesis?"", IUBMB LIFE, vol. 58, no. 9, September 2006 (2006-09-01), pages 556 - 558, XP002551147, ISSN: 1521-6543;;GREENBERG Y ET AL: ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells"", FASEB JOURNAL, vol. 22, no. 5, May 2008 (2008-05-01), pages 1597 - 1605, XP002551148, ISSN: 0892-6638",PENDING
67,US,B2,US 8404471 B2,037-781-312-212-65X,2013-03-26,2013,US 49292509 A,2009-06-26,US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN;;ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2009-08-20),https://lens.org/037-781-312-212-65X,Granted Patent,yes,96,70,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/00;;C12N15/00;;C12P21/04;;C12P21/06,435/183;;435/440;;435/69.1;;435/71.1,100,53,110-114-372-343-72X;;065-727-315-943-720;;124-051-595-355-739;;031-195-957-275-914;;018-625-854-727-523;;010-475-981-497-60X;;080-480-704-978-03X;;074-484-564-852-275;;058-442-026-595-149;;008-120-631-983-38X;;016-719-496-909-822;;072-370-062-059-009;;100-286-864-518-416;;000-938-322-005-89X;;042-538-952-084-036;;061-440-907-424-357;;124-597-012-019-86X;;010-104-034-278-991;;069-284-161-422-046;;137-947-974-286-554;;003-833-567-529-198;;061-877-472-955-053;;048-224-553-579-724;;075-329-526-485-685;;043-049-550-318-61X;;069-909-492-133-801;;061-756-489-300-343;;024-848-900-594-940;;050-112-382-936-584;;005-508-391-866-003;;186-769-565-336-221;;006-032-167-067-384;;057-586-627-671-06X;;112-807-205-590-664;;038-537-780-543-160;;103-932-348-507-545;;017-823-334-797-983;;079-728-014-732-885;;049-582-995-278-861;;104-710-913-908-169;;080-312-409-237-586;;035-778-345-312-446;;023-195-237-666-538;;019-517-263-323-058;;046-564-817-915-380;;080-491-804-329-954;;025-930-820-482-18X;;061-770-703-217-171;;042-469-180-582-521;;013-204-928-410-151;;061-859-656-899-093;;002-460-257-894-311;;132-695-844-930-786,17544401;;10.1016/j.febslet.2007.05.046;;10.1016/s0021-9258(19)61975-7;;7961834;;18165356;;10.1096/fj.07-9973com;;10.1080/15216540600735974;;17002984;;16982418;;10.1016/j.neuron.2006.08.027;;10.1073/pnas.012602099;;pmc117534;;11773626;;10.1093/nar/23.8.1307;;7753621;;pmc306854;;10.1126/science.287.5461.2185;;10731132;;10.1093/nar/21.18.4344;;8414990;;pmc310070;;9812895;;10.1126/science.282.5392.1315;;10.1016/j.vph.2009.11.009;;19962454;;15994074;;10.1016/j.copbio.2005.06.004;;1458545;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;10944397;;12416978;;10.1021/bi020537k;;10.1084/jem.20070846;;pmc2413039;;18519646;;pmc1905094;;10.1046/j.1365-2249.1998.00720.x;;9822271;;10.1016/s0969-2126(97)00166-4;;9016717;;10.2210/pdb1eiy/pdb;;10.1016/s0969-2126(02)00699-8;;12005430;;19710017;;10.1074/jbc.m109.030692;;019710017;;pmc2781443;;1992490;;10.1073/pnas.88.3.976;;pmc50937;;15627054;;10.1016/s0021-9258(19)84749-x;;2674137;;10.3410/f.9293.359529;;10.1038/ng1727;;16429158;;18197801;;10.1615/critrevimmunol.v27.i6.60;;pmc2706086;;10.1016/j.chembiol.2009.03.006;;19477417;;10.1126/science.1135308;;17185560;;10.1038/nsmb722;;10.2210/pdb1ulh/pdb;;14730354;;16233987;;10.1016/j.cbpa.2005.10.007;;16702215;;10.1074/jbc.m601189200;;14569199;;10.1097/00002281-200311000-00005;;16801548;;pmc1502431;;10.1073/pnas.0601167103;;pmc2822721;;10.1016/j.tins.2009.11.001;;20152552;;17185601;;10.1126/science.1131262;;10.1073/pnas.0705055104;;pmc2040883;;17595294;;10.1007/978-1-4684-6831-1_14;;10.1016/0378-1119(94)00634-5;;7721108;;12237313;;10.1074/jbc.m207934200;;7806522;;10.1016/s0021-9258(20)30081-8;;10.4049/jimmunol.170.6.2904;;12626541;;17942888;;10.1158/0008-5472.can-07-2377;;18057449;;10.1007/s12010-007-8003-4;;16997858;;10.1189/jlb.0306227;;10.1073/pnas.0905339106;;pmc2702257;;19561293;;10.1002/art.1780350718;;1622421;;10.1189/jlb.1003495;;15155777;;12052707;;10.1016/s0169-409x(02)00020-0;;11956181;;10.1074/jbc.c200126200;;10102815;;10.1126/science.284.5411.147;;12538453;;15029827;;10.1017/s0033583503003901;;7592916;;10.1074/jbc.270.45.26782;;10.1021/bi990993h;;10512619,"Cader et al. Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy. FEBS Lett. Jun. 26, 2007;581(16):2959-64. Epub May 29, 2007.;;GenBank Accession No. U09510, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/595304, Apr. 1, 2010.;;GenBank Accession No. U09587, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/600726, Apr. 1, 2010.;;GenBank Accession No. CR594947, ""full-length cDNA clone CSODE014YCO3 of Placenta of Homo sapiens (human),"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/50475754, Mar. 25, 2010.;;EBI Accession No. GSP: ARB30818, ""Cotton protein for improving plant biological properties, 100753,"" retrieved Oct. 20, 2009.;;International Search Report, mailed Nov. 2, 2009, for PCT/US2009/048915, 8 pages.;;Written Opinion, mailed Nov. 2, 2009, for PCT/US2009/048915, 7 pages.;;Ge et al., ""Primary Structure and Functional Expression of Human Glycyl-tRNA Synthetase, an Autoantigen in Myositis,"" J. Biol. Chem. 269(46): 28790-28797, Nov. 18, 1994.;;Greenberg et al., ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells,"" FASEB J. 22: 1597-1605, 2008.;;Park et al., ""Is There an Answer? Do Aminoacyl-tRNA Synthetases have Biological Functions other than in Protein Biosynthesis?"" IUBMB Life 58(9): 556-558, Sep. 2006.;;Seburn et al., ""An Active Dominant Mutation of Glycyl-tRNA Synthetase Causes Neuropathy in a Charcot-Marie-Tooth 2D Mouse Model,"" Neuron 51: 715-726, Sep. 21, 2006.;;Wakasugi et al., ""A human aminoacyl-tRNA synthetase as a regulator of angiogenesis,"" Proc. Natl. Acad. Sci. USA 99 (1): 173-177, Jan. 8, 2002.;;Williams et al., ""Cloning, sequencing and bacterial expression of human glycine tRNA synthetase,"" Nucleic Acids Res. 23(8): 1307-1310, 1995.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/048915, dated Jan. 5, 2011.;;Office Action for U.S. Appl. No. 12/482,151, mailed Oct. 11, 2011.;;Office Action for U.S. Appl. No. 12/482,151, mailed Mar. 18, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/046910, dated Dec. 13, 2010.;;International Search Report and Written Opinion for International Application No. PCT/US2009/046910, mailed Mar. 4, 2010.;;Supplementary European Search Report for European Application No. EP 06838844, dated Mar. 26, 2009.;;Office Action for U.S. Appl. No. 12/085,884, mailed Jan. 20, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/046106, dated Jun. 4, 2008.;;International Search Report and Written Opinion for International Application No. PCT/US2006/046106, mailed Aug. 9, 2007.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/025642, dated Aug. 30, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/025642, mailed Oct. 29, 2010.;;Office Action for U.S. Appl. No. 12/751,358, mailed Oct. 3, 2011.;;Office Action for U.S. Appl. No. 12/751,358, mailed Mar. 3, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/029377, dated Oct. 4, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/029377, mailed Jan. 26, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/027525, dated Sep. 20, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/027525, mailed Jan. 10, 2011.;;International Search Report for International Application No. PCT/US2010/059964, mailed Aug. 25, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059963, mailed May 12, 2011.;;International Search Report for International Application No. PCT/US2011/000210, mailed Aug. 12, 2011.;;Adams, M. D. et al., ""The genome sequence of Drosophila melanogaster,"" Science, 287(5961):2185-2195, 2000.;;Amaar, Y. G. et al., ""Cloning and characterization of the C. elegans histidyl-tRNA synthetase gene,"" Nucleic Acids Research, 21(18):4344-4347, 1993.;;Broun, P. et al., ""Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,"" Science, 1998, 282:1315-1317.;;Brown, M. V. et al., ""Mammalian aminoacyl-tRNA synthetases: cell signaling functions of the protein translation machinery,"" Vascular Pharmacology, 52(1-2):21-26, 2010.;;Chica, R. A. et al., ""Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design,"" Curr. Opi. Biotechnol., 16:378-384, 2005.;;Delgado, C. et al., ""The uses and properties of PEG-linked proteins,"" Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304, 1992.;;Devos, D. et al., ""Practical limits of function prediction,"" Proteins: Structure, Function, and Genetics, 41:98-107, 2000.;;Ewalt, K. L. et al., ""Activation of Angiogenic Signaling Pathways by Two Human tRNA Synthetases,"" Biochemistry, 41:13344-13349, 2002.;;Frommhold, D. et al., ""Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation,"" Journal of Experimental Medicine, 205(6):1435-1446, 2008.;;Garcia-Lozano, J. R. et al., ""Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region,"" Clin. Exp. Immunol., 114:161-165, 1998.;;GenBank Accession No. AA174042, Sep. 30, 1997.;;GenBank Accession No. A1963202, Aug. 20, 1999.;;GenBank Accession No. AK074524, Mar. 25, 2002.;;GenBank Accession No. AU126197, Oct. 23, 2000.;;GenBank Accession No. AW976267, Jun. 2, 2000.;;GenBank Accession No. BI258770, Jul. 16, 2001.;;GenBank Accession No. BP423196, May 27, 2005.;;GenBank Accession No. CA314607, Nov. 4, 2002.;;GenBank Accession No. DA018291, Nov. 2, 2005.;;GenBank Accession No. DA386636, Nov. 5, 2005.;;GenBank Accession No. DA478765, Nov. 6, 2005.;;GenBank Accession No. DA552410, Nov. 5, 2005.;;GenBank Accession No. DA576766, Nov. 5, 2005.;;GenBank Accession No. DB488998, Mar. 31, 2006.;;GenBank Accession No. DC366890, Apr. 27, 2007.;;GenBank Accession No. DB058369, Dec. 10, 2005.;;GenBank Accession No. Q9VV60, published May 1, 2000.;;GenBank Accession No. Q7QD89, Anopheles gambiae Sequence Committee, submitted Apr. 2002 (Retrieved from the Internet on Apr. 24, 2007): http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=74803944.;;Goldgur, Y. et al., ""The crystal structure of phenylalanyl-tRNA synthetase from Thermus thermophilus complexed with cognate tRNA,"" Structure, 5:59-68, 1997.;;Greene, L. A., ""Polypeptide Structural Motifs Associated with Cell Signaling Activity,"" U.S. Appl. No. 13/203,831, filed Aug. 29, 2011.;;Guijarro, J. I. et al., ""Structure and Dynamics of the Anticodon Arm Binding Domain of Bacillus stearothermophilus Tyrosyl-tRNA Synthetase,"" Structure, 10:311-317, 2002.;;Guo, R-T et al., ""Crystal structures and biochemical analyses suggest a unique mechanism and role for human glycyl-tRNA synthetase in Ap4A homeostasis,"" Journal of Biological Chemistry, 284(42):28968-28976, 2009.;;Hou, Y-M. et al., ""Sequence determination and modeling of structural motifs for the smallest monomeric aminoacyl-tRNA synthetase,"" Proc. Nat. Acad. Sci., 88(3):976-980, 1991.;;Ivakhno, S. S. et al., ""Cytokine-Like Activities of Some Aminoacyl-tRNA Synthetases and Auxiliary p43 Cofactor of Aminoacylation Reaction and Their Role in Oncogenesis,"" Exp. Oncol., 26(4):250-255, 2004.;;Jacobo-Molina, A. et al., ""cDNA Sequence, Predicted Primary Structure, and Evolving Amphiphilic Helix of Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 264(28):16608-16612, 1989.;;Jordanova, A. et al., ""Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy,"" Nature Genetics, 38(2):197-202, 2006.;;Jura, M. et al., ""Comprehensive Insight into Human Aminoacyl-tRNA Synthetases as Autoantigens in Idiopathic Inflammatory Myopathies,"" Critical Reviews in Immunology, 27(6):559-572, 2007.;;Kapoor, M. et al., ""Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase,"" Chemistry & Biology, 16(5):531-539, 2009.;;Kimchi-Sarfaty, C. et al., ""A 'Silent' polymorphism in the MDR1 gene changes substrate specificty,"" Science, 315:525-528, 2007.;;Kise, Y. et al., ""A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase,"" Nature Structural & Molecular Biology, 11(2):149-156, 2004.;;Kochendoerfer, G. G., ""Site-specific polymer modification of therapeutic proteins,"" Current Opinion in Chemical Biology, 9:555-560, 2005.;;Kovaleski, B. J. et al.,""In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase,"" J. Bio. Chem., 281(28):9449-9456, 2006.;;Levine, S. M. et al., ""Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies,"" Current Opinion in Rheumatology, 15(6):708-713, 2003.;;Link, A. J. et al., ""Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids,"" Proc. Nat. Acad. Sci., 103(27):10180-10185, 2006.;;Motley, W. W. et al., ""GARS axonopathy: not every neuron's cup of tRNA,"" Trends Neurosci., 33(2):59, 2010.;;Nackley, A. G. et al., ""Human Caechol-O-Methytransferase haplotypes modulate protein expression by altering mRNA secondary structure,"" Science, 314:1930-1933, 2006.;;Nangle, L. A. et al., ""Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect,"" PNAS, 104(27):11239-11244, 2007.;;Ngo, J. T. et al., ""Computational complexity, protein structure prediction, and the Levinthal paradox,"" The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, 1994.;;Nichols, R. C. et al., ""Human isoleucyl-tRNA synthetase: sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension,"" Gene, 155(2):299-304, 1995.;;Park, S. G. et al., ""Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis,"" The Journal of Biological Chemistry, 277(47):45243-45248, 2002.;;Quesniaux, V. F.J. et al., ""Hematopoiesis, including lymphocyte developmet and maturation,"" Principles of Immunopharmacology, 2005-A, pp. 3-17.;;Reed, V. S. et al., ""Characterization of a Novel N-terminal Peptide in Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 269(52):32937-32941, 1994.;;Richardson, R. M. et al., ""Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation,"" Journal of Immunology, 170(6):2904-2911, 2003.;;Sauna, Z. E. et al., ""Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer,"" Cancer Res., 67(20):9609-9612, 2007.;;Sen, S. et al., ""Developments in directed evolution for improving enzyme functions,"" Appl. Biochem. Biotechnol., 143:212-223, 2007.;;Smith, D. F. et al., ""Leukocyte phosphoinositide-3 kinase gamma is required for chemokine-induced, sustained adhesion under flow in vivo,"" Journal of Leukocyte Biology, 80(6):1491-1499, 2006.;;Storkebaum, E. et al., ""Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy,"" PNAS, 106(28):11782-11787, 2009.;;Targoff, I. N. et al., ""Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease,"" Arthritis Rheum., 35(7):821-830, 1992.;;Traves, S. L. et al., ""Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2,"" Journal of Leukocyte Biology, 76(2):441-450, 2004.;;Veronese, F. M. et al., ""Preface: Introduction and overview of peptide and protein pegylation,"" Advanced Drug Delivery Reviews, 54:453-456, 2002.;;Wakasugi, K. et al., ""Induction of angiogenesis by a frament of human tyrosyl-tRNA synthetase,"" The Journal of Biological Chemistry, 277(23):20124-20126, 2002.;;Wakasugi, K. et al., ""Two distinct cytokines released from a human aminoacyl-tRNA synthetase,"" Science, 284:147-151, 1999.;;Wasenius, V-M et al., ""Hepatocyte Growth Factor Receptor, Matrix Metalloproteinase-11, Tissue Inhibitor of Metalloproteinase-1, and Fibronectin Are Up-Regulated in Papillary Thyroid Carcinoma: A cDNA and Tissue Microarray Study,"" Clin. Cancer Res., 9:68-75, 2003.;;Watkins, ""Aminoacyl-tRNA Synthetases for Modulating Hematopoieses,"" U.S. Appl. No. 13/162,559, filed Jun. 16, 2011.;;Whisstock, J. C. et al., ""Prediction of protein function from protein sequence and structure,"" Q. Rev. Biophysics., 36(3):307-340, 2003.;;Wishart, M. J. et al., ""A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase,"" J. Biol. Chem., 270(45):26782-26785, 1995.;;Witkowski, A. et al., ""Conversion of beta-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine,"" Biochemistry, 38:11643-11650, 1999.",ACTIVE
68,US,A1,US 2014/0363415 A1,044-967-128-173-24X,2014-12-11,2014,US 201414262247 A,2014-04-25,US 201414262247 A;;US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/044-967-128-173-24X,Patent Application,yes,0,7,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/00,424/94.5;;435/375,0,0,,,,ACTIVE
69,US,A1,US 2017/0296635 A1,041-726-919-459-758,2017-10-19,2017,US 201715415328 A,2017-01-25,US 201715415328 A;;US 201514844666 A;;US 201414262247 A;;US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/041-726-919-459-758,Patent Application,yes,0,2,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,A61K38/53;;C07K1/14;;C12N9/00;;C12N9/96;;C12N15/10,,0,0,,,,DISCONTINUED
70,JP,A,JP 2015109864 A,144-190-581-630-125,2015-06-18,2015,JP 2015042000 A,2015-03-04,US 7609808 P;;US 9554808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"PROBLEM TO BE SOLVED: To provide compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities.SOLUTION: The invention provides an isolated glycyl-tRNA synthetase polypeptide and polynucleotide having non-canonical biological activities, as well as compositions and methods associated with the same. In certain embodiments, a non-canonical biological activity exhibited by a GlyRS polypeptide of the invention may include, but is not limited to, modulation of cell proliferation, modulation of apoptosis, modulation of cell migration, modulation of cell signaling and/or modulation of cytokine production and/or secretion.",ATYR PHARMA INC,LESLLE ANN GREENE;;RYAN ANDREW ADAMS;;HONG FEI;;ZHAO JI;;EVA REBECKA STEPHANIE ARMOUR;;KRISTI HELEN PIEHL,,https://lens.org/144-190-581-630-125,Patent Application,no,0,0,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N15/09;;A61K38/53;;A61K39/395;;A61K48/00;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/06;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N9/96;;C12Q1/02;;C12Q1/48;;G01N33/15;;G01N33/50,,0,0,,,,ACTIVE
71,US,A1,US 2013/0236455 A1,156-034-330-277-823,2013-09-12,2013,US 201313753272 A,2013-01-29,US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/156-034-330-277-823,Patent Application,yes,0,30,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/00;;C12N9/96,424/134.1;;424/94.3;;424/94.5,0,0,,,,ACTIVE
72,US,B2,US 9157076 B2,010-783-002-339-515,2015-10-13,2015,US 201414262247 A,2014-04-25,US 201414262247 A;;US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/010-783-002-339-515,Granted Patent,yes,99,2,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,A61K38/51;;A61K38/53;;C07H21/04;;C07K1/14;;C12N9/00;;C12N9/96;;C12N15/00;;C12N15/10,,99,48,074-484-564-852-275;;058-442-026-595-149;;005-134-238-831-599;;069-966-428-216-793;;018-694-717-457-677;;008-120-631-983-38X;;016-719-496-909-822;;110-114-372-343-72X;;072-370-062-059-009;;100-286-864-518-416;;000-938-322-005-89X;;042-538-952-084-036;;061-440-907-424-357;;124-597-012-019-86X;;065-727-315-943-720;;010-104-034-278-991;;124-051-595-355-739;;069-284-161-422-046;;137-947-974-286-554;;057-924-326-482-635;;031-357-957-515-526;;064-734-728-506-958;;003-833-567-529-198;;061-877-472-955-053;;048-224-553-579-724;;075-329-526-485-685;;043-049-550-318-61X;;069-909-492-133-801;;061-756-489-300-343;;024-848-900-594-940;;050-112-382-936-584;;005-508-391-866-003;;186-769-565-336-221;;006-032-167-067-384;;010-063-101-427-224;;057-586-627-671-06X;;112-807-205-590-664;;038-537-780-543-160;;103-932-348-507-545;;017-823-334-797-983;;002-116-605-784-264;;079-728-014-732-885;;031-195-957-275-914;;001-572-426-072-168;;049-582-995-278-861;;104-710-913-908-169;;080-312-409-237-586;;018-625-854-727-523,10.1126/science.287.5461.2185;;10731132;;10.1093/nar/21.18.4344;;8414990;;pmc310070;;10.1523/jneurosci.1671-06.2006;;17035524;;pmc6674701;;19593442;;pmc2704870;;10.1371/journal.pone.0006218;;19412816;;10.3109/17482960902849823;;pmc2864347;;9812895;;10.1126/science.282.5392.1315;;10.1016/j.vph.2009.11.009;;19962454;;17544401;;10.1016/j.febslet.2007.05.046;;15994074;;10.1016/j.copbio.2005.06.004;;1458545;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;10944397;;12416978;;10.1021/bi020537k;;10.1084/jem.20070846;;pmc2413039;;18519646;;pmc1905094;;10.1046/j.1365-2249.1998.00720.x;;9822271;;10.1016/s0021-9258(19)61975-7;;7961834;;10.1016/s0969-2126(97)00166-4;;9016717;;10.2210/pdb1eiy/pdb;;18165356;;10.1096/fj.07-9973com;;10.1016/s0969-2126(02)00699-8;;12005430;;19710017;;10.1074/jbc.m109.030692;;019710017;;pmc2781443;;10.1016/j.febslet.2009.11.064;;19932696;;pmc2826164;;20700144;;10.1038/nrm2956;;pmc3042954;;pmc2583229;;10.1111/j.1574-6976.2008.00119.x;;18522650;;1992490;;10.1073/pnas.88.3.976;;pmc50937;;15627054;;10.1016/s0021-9258(19)84749-x;;2674137;;10.3410/f.9293.359529;;10.1038/ng1727;;16429158;;18197801;;10.1615/critrevimmunol.v27.i6.60;;pmc2706086;;10.1016/j.chembiol.2009.03.006;;19477417;;10.1126/science.1135308;;17185560;;10.1038/nsmb722;;10.2210/pdb1ulh/pdb;;14730354;;16233987;;10.1016/j.cbpa.2005.10.007;;16702215;;10.1074/jbc.m601189200;;14569199;;10.1097/00002281-200311000-00005;;16801548;;pmc1502431;;10.1073/pnas.0601167103;;10.1371/journal.pgen.1002399;;pmc3228828;;22144914;;pmc2822721;;10.1016/j.tins.2009.11.001;;20152552;;17185601;;10.1126/science.1131262;;10.1073/pnas.0705055104;;pmc2040883;;17595294;;10.1007/978-1-4684-6831-1_14;;10.1016/0378-1119(94)00634-5;;7721108;;10.1073/pnas.0802862105;;18682559;;pmc2516211;;12237313;;10.1074/jbc.m207934200;;10.1080/15216540600735974;;17002984;;pmc3306665;;10.1073/pnas.1200194109;;22345558;;7806522;;10.1016/s0021-9258(20)30081-8;;10.4049/jimmunol.170.6.2904;;12626541;;17942888;;10.1158/0008-5472.can-07-2377;;16982418;;10.1016/j.neuron.2006.08.027,"Office Action for U.S. Appl. No. 12/492,925, mailed on Jan. 6, 2012.;;Office Action for U.S. Appl. No. 12/492,925, mailed on Jun. 11, 2012.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/048915, dated Jan. 5, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2009/048915, mailed Nov. 2, 2009.;;Office Action for U.S. Appl. No. 13/753,272, mailed on Jul. 19, 2013.;;Office Action for U.S. Appl. No. 12/482,151, mailed Oct. 11, 2011.;;Office Action for U.S. Appl. No. 12/482,151, mailed Mar. 18, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/046910, dated Dec. 13, 2010.;;International Search Report and Written Opinion for International Application No. PCT/US2009/046910, mailed Mar. 4, 2010.;;Supplementary European Search Report for European Application No. 06838844.6, mailed Apr. 9, 2009.;;Office Action for European Patent Application No. 06838844.6, mailed Apr. 9, 2009.;;Office Action for U.S. Appl. No. 12/085,884, mailed Jan. 20, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/046106, dated Jun. 4, 2008.;;International Search Report and Written Opinion for International Application No. PCT/US2006/046106, mailed Aug. 9, 2007.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/025642, dated Aug. 30, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/025642, mailed Oct. 29, 2010.;;Office Action for U.S. Appl. No. 12/751,358, mailed Oct. 3, 2011.;;Office Action for U.S. Appl. No. 12/751,358, mailed Mar. 3, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/029377, dated Oct. 4, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/029377, mailed Jan. 26, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/027525, dated Sep. 20, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/027525, mailed Jan. 10, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059964, mailed Aug. 25, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059963, mailed May 12, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2011/000210, mailed Aug. 12, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2011/043756, dated Jan. 15, 2013.;;Adams, M. D. et al., ""The genome sequence of drosophila melanogaster,"" Science, 287(5961):2185-2195 (2000).;;Amaar, Y. G. et al., ""Cloning and characterization of the C.elegans histidyl-tRNA synthetase gene,"" Nucleic Acids Research, 21(18):4344-4347 (1993).;;Antonellis, A. et al., ""Functional Analyses of Glycyl-tRNA Synthetase Mutations Suggest a Key Role for tRNA-Charging Enzymes in Peripheral Axons,"" The Journal of Neuroscience, 26(41):10397-10406 (2006).;;Banks, G. T. et al., ""Mutant Glycyl-tRNA Synthetase (Gars) Ameliorates SOD1G93A Motor Neuron Degeneration Phenotype but Has Little Affect on Loa Dynein Heavy Chain Mutant Mice,"" PLoS One, 4(7):e6218 (2009).;;Blumen, S. C. et al., ""Mutational analysis of glycyl-tRNA synthetase (GARS) gene in Hirayama Disease,"" Amyotroph Lateral Scler., 11(1-2):237-239 (2010).;;Broun, P. et al., ""Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,"" Science, 282:1315-1317 (1998).;;Brown, M. V. et al., ""Mammalian aminoacyl-tRNA synthetases: Cell signaling functions of the protein translation machinery,"" Vascular Pharmacology, 52(1-2):21-26 (2010).;;Cader, M. Z. et al., ""Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy,"" FEBS Letters, 581(16):2959-2964 (2007).;;Chica, R. A. et al., ""Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design,"" Curr. Opin. Biotechnol., 16:378-384 (2005).;;Delgado, C. et al., ""The uses and properties of PEG-linked proteins,"" Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304 (1992).;;Devos, D. et al., ""Practical limits of function prediction,"" Proteins: Structure, Function, and Genetics, 41:98-107 (2000).;;EBI Accession No. GSP: ARB30818, ""Cotton protein for improving plant biological properties, 100753,"" retrieved Oct. 20, 2009.;;Ewalt, K. L. et al., ""Activation of Angiogenic Signaling Pathways by Two Human tRNA Synthetases,"" Biochemistry, 41(45):13344-13349 (2002).;;Frommhold, D. et al., ""Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation,"" Journal of Experimental Medicine, 205(6):1435-1446 (2008).;;Garcia-Lozano, J. R. et al., ""Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region,"" Clin. Exp. Immunol., 114:161-165 (1998).;;Ge, Q. et al., ""Primary Structure and Functional Expression of Human Glycyl-tRNA Synthetase, an Autoantigen in Myositis,"" The Journal of Biological Chemistry, 269(46):28790-28797 (1994).;;GenBank Accession No. AK074524, Mar. 25, 2002.;;GenBank Accession No. AU126197, Oct. 23, 2000.;;GenBank Accession No. AW976267, Jun. 2, 2000.;;GenBank Accession No. BI258770, Jul. 16, 2001.;;GenBank Accession No. BP423196, May 27, 2005.;;GenBank Accession No. CA314607, Nov. 4, 2002.;;GenBank Accession No. DA018291, Nov. 2, 2005.;;GenBank Accession No. DA386636, Nov. 5, 2005.;;GenBank Accession No. DA478765, Nov. 6, 2005.;;GenBank Accession No. DA552410, Nov. 5, 2005.;;GenBank Accession No. DA576766, Nov. 5, 2005.;;GenBank Accession No. DB488998, Mar. 31, 2006.;;GenBank Accession No. DC366890, Apr. 27, 2007.;;GenBank Accession No. DB058369, Dec. 10, 2005.;;GenBank Accession No. AA174042, Sep. 30, 1997.;;GenBank Accession No. AI963202, Aug. 20, 1999.;;GenBank Accession No. CR594947, ""full-length cDNA clone CS0DE014YC03 of Placenta of Homo sapiens (human),"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/50475754, Mar. 25, 2010.;;GenBank Accession No. Q7QD89, Anopheles gambiae Sequence Committee, submitted Apr. 2002, [Retrieved from the Internet Apr. 24, 2007], .;;GenBank Accession No. Q9VV60, published May 1, 2000.;;GenBank Accession No. U09510, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/595304, Apr. 1, 2010.;;GenBank Accession No. U09587, Human glycyl-tRNA synthetase mRNA, complete cds, Dec. 9, 1994.;;Goldgur, Y. et al., ""The crystal structure of phenylalanyl-tRNA synthetase from Thermus thermophilus complexed with cognate tRNA,"" Structure, 5:59-68 (1997).;;Greenberg, Y. et al., ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells,"" FASEB Journal, 22(5):1597-1605 (2008).;;Guijarro, J. I. et al., ""Structure and Dynamics of the Anticodon Arm Binding Domain of Bacillus stearothermophilus Tyrosyl-tRNA Synthetase,"" Structure, 10:311-317 (2002).;;Guo, R-T. et al., ""Crystal structures and biochemical analyses suggest a unique mechanism and role for human glycyl-tRNA synthetase in Ap4A homeostasis,"" Journal of Biological Chemistry, 284(42):28968-28976 (2009).;;Guo, M. et al., ""Functional expansion of human tRNA synthetases achieved by structural inventions,"" FEBS Letters, 584(2):434-442 (2010).;;Guo, M. et al., ""New functions of aminoacyl-tRNA synthetases beyond translation,"" Nature Reviews Molecular Cell Biology, 11:668-674 (2010).;;Hausmann, C. D. et al., ""Aminoacyl-tRNA synthetase complexes: molecular multitasking revealed,"" FEMS Microbiol. Rev., 32(4):705-721 (2008).;;Hou, Y-M. et al., ""Sequence determination and modeling of structural motifs for the smallest monomeric aminoacyl-tRNA synthetase,"" Proc. Nat. Acad. Sci., 88(3):976-980 (1991).;;Ivakhno, S. S. et al., ""Cytokine-Like Activities of Some Aminoacyl-tRNA Synthetases and Auxiliary p43 Cofactor of Aminoacylation Reation and Their Role in Oncogenesis,"" Exp. Oncol., 26(4):250-255 (2004).;;Jacobo-Molina, A. et al., ""cDNA Sequence, Predicted Primary Structure, and Evolving Amphiphilic Helix of Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 264(28):16608-16612 (1989).;;Jordanova, A. et al., ""Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy,"" Nature Genetics, 38(2):197-202 (2006).;;Jura, M. et al., ""Comprehensive Insight into Human Aminoacyl-tRNA Synthetases as Autoantigens in Idiopathic Inflammatory Myopathies,"" Critical Reviews in Immunology, 27(6):559-572 (2007).;;Kapoor, M. et al., ""Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase,"" Chemistry & Biology, 16(5):531-539 (2009).;;Kimchi-Sarfaty, C. et al., ""A 'Silent' polymorphism in the MDR1 gene changes substrate specificty,"" Science, 315:525-528 (2007).;;Kise, Y. et al., ""A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase,"" Nature Structural & Molecular Biology, 11(2):149-156 (2004).;;Kochendoerfer, G. G., ""Site-specific polymer modification of therapeutic proteins,"" Current Opinion in Chemical Biology, 9:555-560 (2005).;;Kovaleski, B. J. et al.,""In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase,"" J. Bio. Chem., 281(28):19449-19456 (2006).;;Levine, S. M. et al., ""Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies,"" Current Opinion in Rheumatology, 15(6):708-713 (2003).;;Link, A. J. et al., ""Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids,"" Proc. Nat. Acad. Sci., 103(27):10180-10185 (2006).;;Molecular Modeling Database (MMDB), ""Solution Structures of the Whep-trs domain of human histidyl-trna synthetase,"" MMDB ID No. 35920, available for www.ncbi.nlm.nih.gov/Structure/mmdb, accessed Aug. 24, 2012.;;Motley et al., ""Charcot-Marie-Tooth-Linked Mutant GARS is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels,"" PLoS Genetics, 7(12):e1002399 (2011).;;Motley, W. W. et al., ""GARS axonopathy: not every neuron's cup of tRNA,"" Trends Neurosci., 33(2):59 (2010).;;Nackley, A. G. et al., ""Human Caechol-O-Methytransferase haplotypes modulate protein expression by altering mRNA secondary structure,"" Science, 314:1930-1933 (2006).;;Nangle, L. A. et al., ""Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect,"" PNAS, 104(27):11239-11244 (2007).;;Ngo, J. T. et al., ""Computational complexity, protein structure prediction, and the Levinthal paradox,"" In the Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495 (1994).;;Nichols, R. C. et al., ""Human isoleucyl-tRNA synthetase: sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension,"" Gene, 155(2):299-304 (1995).;;Park, S. G., et al., ""Aminoacyl tRNA synthetases and their connections to disease,"" PNAS, 105(32):1104311049 (2008).;;Park, S. G. et al., ""Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis,"" The Journal of Biological Chemistry, 277(47):45243-45248 (2002).;;Park, S. G. et al., ""Is there an answer? Do aminoacyl-tRNA synthetases have biological functions other than in protein biosynthesis?"" IUBMB Life, 58(9):556-558 (2006).;;Park, M. C. et al., ""Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis,"" Proc. Natl. Acad. Sci. USA [online], Retrieved from the Internet: , Published on Feb. 15, 2012.;;Protein Purification-Handbook, Amersham Parmacia Biotech AB (1999).;;Quesniaux, V. F.J. et al., ""Hematopoiesis, including lymphocyte developmet and maturation,"" Principles of Immunopharmacology, pp. 3-17 (2005).;;Reed, V. S. et al., ""Characterization of a Novel N-terminal Peptide in Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 269(52):32937-32941 (1994).;;Richardson, R. M. et al., ""Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation,"" Journal of Immunology, 170(6):2904-2911 (2003).;;Sauna, Z. E. et al., ""Silent polymorhisms speak: How they affect pharmacogenomics and the treatment of cancer,"" Cancer Res., 67(20):9609-9612 (2007).;;Seburn, K. L. et al., ""An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model,"" Neuron, 51(6):715-726 (2006).",ACTIVE
73,CN,A,CN 106434576 A,178-413-038-089-09X,2017-02-22,2017,CN 201610829018 A,2009-06-26,US 7609808 P;;US 9554808 P;;CN 200980132761 A,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,PIEHL KRISTI HELEN;;GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE,,https://lens.org/178-413-038-089-09X,Patent Application,no,2,0,20,20,0,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/00;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;C07K16/40;;C07K19/00;;C12N15/52;;C12Q1/25,,1,1,018-625-854-727-523,16982418;;10.1016/j.neuron.2006.08.027,"KEVIN L: ""An Active Dominant Mutation of Glycyl-tRNA Synthetase Causes Neuropathy in a Charcot-Marie-Tooth 2D Mouse Model"", 《NEURON》",DISCONTINUED
74,CN,A,CN 102159708 A,024-817-864-634-332,2011-08-17,2011,CN 200980132761 A,2009-06-26,US 2009/0048915 W;;US 7609808 P;;US 9554808 P,2008-06-26,Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,HELEN PIEHL KRISTI;;ANN GREENE LESLIE;;ANDREW ADAMS RYAN;;FEI HONG;;JI ZHAO;;STEPHANIE ARMOUR EVA REBECKA,,https://lens.org/024-817-864-634-332,Patent Application,no,0,2,20,20,0,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/64,,0,0,,,,ACTIVE
75,US,B2,US 8747840 B2,095-714-944-067-626,2014-06-10,2014,US 201313753272 A,2013-01-29,US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/095-714-944-067-626,Granted Patent,yes,100,12,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,A61K38/43;;A61K38/53;;C07H21/04;;C07K1/14;;C12N1/20;;C12N5/04;;C12N9/00;;C12N15/00;;C12N15/10;;C12P21/04,424/94.1;;435/183;;435/440;;435/71.1;;435/412;;435/252.3;;435/320.1;;536/23.2,100,51,074-484-564-852-275;;058-442-026-595-149;;008-120-631-983-38X;;016-719-496-909-822;;110-114-372-343-72X;;072-370-062-059-009;;100-286-864-518-416;;000-938-322-005-89X;;042-538-952-084-036;;061-440-907-424-357;;124-597-012-019-86X;;065-727-315-943-720;;010-104-034-278-991;;124-051-595-355-739;;069-284-161-422-046;;137-947-974-286-554;;003-833-567-529-198;;061-877-472-955-053;;048-224-553-579-724;;075-329-526-485-685;;043-049-550-318-61X;;069-909-492-133-801;;061-756-489-300-343;;024-848-900-594-940;;050-112-382-936-584;;005-508-391-866-003;;186-769-565-336-221;;006-032-167-067-384;;057-586-627-671-06X;;112-807-205-590-664;;038-537-780-543-160;;103-932-348-507-545;;017-823-334-797-983;;079-728-014-732-885;;031-195-957-275-914;;049-582-995-278-861;;104-710-913-908-169;;080-312-409-237-586;;018-625-854-727-523;;035-778-345-312-446;;023-195-237-666-538;;019-517-263-323-058;;046-564-817-915-380;;080-491-804-329-954;;025-930-820-482-18X;;010-475-981-497-60X;;061-770-703-217-171;;042-469-180-582-521;;013-204-928-410-151;;061-859-656-899-093;;080-480-704-978-03X,10.1126/science.287.5461.2185;;10731132;;10.1093/nar/21.18.4344;;8414990;;pmc310070;;9812895;;10.1126/science.282.5392.1315;;10.1016/j.vph.2009.11.009;;19962454;;17544401;;10.1016/j.febslet.2007.05.046;;15994074;;10.1016/j.copbio.2005.06.004;;1458545;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;10944397;;12416978;;10.1021/bi020537k;;10.1084/jem.20070846;;pmc2413039;;18519646;;pmc1905094;;10.1046/j.1365-2249.1998.00720.x;;9822271;;10.1016/s0021-9258(19)61975-7;;7961834;;10.1016/s0969-2126(97)00166-4;;9016717;;10.2210/pdb1eiy/pdb;;18165356;;10.1096/fj.07-9973com;;10.1016/s0969-2126(02)00699-8;;12005430;;19710017;;10.1074/jbc.m109.030692;;019710017;;pmc2781443;;1992490;;10.1073/pnas.88.3.976;;pmc50937;;15627054;;10.1016/s0021-9258(19)84749-x;;2674137;;10.3410/f.9293.359529;;10.1038/ng1727;;16429158;;18197801;;10.1615/critrevimmunol.v27.i6.60;;pmc2706086;;10.1016/j.chembiol.2009.03.006;;19477417;;10.1126/science.1135308;;17185560;;10.1038/nsmb722;;10.2210/pdb1ulh/pdb;;14730354;;16233987;;10.1016/j.cbpa.2005.10.007;;16702215;;10.1074/jbc.m601189200;;14569199;;10.1097/00002281-200311000-00005;;16801548;;pmc1502431;;10.1073/pnas.0601167103;;pmc2822721;;10.1016/j.tins.2009.11.001;;20152552;;17185601;;10.1126/science.1131262;;10.1073/pnas.0705055104;;pmc2040883;;17595294;;10.1007/978-1-4684-6831-1_14;;10.1016/0378-1119(94)00634-5;;7721108;;12237313;;10.1074/jbc.m207934200;;10.1080/15216540600735974;;17002984;;7806522;;10.1016/s0021-9258(20)30081-8;;10.4049/jimmunol.170.6.2904;;12626541;;17942888;;10.1158/0008-5472.can-07-2377;;16982418;;10.1016/j.neuron.2006.08.027;;18057449;;10.1007/s12010-007-8003-4;;16997858;;10.1189/jlb.0306227;;10.1073/pnas.0905339106;;pmc2702257;;19561293;;10.1002/art.1780350718;;1622421;;10.1189/jlb.1003495;;15155777;;12052707;;10.1016/s0169-409x(02)00020-0;;10.1073/pnas.012602099;;pmc117534;;11773626;;11956181;;10.1074/jbc.c200126200;;10102815;;10.1126/science.284.5411.147;;12538453;;15029827;;10.1017/s0033583503003901;;10.1093/nar/23.8.1307;;7753621;;pmc306854,"Protein Purification. (Amersham Parmacia Biotech AB. 1999.;;Office Action for U.S. Appl. No. 12/492,925, mailed on Jan. 6, 2012.;;Office Action for U.S. Appl. No. 12/492,925, mailed on Jun. 11, 2012.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/048915, dated Jan. 5, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2009/048915, mailed Nov. 2, 2009.;;Office Action for U.S. Appl. No. 12/482,151, mailed Oct. 11, 2011.;;Office Action for U.S. Appl. No. 12/482,151, mailed Mar. 18, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/046910, dated Dec. 13, 2010.;;International Search Report and Written Opinion for International Application No. PCT/US2009/046910, mailed Mar. 4, 2010.;;Supplementary European Search Report for European Application No. EP06838844, dated Mar. 26, 2009.;;Office Action for European Patent Application No. EP 06838844.6, dated Apr. 9, 2009.;;Office Action for U.S. Appl. No. 12/085,884, mailed Jan. 20, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/046106, dated Jun. 4, 2008.;;International Search Report and Written Opinion for International Application No. PCT/US2006/046106, mailed Aug. 9, 2007.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/025642, dated Aug. 30, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/025642, mailed Oct. 29, 2010.;;Office Action for U.S. Appl. No. 12/751,358, mailed Oct. 3, 2011.;;Office Action for U.S. Appl. No. 12/751,358, mailed Mar. 3, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/029377, dated Oct. 4, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/029377, mailed Jan. 26, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/027525, dated Sep. 20, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/027525, mailed Jan. 10, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059964, mailed Aug. 25, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059963, mailed May 12, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2011/000210, mailed Aug. 12, 2011.;;Adams, M. D. et al., ""The genome sequence of drosophila melanogaster,"" Science, 287(5961):2185-2195 (2000).;;Amaar, Y. G. et al., ""Cloning and characterization of the C.elegans histidyl-tRNA synthetase gene,"" Nucleic Acids Research, 21(18):4344-4347 (1993).;;Broun, P. et al., ""Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,"" Science, 282:1315-1317 (1998).;;Brown, M. V. et al., ""Mammalian aminoacyl-tRNA synthetases: cell signaling functions of the protein translation machinery,"" Vascular Pharmacology, 52(1-2):21-26 (2010).;;Cader et al., ""Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy,"" FEBS Letters, 581(16):2959-2964 (2007).;;Chica, R. A. et al., ""Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design,"" Curr. Opin. Biotechnol., 16:378-384 (2005).;;Delgado, C. et al., ""The uses and properties of PEG-linked proteins,"" Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304 (1992).;;Devos, D. et al., ""Practical limits of function prediction,"" Proteins: Structure, Function, and Genetics, 41:98-107 (2000).;;EBI Accession No. GSP: ARB30818, ""Cotton protein for improving plant biological properties, 100753,"" (retrieved Oct. 20, 2009).;;Ewalt, K. L. et al., ""Activation of Angiogenic Signaling Pathways by Two Human tRNA Synthetases,"" Biochemistry, 41:13344-13349 (2002).;;Frommhold, D. et al., ""Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation,"" Journal of Experimental Medicine, 205(6):1435-1446 (2008).;;Garcia-Lozano, J. R. et al., ""Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region,"" Clin. Exp. Immunol., 114:161-165 (1998).;;Ge, Q. et al., ""Primary Structure and Functional Expression of Human Glycyl-tRNA Synthetase, an Autoantigen in Myositis,"" The Journal of Biological Chemistry, 269(46): 28790-28797 (1994).;;GenBank Accession No. AA174042, Sep. 30, 1997.;;GenBank Accession No. A1963202, Aug. 20, 1999.;;GenBank Accession No. AK074524, Mar. 25, 2002.;;GenBank Accession No. AU126197, Oct. 23, 2000.;;GenBank Accession No. AW976267, Jun. 2, 2000.;;GenBank Accession No. B1258770, Jul. 16, 2001.;;GenBank Accession No. BP423196, May 27, 2005.;;GenBank Accession No. CA314607, Nov. 4, 2002.;;GenBank Accession No. DA018291, Nov. 2, 2005.;;GenBank Accession No. DA386636, Nov. 5, 2005.;;GenBank Accession No. DA478765, Nov. 6, 2005.;;GenBank Accession No. DA552410, Nov. 5, 2005.;;GenBank Accession No. DA576766, Nov. 5, 2005.;;GenBank Accession No. DB488998, Mar. 31, 2006.;;GenBank Accession No. DC366890, Apr. 27, 2007.;;GenBank Accession No. DB058369, Dec. 10, 2005.;;GenBank Accession No. Q9VV60, published May 1, 2000.;;GenBank Accession No. Q7QD89, Anopheles gambiae Sequence Committee, submitted Apr. 2002 (Retrieved from the Internet on Apr. 24, 2007): http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=74803944.;;GenBank Accession No. U09510, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/595304, Apr. 1, 2010.;;GenBank Accession No. U09587, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/600726, Apr. 1, 2010.;;GenBank Accession No. CR594947, ""full-length cDNA clone CSODE014YCO3 of Placenta of Homo sapiens (human),"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/50475754, Mar. 25, 2010.;;Goldgur, Y. et al., ""The crystal structure of phenylalanyl-tRNA synthetase from Thermus thermophilus complexed with cognate tRNA,"" Structure, 5:59-68 (1997).;;Greenberg, Y. et al., ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells,"" FASEB Journal, 22(5):1597-1605 (2008).;;Guijarro, J. I. et al., ""Structure and Dynamics of the Anticodon Arm Binding Domain of Bacillus stearothermophilus Tyrosyl-tRNA Synthetase,"" Structure, 10:311-317 (2002).;;Guo, R-T. et al., ""Crystal structures and biochemical analyses suggest a unique mechanism and role for human glycyl-tRNA synthetase in Ap4A homeostasis,"" Journal of Biological Chemistry, 284(42):28968-28976 (2009).;;Hou, Y-M. et al., ""Sequence determination and modeling of structural motifs for the smallest monomeric aminoacyl-tRNA synthetase,"" Proc. Nat. Acad. Sci., 88(3):976-980 (1991).;;Ivakhno, S. S. et al., ""Cytokine-Like Activities of Some Aminoacyl-tRNA Synthetases and Auxiliary p43 Cofactor of Aminoacylation Reaction and Their Role in Oncogenesis,"" Exp. Oncol., 26(4):250-255 (2004).;;Jacobo-Molina, A. et al., ""cDNA Sequence, Predicted Primary Structure, and Evolving Amphiphilic Helix of Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 264(28):16608-16612 (1989).;;Jordanova, A. et al., ""Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy,"" Nature Genetics, 38(2):197-202 (2006).;;Jura, M. et al., ""Comprehensive Insight into Human Aminoacyl-tRNA Synthetases as Autoantigens in Idiopathic Inflammatory Myopathies,"" Critical Reviews in Immunology, 27(6):559-572 (2007).;;Kapoor, M. et al., ""Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase,"" Chemistry & Biology, 16(5):531-539 (2009).;;Kimchi-Sarfaty, C. et al., ""A 'Silent' polymorphism in the MDR1 gene changes substrate specificty,"" Science, 315:525-528 (2007).;;Kise, Y. et al., ""A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase,"" Nature Structural & Molecular Biology, 11(2):149-156 (2004).;;Kochendoerfer, G. G., ""Site-specific polymer modification of therapeutic proteins,"" Current Opinion in Chemical Biology, 9:555-560 (2005).;;Kovaleski, B. J. et al., ""In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase,"" J. Bio. Chem., 281(28):9449-9456 (2006).;;Levine, S. M. et al., ""Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies,"" Current Opinion in Rheumatology, 15(6):708-713 (2003).;;Link, A. J. et al., ""Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids, "" Proc. Nat. Acad. Sci., 103(27):10180-10185 (2006).;;Molecular Modeling Database (MMDB), ""Solution Structures of the Whep-trs domain of human histidyl-trna synthetase,"" MMDB ID No. 35920, available for www.ncbi.nlm.nih.gov/Structure/mmdb (accessed Aug. 24, 2012).;;Motley, W. W. et al., ""GARS axonopathy: not every neuron's cup of tRNA,"" Trends Neurosci., 33(2):59 (2010).;;Nackley et al., ""Human Caechol-O-Methytransferase haplotypes modulate protein expression by altering mRNA secondary structure,"" Science, 314:1930-1933 (2006).;;Nangle, L. A. et al., ""Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect,"" PNAS, 104(27):11239-11244 (2007).;;Ngo, J. T. et al., ""Computational complexity, protein structure prediction, and the Levinthal paradox,"" The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495 (1994).;;Nichols, R. C. et al., ""Human isoleucyl-tRNA synthetase: sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension,"" Gene, 155(2):299-304 (1995).;;Park, S. G. et al., ""Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis,"" The Journal of Biological Chemistry, 277(47):45243-45248 (2002).;;Park, S. G. et al., ""Is there an answer? Do aminoacyl-tRNA synthetases have biological functions other than in protein biosynthesis?"" IUBMB Life, 58(9):556-558 (2006).;;Quesniaux, V. F.J. et al., ""Hematopoiesis, including lymphocyte developmet and maturation,"" Principles of Immunopharmacology, 2005-A, pp. 3-17 (2005).;;Reed, V. S. et al., ""Characterization of a Novel N-terminal Peptide in Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 269(52):32937-32941 (1994).;;Richardson, R. M. et al., ""Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation,"" Journal of Immunology, 170(6):2904-2911 (2003).;;Sauna, Z. E. et al., ""Silent polymorhisms speak: How they affect pharmacogenomics and the treatment of cancer,"" Cancer Res., 67(20):9609-9612 (2007).;;Seburn, K. L. et al., ""An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model,"" Neuron, 51(6):715-726 (2006).;;Sen, S. et al., ""Developments in directed evolution for improving enzyme functions,"" Appl. Biochem. Biotechnol., 143:212-223 (2007).;;Smith, D. F. et al., ""Leukocyte phosphoinositide-3 kinase y is required for chemokine-induced, sustained adhesion under flow in vivo,"" Journal of Leukocyte Biology, 80(6):1491-1499 (2006).;;Storkebaum, E. et al., ""Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy,"" PNAS, 106(28):11782-11787 (2009).;;Targoff, I. N. et al., ""Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease,"" Arthritis Rheum., 35(7):821-830 (1992).;;Traves, S. L. et al., ""Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2,"" Journal of Leukocyte Biology, 76(2):441-450 (2004).;;Veronese, F. M. et al., ""Preface: Introduction and overview of peptide and protein pegylation,"" Advanced Drug Delivery Reviews, 54:453-456 (2002).;;Wakasugi, K. et al., ""A human aminoacyl-tRNA synthetase as a regulator of angiogenesis,"" Proc. Natl. Acad. Sci., 99(1):173-177 (2002).;;Wakasugi, K. et al., ""Induction of angiogenesis by a frament of human tyrosyl-tRNA synthetase,"" The Journal of Biological Chemistry, 277(23):20124-20126 (2002).;;Wakasugi, K. et al., ""Two distinct cytokines released from a human aminoacyl-tRNA synthetase,"" Science, 284:147-151 (1999).;;Wasenius, V-M et al., ""Hepatocyte Growth Factor Receptor, Matrix Metalloproteinase-11, Tissue Inhibitor of Metalloproteinase-1, and Fibronectin Are Up-Regulated in Papillary Thyroid Carcinoma: a cDNA and Tissue Microarray Study,"" Clin. Cancer Res., 9:68-75 (2003).;;Whisstock, J. C. et al., ""Prediction of protein function from protein sequence,"" Q. Rev. Biophysics., 36(3):307-340 (2003).;;Williams et al., ""Cloning, sequencing and bacterial expression of human glycine tRNA synthetase,"" Nucleic Acids Res., 23(8):1307-1310 (1995).",ACTIVE
76,US,A1,US 2010/0028352 A1,037-145-847-874-134,2010-02-04,2010,US 49292509 A,2009-06-26,US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2009-08-20),https://lens.org/037-145-847-874-134,Patent Application,yes,49,96,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,A61K39/395;;A61K31/7088;;A61K38/43;;C07H21/04;;C12N5/00;;C12N5/02;;C12N9/00;;C12N15/63;;C12Q1/68;;G01N33/53;;G01N33/573,424/139.1;;435/183;;536/23.2;;435/320.1;;435/325;;435/375;;424/94.1;;X514 44  R;;435/6;;435/7.1;;435/7.4,1,1,110-114-372-343-72X,17544401;;10.1016/j.febslet.2007.05.046,"Cader et al. Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy. FEBS Lett. 2007 Jun 26;581(16):2959-64. Epub 2007 May 29.",ACTIVE
77,JP,A,JP 2016154561 A,091-582-044-694-184,2016-09-01,2016,JP 2016104002 A,2016-05-25,US 7609808 P;;US 9554808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"PROBLEM TO BE SOLVED: To provide compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities.SOLUTION: Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. In certain embodiments, a non-canonical biological activity exhibited by a GlyRS polypeptide of the invention may include, but is not limited to, modulation of cell proliferation, modulation of apoptosis, modulation of cell migration, modulation of cell signaling and/or modulation of cytokine production and/or secretion.SELECTED DRAWING: Figure 2",ATYR PHARMA INC,LESLLE ANN GREENE;;RYAN ANDREW ADAMS;;HONG FEI;;ZHAO JI;;EVA REBECKA STEPHANIE ARMOUR;;KRISTI HELEN PIEHL,,https://lens.org/091-582-044-694-184,Patent Application,no,2,0,20,20,11,A61K38/53;;C07K16/40;;C12N9/93;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C07K2319/00;;C12Y601/01014;;C12N9/93;;A61K38/53;;C12N15/102;;C12N9/96;;A61P25/00;;A61P29/00;;A61P3/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;C12Y601/01014;;C12N9/93;;C12N9/96;;A61K38/53;;C07K1/14;;C12N15/102,C12N9/00;;A61K38/53;;A61K39/395;;A61K48/00;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/06;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/09;;C12Q1/02,,0,0,,,,DISCONTINUED
78,US,B2,US 9585946 B2,097-734-818-466-854,2017-03-07,2017,US 201514844666 A,2015-09-03,US 201514844666 A;;US 201414262247 A;;US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/097-734-818-466-854,Granted Patent,yes,99,1,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/00;;A61K38/43;;A61K38/53;;C07K1/14;;C12N9/96;;C12N15/00;;C12N15/10;;C12P21/04;;C12P21/06,,100,49,065-727-315-943-720;;074-484-564-852-275;;058-442-026-595-149;;005-134-238-831-599;;069-966-428-216-793;;018-694-717-457-677;;008-120-631-983-38X;;016-719-496-909-822;;110-114-372-343-72X;;072-370-062-059-009;;100-286-864-518-416;;000-938-322-005-89X;;042-538-952-084-036;;061-440-907-424-357;;124-597-012-019-86X;;010-104-034-278-991;;124-051-595-355-739;;069-284-161-422-046;;137-947-974-286-554;;057-924-326-482-635;;031-357-957-515-526;;064-734-728-506-958;;003-833-567-529-198;;061-877-472-955-053;;048-224-553-579-724;;075-329-526-485-685;;043-049-550-318-61X;;069-909-492-133-801;;061-756-489-300-343;;024-848-900-594-940;;050-112-382-936-584;;005-508-391-866-003;;186-769-565-336-221;;006-032-167-067-384;;010-063-101-427-224;;057-586-627-671-06X;;112-807-205-590-664;;038-537-780-543-160;;103-932-348-507-545;;017-823-334-797-983;;002-116-605-784-264;;079-728-014-732-885;;031-195-957-275-914;;001-572-426-072-168;;049-582-995-278-861;;104-710-913-908-169;;080-312-409-237-586;;018-625-854-727-523;;035-778-345-312-446,10.1016/s0021-9258(19)61975-7;;7961834;;10.1126/science.287.5461.2185;;10731132;;10.1093/nar/21.18.4344;;8414990;;pmc310070;;10.1523/jneurosci.1671-06.2006;;17035524;;pmc6674701;;19593442;;pmc2704870;;10.1371/journal.pone.0006218;;19412816;;10.3109/17482960902849823;;pmc2864347;;9812895;;10.1126/science.282.5392.1315;;10.1016/j.vph.2009.11.009;;19962454;;17544401;;10.1016/j.febslet.2007.05.046;;15994074;;10.1016/j.copbio.2005.06.004;;1458545;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.3.co;2-j;;10.1002/1097-0134(20001001)41:1<98::aid-prot120>3.0.co;2-s;;10944397;;12416978;;10.1021/bi020537k;;10.1084/jem.20070846;;pmc2413039;;18519646;;pmc1905094;;10.1046/j.1365-2249.1998.00720.x;;9822271;;10.1016/s0969-2126(97)00166-4;;9016717;;10.2210/pdb1eiy/pdb;;18165356;;10.1096/fj.07-9973com;;10.1016/s0969-2126(02)00699-8;;12005430;;19710017;;10.1074/jbc.m109.030692;;019710017;;pmc2781443;;10.1016/j.febslet.2009.11.064;;19932696;;pmc2826164;;20700144;;10.1038/nrm2956;;pmc3042954;;pmc2583229;;10.1111/j.1574-6976.2008.00119.x;;18522650;;1992490;;10.1073/pnas.88.3.976;;pmc50937;;15627054;;10.1016/s0021-9258(19)84749-x;;2674137;;10.3410/f.9293.359529;;10.1038/ng1727;;16429158;;18197801;;10.1615/critrevimmunol.v27.i6.60;;pmc2706086;;10.1016/j.chembiol.2009.03.006;;19477417;;10.1126/science.1135308;;17185560;;10.1038/nsmb722;;10.2210/pdb1ulh/pdb;;14730354;;16233987;;10.1016/j.cbpa.2005.10.007;;16702215;;10.1074/jbc.m601189200;;14569199;;10.1097/00002281-200311000-00005;;16801548;;pmc1502431;;10.1073/pnas.0601167103;;10.1371/journal.pgen.1002399;;pmc3228828;;22144914;;pmc2822721;;10.1016/j.tins.2009.11.001;;20152552;;17185601;;10.1126/science.1131262;;10.1073/pnas.0705055104;;pmc2040883;;17595294;;10.1007/978-1-4684-6831-1_14;;10.1016/0378-1119(94)00634-5;;7721108;;10.1073/pnas.0802862105;;18682559;;pmc2516211;;12237313;;10.1074/jbc.m207934200;;10.1080/15216540600735974;;17002984;;pmc3306665;;10.1073/pnas.1200194109;;22345558;;7806522;;10.1016/s0021-9258(20)30081-8;;10.4049/jimmunol.170.6.2904;;12626541;;17942888;;10.1158/0008-5472.can-07-2377;;16982418;;10.1016/j.neuron.2006.08.027;;18057449;;10.1007/s12010-007-8003-4,"Ge et al. Primary structure and functional expression of human Glycyl-tRNA synthetase, an autoantigen in myositis. J Biol Chem. Nov. 18, 1994;269(46):28790-7.;;Office Action for U.S. Appl. No. 12/492,925, mailed on Jan. 6, 2012.;;Office Action for U.S. Appl. No. 12/492,925, mailed on Jun. 11, 2012.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/048915, dated Jan. 5, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2009/048915, mailed Nov. 2, 2009.;;Office Action for U.S. Appl. No. 13/753,272, mailed on Jul. 19, 2013.;;Office Action for U.S. Appl. No. 12/482,151, mailed Oct. 11, 2011.;;Office Action for U.S. Appl. No. 12/482,151, mailed Mar. 18, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/046910, dated Dec. 13, 2010.;;International Search Report and Written Opinion for International Application No. PCT/US2009/046910, mailed Mar. 4, 2010.;;Supplementary European Search Report for European Application No. 06838844.6, mailed Apr. 9, 2009.;;Office Action for European Patent Application No. 06838844.6, mailed Apr. 9, 2009.;;Office Action for U.S. Appl. No. 12/085,884, mailed Jan. 20, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2006/046106, dated Jun. 4, 2008.;;International Search Report and Written Opinion for International Application No. PCT/US2006/046106, mailed Aug. 9, 2007.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/025642, dated Aug. 30, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/025642, mailed Oct. 29, 2010.;;Office Action for U.S. Appl. No. 12/751,358, mailed Oct. 3, 2011.;;Office Action for U.S. Appl. No. 12/751,358, mailed Mar. 3, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/029377, dated Oct. 4, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/029377, mailed Jan. 26, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/027525, dated Sep. 20, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/027525, mailed Jan. 10, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059964, mailed Aug. 25, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2010/059963, mailed May 12, 2011.;;International Search Report and Written Opinion for International Application No. PCT/US2011/000210, mailed Aug. 12, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2011/043756, dated Jan. 15, 2013.;;Adams, M. D. et al., ""The genome sequence of drosophila melanogaster,"" Science, 287(5961):2185-2195 (2000).;;Amaar, Y. G. et al., ""Cloning and characterization of the C.elegans histidyl-tRNA synthetase gene,"" Nucleic Acids Research, 21(18):4344-4347 (1993).;;Antonellis, A. et al., ""Functional Analyses of Glycyl-tRNA Synthetase Mutations Suggest a Key Role for tRNA-Charging Enzymes in Peripheral Axons,"" The Journal of Neuroscience, 26(41):10397-10406 (2006).;;Banks, G. T. et al., ""Mutant Glycyl-tRNA Synthetase (Gars) Ameliorates SOD1G93A Motor Neuron Degeneration Phenotype but Has Little Affect on Loa Dynein Heavy Chain Mutant Mice,"" PLoS One, 4(7):e6218 (2009).;;Blumen, S. C. et al., ""Mutational analysis of glycyl-tRNA synthetase (GARS) gene in Hirayama Disease,"" Amyotroph Lateral Scler., 11(1-2):237-239 (2010).;;Broun, P. et al., ""Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,"" Science, 282:1315-1317 (1998).;;Brown, M. V. et al., ""Mammalian aminoacyl-tRNA synthetases: Cell signaling functions of the protein translation machinery,"" Vascular Pharmacology, 52(1-2):21-26 (2010).;;Cader, M. Z. et al., ""Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy,"" FEBS Letters, 581(16):2959-2964 (2007).;;Chica, R. A. et al., ""Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design,"" Curr. Opin. Biotechnol., 16:378-384 (2005).;;Delgado, C. et al., ""The uses and properties of PEG-linked proteins,"" Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304 (1992).;;Devos, D. et al., ""Practical limits of function prediction,"" Proteins: Structure, Function, and Genetics, 41:98-107 (2000).;;EBI Accession No. GSP: ARB30818, ""Cotton protein for improving plant biological properties, 100753,"" retrieved Oct. 20, 2009.;;Ewalt, K. L. et al., ""Activation of Angiogenic Signaling Pathways by Two Human tRNA Synthetases,"" Biochemistry, 41(45):13344-13349 (2002).;;Frommhold, D. et al., ""Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation,"" Journal of Experimental Medicine, 205(6):1435-1446 (2008).;;Garcia-Lozano, J. R. et al., ""Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region,"" Clin. Exp. Immunol., 114:161-165 (1998).;;GenBank Accession No. AK074524, Mar. 25, 2002.;;GenBank Accession No. AU126197, Oct. 23, 2000.;;GenBank Accession No. AW976267, Jun. 2, 2000.;;GenBank Accession No. B1258770, Jul. 16, 2001.;;GenBank Accession No. BP423196, May 27, 2005.;;GenBank Accession No. CA314607, Nov. 4, 2002.;;GenBank Accession No. DA018291, Nov. 2, 2005.;;GenBank Accession No. DA386636, Nov. 5, 2005.;;GenBank Accession No. DA478765, Nov. 6, 2005.;;GenBank Accession No. DA552410, Nov. 5, 2005.;;GenBank Accession No. DA576766, Nov. 5, 2005.;;GenBank Accession No. DB488998, Mar. 31, 2006.;;GenBank Accession No. DC366890, Apr. 27, 2007.;;GenBank Accession No. DB058369, Dec. 10, 2005.;;GenBank Accession No. AA174042, Sep. 30, 1997.;;GenBank Accession No. A1963202, Aug. 20, 1999.;;GenBank Accession No. CR594947, ""full-length cDNA clone CS0DE014YC03 of Placenta of Homo sapiens (human),"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/50475754, Mar. 25, 2010.;;GenBank Accession No. Q7QD89, Anopheles gambiae Sequence Committee, submitted Apr. 2002, [Retrieved from the Internet Apr. 24, 2007], .;;GenBank Accession No. Q9W60, published May 1, 2000.;;GenBank Accession No. U09510, ""Human glycyl-tRNA synthetase mRNA, complete cds,"" retrieved from http://www.ncbi.nlm.nih.gov/nuccore/595304, Apr. 1, 2010.;;GenBank Accession No. U09587, Human glycyl-tRNA synthetase mRNA, complete cds, Dec. 9, 1994.;;Goldgur, Y. et al., ""The crystal structure of phenylalanyl-tRNA synthetase from Thermus thermophilus complexed with cognate tRNA,"" Structure, 5:59-68 (1997).;;Greenberg, Y. et al., ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells,"" FASEB Journal, 22(5):1597-1605 (2008).;;Guijarro, J. I. et al., ""Structure and Dynamics of the Anticodon Arm Binding Domain of Bacillus stearothermophilus Tyrosyl-tRNA Synthetase,"" Structure, 10:311-317 (2002).;;Guo, R-T. et al., ""Crystal structures and biochemical analyses suggest a unique mechanism and role for human glycyl-tRNA synthetase in Ap4A homeostasis,"" Journal of Biological Chemistry, 284(42):28968-28976 (2009).;;Guo, M. et al., ""Functional expansion of human tRNA synthetases achieved by structural inventions,"" FEBS Letters, 584(2):434-442 (2010).;;Guo, M. et al., ""New functions of aminoacyl-tRNA synthetases beyond translation,"" Nature Reviews Molecular Cell Biology, 11:668-674 (2010).;;Hausmann, C. D. et al., ""Aminoacyl-tRNA synthetase complexes: molecular multitasking revealed,"" FEMS Microbiol. Rev., 32(4):705-721 (2008).;;Hou, Y-M. et al., ""Sequence determination and modeling of structural motifs for the smallest monomeric aminoacyl-tRNA synthetase,"" Proc. Nat. Acad. Sci., 88(3):976-980 (1991).;;Ivakhno, S. S. et al., ""Cytokine-Like Activities of Some Aminoacyl-tRNA Synthetases and Auxiliary p43 Cofactor of Aminoacylation Reaction and Their Role in Oncogenesis,"" Exp. Oncol., 26(4):250-255 (2004).;;Jacobo-Molina, A. et al., ""cDNA Sequence, Predicted Primary Structure, and Evolving Amphiphilic Helix of Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 264(28):16608-16612 (1989).;;Jordanova, A. et al., ""Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy,"" Nature Genetics, 38(2):197-202 (2006).;;Jura, M. et al., ""Comprehensive Insight into Human Aminoacyl-tRNA Synthetases as Autoantigens in Idiopathic Inflammatory Myopathies,"" Critical Reviews in Immunology, 27(6):559-572 (2007).;;Kapoor, M. et al., ""Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase,"" Chemistry & Biology, 16(5):531-539 (2009).;;Kimchi-Sarfaty, C. et al., ""A 'Silent' polymorphism in the MDR1 gene changes substrate specificty,"" Science, 315:525-528 (2007).;;Kise, Y. et al., ""A short peptide insertion crucial for angiostatic activity of human tryptophanyl-tRNA synthetase,"" Nature Structural & Molecular Biology, 11(2):149-156 (2004).;;Kochendoerfer, G. G., ""Site-specific polymer modification of therapeutic proteins,"" Current Opinion in Chemical Biology, 9:555-560 (2005).;;Kovaleski, B. J. et al.,""In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase,"" J. Bio. Chem., 281(28):19449-19456 (2006).;;Levine, S. M. et al., ""Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies,"" Current Opinion in Rheumatology, 15(6):708-713 (2003).;;Link, A. J. et al., ""Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids,"" Proc. Nat. Acad. Sci., 103(27):10180-10185 (2006).;;Molecular Modeling Database (MMDB), ""Solution Structures of the Whep-trs domain of human histidyl-trna synthetase,"" MMDB ID No. 35920, available for www.ncbi.nlm.nih.gov/Structure/mmdb, accessed Aug. 24, 2012.;;Motley et al., ""Charcot-Marie-Tooth-Linked Mutant GARS is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels,"" PLoS Genetics, 7(12):e1002399 (2011).;;Motley, W. W. et al., ""GARS axonopathy: not every neuron's cup of tRNA,"" Trends Neurosci., 33(2):59 (2010).;;Nackley, A. G. et al., ""Human Caechol-O-Methytransferase haplotypes modulate protein expression by altering mRNA secondary structure,"" Science, 314:1930-1933 (2006).;;Nangle, L. A. et al., ""Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect,"" PNAS, 104(27):11239-11244 (2007).;;Ngo, J. T. et al., ""Computational complexity, protein structure prediction, and the Levinthal paradox,"" In the Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495 (1994).;;Nichols, R. C. et al., ""Human isoleucyl-tRNA synthetase: sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension,"" Gene, 155(2):299-304 (1995).;;Park, S. G., et al., ""Aminoacyl tRNA synthetases and their connections to disease,"" PNAS, 105(32):11043-11049 (2008).;;Park, S. G. et al., ""Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis,"" The Journal of Biological Chemistry, 277(47):45243-45248 (2002).;;Park, S. G. et al., ""Is there an answer? Do aminoacyl-tRNA synthetases have biological functions other than in protein biosynthesis?"" IUBMB Life, 58(9):556-558 (2006).;;Park, M. C. et al., ""Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis,"" Proc. Natl. Acad. Sci. USA [online], Retrieved from the Internet: , Published on Feb. 15, 2012.;;Protein Purification-Handbook, Amersham Parmacia Biotech AB (1999).;;Quesniaux, V. F.J. et al., ""Hematopoiesis, including lymphocyte developmet and maturation,"" Principles of Immunopharmacology, pp. 3-17 (2005).;;Reed, V. S. et al., ""Characterization of a Novel N-terminal Peptide in Human Aspartyl-tRNA Synthetase,"" Journal of Biological Chemistry, 269(52):32937-32941 (1994).;;Richardson, R. M. et al., ""Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation,"" Journal of Immunology, 170(6):2904-2911 (2003).;;Sauna, Z. E. et al., ""Silent polymorhisms speak: How they affect pharmacogenomics and the treatment of cancer,"" Cancer Res., 67(20):9609-9612 (2007).;;Seburn, K. L. et al., ""An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model,"" Neuron, 51(6):715-726 (2006).;;Sen, S. et al., ""Developments in directed evolution for improving enzyme functions,"" Appl. Biochem. Biotechnol., 143:212-223 (2007).",ACTIVE
79,EP,A1,EP 3176261 A1,005-601-540-267-001,2017-06-07,2017,EP 16183399 A,2009-06-26,US 7609808 P;;US 9554808 P;;EP 09771180 A,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
",ATYR PHARMA INC,PIEHL KRISTI HELEN;;GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE,,https://lens.org/005-601-540-267-001,Patent Application,yes,24,0,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/64;;A61K38/53;;C07K1/14;;C12N9/96,,73,49,018-625-854-727-523;;031-195-957-275-914;;124-051-595-355-739;;010-475-981-497-60X;;062-200-278-153-884;;038-383-743-124-048;;026-164-216-541-151;;082-474-862-036-218;;032-728-154-591-070;;085-764-009-624-439;;028-862-168-091-90X;;056-201-471-905-934;;090-327-557-741-105;;095-849-513-154-961;;025-930-820-482-18X;;050-112-382-936-584;;010-884-480-301-434;;098-439-753-482-558;;049-687-215-716-359;;099-036-591-479-160;;000-399-172-683-854;;035-545-255-869-788;;007-141-101-622-305;;052-235-244-371-629;;019-206-191-830-81X;;003-931-599-928-408;;189-324-868-412-25X;;036-433-596-884-038;;026-944-353-804-488;;073-446-761-167-644;;064-187-018-698-676;;055-841-217-829-293;;077-191-630-888-015;;004-287-544-762-57X;;002-264-966-090-625;;066-523-748-390-895;;079-951-457-685-944;;061-625-607-036-599;;124-569-704-081-471;;042-204-626-457-327;;045-094-249-115-990;;006-574-964-805-278;;073-446-761-167-644;;046-741-248-612-500;;059-393-958-757-089;;034-469-385-219-320;;059-393-958-757-089;;034-469-385-219-320;;142-164-369-109-701,16982418;;10.1016/j.neuron.2006.08.027;;10.1080/15216540600735974;;17002984;;18165356;;10.1096/fj.07-9973com;;10.1073/pnas.012602099;;pmc117534;;11773626;;2314296;;10.1016/0076-6879(90)83041-7;;10.1093/bioinformatics/5.2.151;;2720464;;3382986;;10.1093/bioinformatics/4.1.11;;pmc393452;;6572363;;10.1073/pnas.80.3.726;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;2936651;;10.1016/0378-1119(85)90022-8;;pmc386907;;3095831;;10.1073/pnas.83.21.8258;;12052707;;10.1016/s0169-409x(02)00020-0;;16233987;;10.1016/j.cbpa.2005.10.007;;10.1016/0076-6879(87)53076-2;;2828848;;15981328;;10.1002/j.1460-2075.1987.tb04755.x;;pmc553396;;6719112;;10.1126/science.6719112;;1803426;;10.1007/978-3-540-46712-0_7;;pmc43548;;10.1073/pnas.91.8.3224;;8159729;;pmc345277;;10.1073/pnas.81.12.3655;;6587381;;10.1007/978-3-540-48037-2_6;;8036313;;10.1016/0092-8674(77)90333-6;;194704;;10.1073/pnas.77.6.3567;;pmc349658;;6251468;;10.1016/0022-2836(81)90321-1;;6271971;;pmc282351;;10.1073/pnas.85.21.8047;;3054879;;8528414;;10.1385/0-89603-328-7:121;;10.1021/ja00897a025;;2197980;;10.1146/annurev.bi.59.070190.002255;;10.1146/annurev.biochem.59.1.439;;825377;;10.1002/eji.1830060713;;pmc427010;;4560694;;10.1073/pnas.69.9.2659;;938638;;10.1021/bi00657a034;;10.1021/bi00558a029;;6157405;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;1987490;;10.1038/349293a0;;10.1073/pnas.86.11.4220;;2726771;;pmc287422;;3584980;;3555775;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;10.1038/321522a0;;3713831;;2197980;;10.1146/annurev.bi.59.070190.002255;;10.1146/annurev.biochem.59.1.439;;10.1385/mb:24:2:111;;12746552;;10.1038/35078107;;11373684;;11726523;;10.1093/emboj/20.23.6877;;pmc125328;;10.1038/35078107;;11373684;;11726523;;10.1093/emboj/20.23.6877;;pmc125328;;10.1021/bk-1994-0580.ch002,"SEBURN KEVIN L ET AL: ""An active dominant mutation of Glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model"", NEURON, vol. 51, no. 6, September 2006 (2006-09-01), pages 715 - 726, XP002551146, ISSN: 0896-6273;;PARK SANG GYU ET AL: ""Do aminoacyl-tRNA synthetases have biological functions other than in protein biosynthesis?"", IUBMB LIFE, vol. 58, no. 9, September 2006 (2006-09-01), pages 556 - 558, XP002551147, ISSN: 1521-6543;;GREENBERG Y ET AL: ""The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells"", FASEB JOURNAL, vol. 22, no. 5, May 2008 (2008-05-01), pages 1597 - 1605, XP002551148, ISSN: 0892-6638;;WAKASUGI, PROC. NATL. ACAD. SCI., vol. 99, 2002, pages 173 - 177;;SAMBROOK: ""Molecular Cloning: A Laboratory Manual"", 1989;;MANIATIS: ""Molecular Cloning: A Laboratory Manual"", 1982;;""DNA Cloning: A Practical Approach"", vol. I & II;;""Oligonucleotide Synthesis"", 1984;;""Nucleic Acid Hybridization"", 1985;;""Transcription and Translation"", 1984;;""Animal Cell Culture"", 1986;;""A Practical Guide to Molecular Cloning"", 1984;;DAYHOFF, M.O.: ""Atlas of Protein Sequence and Structure"", vol. 5, 1978, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, article ""A model of evolutionary change in proteins - Matrices for detecting distant relationships"", pages: 345 - 358;;HEIN J.: ""Methods in Enzymology"", vol. 183, 1990, ACADEMIC PRESS, INC., article ""Unified Approach to Alignment and Phylogenes"", pages: 626 - 645;;HIGGINS, D.G.; SHARP, P.M., CAB/OS, vol. 5, 1989, pages 151 - 153;;MYERS, E.W.; MULLER W., CAB/OS, vol. 4, 1988, pages 11 - 17;;ROBINSON, E.D., COMB. THEOR, vol. 11, 1971, pages 105;;SANTOU, N.; NES, M., MOL. BIOI. EVAL., vol. 4, 1987, pages 406 - 425;;SNEATH, P.H.A.; SOKAL, R.R.: ""Numerical Taxonomy- the Principles and Practice of Numerical Taxonomy"", 1973, FREEMAN PRESS;;WILBUR, W.J.; LIPMAN, D.J., PROC. NAT/ACAD., SCI. USA, vol. 80, 1983, pages 726 - 730;;SMITH; WATERMAN, ADD. APL. MATH, vol. 2, 1981, pages 482;;NEEDLEMAN; WUNSCH, J. MOL. BIOI., vol. 48, 1970, pages 443;;PEARSON; LIPMAN, PROC. NAT'/ ACAD. SCI. USA, vol. 85, 1988, pages 2444;;ALTSCHUL, NUCL. ACIDS RES., vol. 25, 1977, pages 3389 - 3402;;ALTSCHUL, J. MOL. BIOI., vol. 215, 1990, pages 403 - 410;;MARATEA, GENE, vol. 40, 1985, pages 39 - 46;;MURPHY, PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 8258 - 8262;;VERONESE; HARRIS, ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 453 - 456;;KOCHENDOERFER, CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 9, 2005, pages 555 - 560;;SAMBROOK: ""Molecular Cloning, A Laboratory Manual"", 1989;;AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1989;;VAN HEEKE; SCHUSTER, J. BIOI. CHERN., vol. 264, 1989, pages 5503 - 5509;;GRANT, METHODS ENZYMOL., vol. 153, 1987, pages 516 - 544;;TAKAMATSU, EMBO J., vol. 6, 1987, pages 307 - 311;;CORUZZI, EMBO J., vol. 3, 1984, pages 1671 - 1680;;BROGLIE ET AL., SCIENCE, vol. 224, 1984, pages 838 - 843;;WINTER, RESULTS PROBL. CELL DIFFER., vol. 17, 1991, pages 85 - 105;;HOBBS: ""Yearbook of Science and Technology"", 1992, MCGRAW HILL, pages: 191 - 196;;ENGELHARD, PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 3224 - 3227;;LOGAN; SHENK, PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 3655 - 3659;;SCHARF, RESULTS PROBL. CELL DIFFER., vol. 20, 1994, pages 125 - 162;;WIGLER, CELL, vol. 11, 1977, pages 223 - 232;;LOWY, CELL, vol. 22, 1990, pages 817 - 823;;WIGLER, PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 3567 - 70;;COLBERE-GARAPIN, J. MOL. BIOI., vol. 150, 1981, pages 1 - 14;;HARTMAN; MULLIGAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 8047 - 51;;RHODES, METHODS MOL. BIOI., vol. 55, 1995, pages 121 - 131;;HAMPTON: ""Serological Methods, a Laboratory Manual"", 1990;;MADDOX, J. EXP. MED., vol. 158, 1983, pages 1211 - 1216;;MERRIFIELD, J. AM. CHERN. SOC., vol. 85, 1963, pages 2149 - 2154;;DAVIES, ANNUAL REV. BIOCHEM., vol. 59, 1990, pages 439 - 473;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;KOHLER; MILSTEIN, EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 519;;INBAR, PROC. NAT. ACAD. SCI. USA, vol. 69, 1972, pages 2659 - 2662;;HOCHMAN, BIOCHEM, vol. 15, 1976, pages 2706 - 2710;;EHRLICH, BIOCHEM, vol. 19, 1980, pages 4091 - 4096;;HUSTON, PROC. NAT. ACAD. SCI. USA, vol. 85, no. 16, 1988, pages 5879 - 5883;;WINTER, NATURE, vol. 349, 1991, pages 293 - 299;;LOBUGLIO, PROC. NAT. ACAD. SCI. USA, vol. 86, 1989, pages 4220 - 4224;;SHAW, J IMMUNOL., vol. 138, 1987, pages 4534 - 4538;;BROWN, CANCER RES., vol. 47, 1987, pages 3577 - 3583;;RIECHMANN, NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN, SCIENCE, vol. 239, 1988, pages 1534 - 1536;;JONES, NATURE, vol. 321, 1986, pages 522 - 525;;DAVIES, ANN. REV. BIOCHEM., vol. 59, 1990, pages 439 - 473;;LAMBERTON, J.S.; CHRISTIAN, A.T., MOLECULAR BIOTECHNOLOGY, vol. 24, 2003, pages 111 - 119;;ELSHABIR, S.M., NATURE, vol. 411, 2001, pages 494 - 498;;ELSHABIR, S.M., EMBO, vol. 20, 2001, pages 6877 - 6888;;EISHABIR, S., NATURE, vol. 411, 2001, pages 494 - 498;;ELSHABIR, S., EMBO J., vol. 20, 2001, pages 6877 - 6888;;HUNZIKER: ""Modern Synthetic Methods"", 1995, VCH, article ""Nucleic Acid Analogues: Synthesis and Properties"", pages: 331 - 417;;MESMAEKER: ""Carbohydrate Modifications in Antisense Research"", 1994, ACS, article ""Novel Backbone Replacements for Oligonucleotides"", pages: 24 - 39;;""Remington's Pharmaceutical Sciences"", pages: 1035 - 1038,157",DISCONTINUED
80,EP,A1,EP 2310498 A1,003-150-252-720-85X,2011-04-20,2011,EP 09771180 A,2009-06-26,US 2009/0048915 W;;US 7609808 P;;US 9554808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,,ATYR PHARMA INC,PIEHL KRISTI HELEN;;GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE,,https://lens.org/003-150-252-720-85X,Patent Application,yes,0,0,20,20,0,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,C12N9/64,,1,0,,,See references of WO 2009158649A1,DISCONTINUED
81,US,A1,US 2016/0114016 A1,109-942-875-422-196,2016-04-28,2016,US 201514844666 A,2015-09-03,US 201514844666 A;;US 201414262247 A;;US 201313753272 A;;US 49292509 A;;US 9554808 P;;US 7609808 P,2008-06-26,COMPOSITIONS AND METHODS COMPRISING GLYCYL-TRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES,"Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.",ATYR PHARMA INC,GREENE LESLIE ANN;;ADAMS RYAN ANDREW;;HONG FEI;;ZHAO JI;;ARMOUR EVA REBECKA STEPHANIE;;PIEHL KRISTI HELEN,ATYR PHARMA INC (2013-07-10),https://lens.org/109-942-875-422-196,Patent Application,yes,0,0,20,20,11,A61K38/53;;A61K38/53;;A61K38/53;;A61P3/00;;A61P9/00;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;C12N9/93;;C07K1/14;;C07K16/40;;C07K2319/00;;C12N9/93;;C12N9/93;;C12N9/96;;C12N9/96;;C12N15/102;;C12N15/102;;C12N15/102;;C12Q1/25;;C12Y601/01014;;C12Y601/01014;;C12Y601/01014,A61K38/53;;C12N9/00;;C12N9/96,,0,0,,,,ACTIVE
82,EP,A2,EP 2482840 A2,187-220-152-389-243,2012-08-08,2012,EP 10807183 A,2010-08-05,US 23237309 P;;US 23238009 P;;US 2010/0044600 W,2009-08-07,VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME,,MANNKIND CORP;;ROSE PHARMA AS,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,MANNKIND CORPORATION (2015-12-16);;ROSE PHARMA A/S (2015-12-16),https://lens.org/187-220-152-389-243,Patent Application,yes,0,0,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61K31/357;;A61K31/496;;A61K38/12;;A61P1/00;;A61P3/10;;A61P9/00,,0,0,,,,DISCONTINUED
83,WO,A4,WO 2011/017554 A4,056-086-833-981-694,2011-09-01,2011,US 2010/0044600 W,2010-08-05,US 23237309 P;;US 23238009 P,2009-08-07,VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.",MANNKIND CORP;;ROSE PHARMA AS;;RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,,https://lens.org/056-086-833-981-694,Patent Application,yes,0,0,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61K31/357;;A61K31/496;;A61P1/00;;A61P3/10;;A61P9/00,,0,0,,,,PENDING
84,US,B2,US 8642548 B2,196-866-580-577-872,2014-02-04,2014,US 201013389410 A,2010-08-05,US 201013389410 A;;US 23237309 P;;US 23238009 P;;US 2010/0044600 W,2009-08-07,Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.",RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE;;MANNKIND CORP;;ROSE PHARMA AS,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,MANNKIND CORPORATION (2011-02-03);;ROSE PHARMA A/S (2011-03-01),https://lens.org/196-866-580-577-872,Granted Patent,yes,19,33,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61P3/10;;A61P7/12;;C07K14/605,514/11.7,9,2,163-026-106-649-788;;129-253-297-372-87X,10.1530/eje.0.1460863;;12039708;;10.1002/1097-4628(20001213)78:12<2213::aid-app190>3.0.co;2-8,"Weissberger, ""Mannkind: Overlooked Biotech With Excellent Prospects (Part V)"" http://www.investorvillage.com/smbd.asp?mb=2885&mn=45817&pt=msg&mid=5021385 (posted on Jun. 19, 2008, accessed on Oct. 18, 2012).;;International Preliminary Report on Patentability, Application No. PCT/US2010/038298 mailed Apr. 3, 2012.;;European Search Report, Application No. 11180288.0 dated Dec. 22, 2011.;;AU Examiners Report, Application No. 2007238000, mailed Mar. 22, 2012.;;CN Office Action cited in Application No. 200880122670.3 mailed on Nov. 23, 2011.;;Hui et al., ""The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects"", European Journal of Endocrinology (2002), 146 : 863-869.;;Glucagon-like peptide-1, http://en.wikipedia.org/wiki/Glucagon-like peptide-1.;;Akerlund et al., Diketopiperazine-Based Polymers from Common Amino Acids. Journal of Applied Polymer Science, vol. 78, 2213-2218 (2000).;;Li, Jun. Chapter 15: Drug Therapy of Metabolic Diseases. Clinical Pharmacotherapy, People's Medical Publishing House, 1st. Edition, pp. 333-335 (2007).",ACTIVE
85,WO,A3,WO 2011/017554 A3,166-297-758-731-676,2011-06-23,2011,US 2010/0044600 W,2010-08-05,US 23237309 P;;US 23238009 P,2009-08-07,VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.",MANNKIND CORP;;ROSE PHARMA AS;;RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,,https://lens.org/166-297-758-731-676,Search Report,yes,4,0,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61K31/357;;A61K31/496;;A61P1/00;;A61P3/10;;A61P9/00,,2,2,060-233-567-818-406;;172-417-990-740-818,10.1111/j.1365-2036.2008.03870.x;;18945254;;16648370;;10.1124/jpet.105.097824,"HELLSTROM, P. M. ET AL.: ""Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study."", ALIMENT. PHARMACOL. THER., vol. 29, no. 2, 10 October 2008 (2008-10-10), pages 198 - 206, XP055062287, DOI: doi:10.1111/j.1365-2036.2008.03870.x;;GREEN, B. D. ET AL.: ""Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP -1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice."", J. PHARMACOL. EXP. THER., vol. 318, no. 2, 28 April 2006 (2006-04-28), pages 914 - 921, XP055062288, DOI: doi:10.1124/jpet.105.097824",PENDING
86,WO,A2,WO 2011/017554 A2,126-932-938-330-449,2011-02-10,2011,US 2010/0044600 W,2010-08-05,US 23237309 P;;US 23238009 P,2009-08-07,VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1 ), analog, ROSE-010.",MANNKIND CORP;;ROSE PHARMA AS;;RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,,https://lens.org/126-932-938-330-449,Patent Application,yes,0,45,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61K31/357;;A61K31/496;;A61P1/00;;A61P3/10;;A61P9/00,,0,0,,,,PENDING
87,US,A1,US 2012/0252728 A1,144-385-910-356-818,2012-10-04,2012,US 201013389410 A,2010-08-05,US 201013389410 A;;US 23237309 P;;US 23238009 P;;US 2010/0044600 W,2009-08-07,Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.",RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,MANNKIND CORPORATION (2011-02-03);;ROSE PHARMA A/S (2011-03-01),https://lens.org/144-385-910-356-818,Patent Application,yes,4,0,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61P1/00;;A61P1/04;;B29B9/12,514/11.7;;264/5,1,0,,,"Weissberger, ""Mannkind: Overlooked Biotech With Excellent Prospects (Part V)"" http://www.investorvillage.com/smbd.asp?mb=2885&mn=45817&pt=msg&mid=5021385 (posted on 6/19/2008, accessed on 10/18/2012).",ACTIVE
88,EP,A4,EP 2482840 A4,061-593-818-991-920,2013-06-26,2013,EP 10807183 A,2010-08-05,US 23237309 P;;US 23238009 P;;US 2010/0044600 W,2009-08-07,VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME,,MANNKIND CORP;;ROSE PHARMA AS,RICHARDSON PETER;;KENNY ENDA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,MANNKIND CORPORATION (2015-12-16);;ROSE PHARMA A/S (2015-12-16),https://lens.org/061-593-818-991-920,Search Report,no,3,0,8,8,0,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,A61K38/26;;A61K31/357;;A61K31/496;;A61K38/12;;A61P1/00;;A61P3/10;;A61P9/00,,1,0,,,"SMITHSON A.: ""Pulmonary Insufflation of ROSE-010 (GLP-1 Peptide Analogue) Completely Suppresses the MMC in the Conscious Rat: Comparison with the Intravenous and Subcutaneous Routes"", 27 August 2009 (2009-08-27), XP002697063, Retrieved from the Internet <URL:http://www.mannkindcorp.com/Collateral/Documents/English-US/2009%20ROSE-010%20poster%20Final%2008.26.09.pdf> [retrieved on 20130504]",DISCONTINUED
89,US,A1,US 2014/0187490 A1,182-617-652-228-60X,2014-07-03,2014,US 201314139714 A,2013-12-23,US 201314139714 A;;US 201213389410 A;;US 2010/0044600 W;;US 23237309 P;;US 23238009 P,2009-08-07,Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and/or Irritable Bowel Syndrome,"A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.",ROSE PHARMA AS;;MANNKIND CORP,RICHARDSON PETER;;KENNY EDNA;;HELLSTROM PER;;GRANT MARSHALL L;;STOWELL GRAYSON W;;DANIELS SCOTT;;SMITHSON ANTHONY;;GREENE STEPHANIE,MANNKIND CORPORATION (2011-02-03);;ROSE PHARMA A/S (2011-03-01),https://lens.org/182-617-652-228-60X,Patent Application,yes,2,30,8,8,3,A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K31/513;;A61P1/00;;A61P1/04;;A61P7/12;;A61P9/00;;A61P3/10;;A61K9/0075;;A61K31/357;;A61K31/496;;A61K38/26;;A61K38/12;;A61K9/1682;;A61K31/513;;A61K38/10;;C07K14/605,C07K14/605;;A61K9/16;;A61K31/513;;A61K38/10,514/11.7;;530/308;;264/5,1,0,,,"Shields, Irritable Bowel Syndrome, archived on 6/21/2009, available online at: https://web.archive.org/web/20090621100502/http://www.gastroenterologistpaloalto.com/conditions-diseases-irritable-bowel-syndrome-palo-alto-ca.html.",DISCONTINUED
90,KR,A,KR 20070084186 A,101-358-348-715-655,2007-08-24,2007,KR 20077010710 A,2005-11-09,US 98746304 A;;US 9120605 A;;US 19403905 A,2004-11-12,SUGARS AND/OR SUGAR ALCOHOLS FOR INHIBITING AND/OR TREATING VAGINAL INFECTION,"A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida (e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. Sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.",KIMBERLY CLARK CO,YANG SHU PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/101-358-348-715-655,Patent Application,no,0,2,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61P15/02,,0,0,,,,INACTIVE
91,EP,B1,EP 1809269 B1,178-912-158-878-313,2010-10-13,2010,EP 05818781 A,2005-11-09,US 2005/0040842 W;;US 98746304 A;;US 9120605 A;;US 19403905 A,2004-11-12,SUGARS AND/OR SUGAR ALCOHOLS FOR INHIBITING AND/OR TREATING VAGINAL INFECTION,,KIMBERLY CLARK CO,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/178-912-158-878-313,Granted Patent,yes,2,1,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/047;;A61K9/00;;A61K31/7004;;A61P31/04;;A61P31/10,,2,0,,,"SWARBRICK J.: ""Encyclopedia of Pharmaceutical Technology - Third Edition"", vol. 2, 2007, INFORMA HEALTHCARE, NEW YORK, pages: 1339 - 1361;;BEERS M.H.; BERKOW R.: ""The Merck Manual of Diagnosis and Therapy, Seventeenth Edition"", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION N.J., pages: 1948 - 1949",ACTIVE
92,DE,D1,DE 602005024160 D1,064-875-021-893-439,2010-11-25,2010,DE 602005024160 T,2005-11-09,US 98746304 A;;US 9120605 A;;US 19403905 A;;US 2005/0040842 W,2004-11-12,ZUCKER UND/ODER ZUCKERALKOHOLE ZUR VERHINDERUNG UND/ODER BEHANDLUNG VAGINALER INFEKTIONEN,,KIMBERLY CLARK CO,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/064-875-021-893-439,Granted Patent,no,0,0,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/047;;A61K9/00;;A61K31/7004;;A61P31/04;;A61P31/10,,0,0,,,,ACTIVE
93,US,A1,US 2006/0105963 A1,071-941-326-868-02X,2006-05-18,2006,US 19403905 A,2005-07-29,US 19403905 A;;US 98746304 A;;US 9120605 A,2004-11-12,Therapeutic agents for inhibiting and/or treating vaginal infection,"A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida (e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. For instance, sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.",KIMBERLY CLARK CO,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,KIMBERLY-CLARK WORLDWIDE INC (2005-09-27),https://lens.org/071-941-326-868-02X,Patent Application,yes,85,40,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/70;;A61K31/045,514/23;;514/738,0,0,,,,INACTIVE
94,WO,A1,WO 2006/053170 A1,132-377-629-153-714,2006-05-18,2006,US 2005/0040842 W,2005-11-09,US 98746304 A;;US 9120605 A;;US 19403905 A,2004-11-12,SUGARS AND/OR SUGAR ALCOHOLS FOR INHIBITING AND/OR TREATING VAGINAL INFECTION,"A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida (e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. Sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.",KIMBERLY CLARK CO;;YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/132-377-629-153-714,Patent Application,yes,9,9,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/047;;A61K9/00;;A61K31/7004;;A61P31/04;;A61P31/10,,3,2,013-752-646-271-648;;021-629-738-742-44X,pmc1011867;;10.1136/sti.61.6.391;;3910547;;3904590,"DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 1954 (1954-07-01), WEEKS J T: ""From a doctor to a doctor."", XP002373316, Database accession no. NLM13176309;;PEETERS M ET AL: ""Adhesion of Gardnerella vaginalis to vaginal epithelial cells: Variables affecting adhesion and inhibition by metronidazole"", GENITOURINARY MEDICINE 1985 UNITED KINGDOM, vol. 61, no. 6, 1985, pages 391 - 395, XP008061700;;REINHART H ET AL: ""Specificity and mechanism of in vitro adherence of Candida albicans"", ANNALS OF CLINICAL AND LABORATORY SCIENCE 1985 UNITED STATES, vol. 15, no. 5, 1985, pages 406 - 413, XP008061699",PENDING
95,US,B2,US 7619008 B2,001-617-600-780-132,2009-11-17,2009,US 19403905 A,2005-07-29,US 19403905 A;;US 98746304 A;;US 9120605 A,2004-11-12,Xylitol for treatment of vaginal infections,"A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis ), Candida (e.g., Candida albicans ), and/or Trichomonas (e.g., Trichomonas vaginalis ) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. For instance, sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.",KIMBERLY CLARK CO,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,KIMBERLY-CLARK WORLDWIDE INC (2005-09-27),https://lens.org/001-617-600-780-132,Granted Patent,yes,102,7,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/045,514/738;;514/724,31,18,033-121-239-113-719;;138-817-955-125-22X;;002-410-933-337-006;;024-354-819-231-798;;003-986-178-245-316;;165-790-925-933-068;;041-770-153-193-658;;001-752-011-651-916;;013-752-646-271-648;;021-629-738-742-44X;;043-037-454-656-434;;057-294-029-719-313;;071-041-571-255-530;;010-354-547-221-255;;010-267-697-393-428;;060-529-974-373-582;;020-732-870-765-699;;090-825-014-764-484,10361623;;10.1016/s0010-7824(99)00010-4;;10.1002/(sici)1521-3773(19980605)37:10<1328::aid-anie1328>3.3.co;2-0;;10.1002/(sici)1521-3773(19980605)37:10<1328::aid-anie1328>3.0.co;2-9;;29710912;;pmc372023;;10.1172/jci109382;;447831;;10.1093/infdis/145.3.337;;7061879;;6435273;;10.1002/(sici)1521-4133(19991)101:1<25::aid-lipi25>3.3.co;2-e;;10.1016/s1461-5347(00)00296-0;;11050460;;13176309;;pmc1011867;;10.1136/sti.61.6.391;;3910547;;3904590;;10.1099/00221287-143-2-331;;9043110;;1656351;;1774052;;10.1136/sti.67.6.475;;pmc1194771;;11801377;;10.1016/s0378-8741(01)00363-4;;10.1016/j.phytochem.2004.11.016;;15652581;;10.1007/bf02887573;;3121479;;10.1021/jf0101915;;11559138;;12086731;;10.1016/s0378-5173(02)00232-6,"U.S. Appl. No. 10/987,463, filed Nov. 12, 2004, Yang et al., A Compound and Method for Prevention and/or Treatment of Vaginal Infections.;;U.S. Appl. No. 11/091,205, filed Mar. 28, 2005, Huang et al., A Method for Preventing and/or Treating Vaginal and Vulval Infections.;;U.S. Appl. No. 11/091,206, filed Mar. 28, 2005, Huang et al., A Method for Preventing and/or Treating Trichomonas Vaginitis.;;U.S. Appl. No. 11/094,496, filed Mar. 30, 2005, Huang et al., Method for Inhibiting and/or Treating Vaginal Infection.;;U.S. Appl. No. 11/194,064, filed Jul. 29, 2005, Martin et al., Vaginal Treatment Composition.;;Article-A Vaginal Fluid Simulant, Owen et al., Contraception, vol. 59, Feb. 1999, pp. 91-95.;;Article-Alkyl Polyglycosides. A New Surfactant Class Based On Renewable Raw Material, Knaut et al., Chimicaoggi, Sep. 1993, 6 pages.;;Article-Alkyl Polyglycosides-Properties and Applications of a new Class of Surfactants, Rybinski et al., Angew. Chem. Int. Ed., vol. 37, 1998, pp. 1328-1345.;;Article-Amine Content of Vaginal Fluid from Untreated and Treated Patients with Nonspecific Vaginitis, Chen et al., The Journal of Clinical Investigation., vol. 63, May 1979, pp. 828-835.;;Article-Biochemical Diagnosis of Vaginitis: Determination of Diamines in Vaginal Fluid, Chen et al., The Journal of Infectious Diseases, vol. 145, No. 3, Mar. 1982, pp. 337-345.;;Article-Effect of long-term, peroral administration of sugar alcohols on man, Kauko K. Mäkinen, Swed Dent J, vol. 8, 1984, pp. 113-124.;;Article-Sugar-based surfactants for consumer products and technical applications, Hill et al., Feu/Lipid, vol. 101, 1999, pp. 25-33.;;Article-The scope and potential of vaginal drug delivery, Vermani et al., Pharm. Sci. Tehnol. Today, Oct. 1, 2000, vol. 3, No. 10, pp. 359-364.;;Fact Sheet on Trichomonas Infection from CDC-Division of Parasitic Diseases, 5 pages, Sep. 29, 2004, www.cdc.com.;;Information-Vaginal Infections from StopGettingSick.com, 2 pages, 2005, www.stopgettingsick.com.;;Product Information on Triton BG-10 Surfactant from DOW Surfactants, 2 pages, no date.;;Product Information on Triton CG-110 Surfactant from DOW Surfactants, 2 pages, no date.;;Article-From a Doctor to a Doctor, J. T. Weeks, The Mississippi Doctor, vol. 32, No. 2, Jun. 1954-May 1955, pp. 56-57.;;Article-Adhesion of Gardnerelle vaginalis to vaginal epithelial cells: variables affecting adhesion and inhibition by metronidazole, Peeters et al., Genitourin Med., vol. 61, 1985, pp. 391-395.;;Article-Specificity and Mechanism of In Vitro Adherence of Candida albicans, Reinhart, et al., Annals of Clinical and Laboratory Science, vol. 15, No. 5, 1985, pp. 406-413.;;Search Report and Written Opinion for PCT/US2005/040842, Apr. 6, 2006.;;Article-Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans, Fu et al., Microbiology, vol. 143, 1992, pp. 331-340.;;Article-Resolution of Resistant Vaginal Trichomoniasis Associated with the Use of Intravaginal Nonoxynol-9, Livengood, III et al., Obstetrics & Gynecology, vol. 78, No. 5, Part 2, Nov. 1991, 954-956.;;Article-The susceptibility of organisms associated with bacterial vaginosis to spermicidal compound, in vitro, Jones et al., Genitourin. Med., vol. 67, 1991, pp. 475-477.;;Search Report and Written Opinion for PCT/US2006/003681, Jun. 7, 2006.;;Article-In vitro antimicrobial activity of extracts and isolated constituents of Rubus ulmifolius, Panizzi et al., Journal of Ethnopharmacology, vol. 79, 2002, pp. 165-168.;;PCT Search Report for Int'l Appl. No. PCT/US2006/01918 date of mailing Feb. 16, 2007.;;Article-Bioactive ellagitannins from Cunonia macrophylla, an endemic Cunoniaceae from New Caledonia, Fogliani et al., Phytochemistry, vol. 66, Elsevier Ltd., 2005, pp. 241-247.;;Article -Antimicrobial Properties of Aromatic Compounds of Plant Origin, Zemek et al., Folia Microbiology, vol. 32, No. 5, 1987, pp. 421-425.;;Article - Effect of Gallic Acid and Catechin on Lactobacillus Hilgardii 5w Growth and Metabolism of Organic Compounds, Alberto et al., Journal of Agriculture and Food Chemistry, vol. 49, 2001, pp. 4359-4363.;;Article -Rheological evaluation of thermosenstive and mucoadhesive vaginal gels in physiological conditions, Chang et al., International Journal of Pharmaceutics 241, 2002, pp. 155-163.",INACTIVE
96,MX,A,MX 2007005678 A,067-859-827-074-765,2007-07-11,2007,MX 2007005678 A,2005-11-09,US 98746304 A;;US 9120605 A;;US 19403905 A;;US 2005/0040842 W,2004-11-12,SUGARS AND/OR SUGAR ALCOHOLS FOR INHIBITING AND/OR TREATING VAGINAL INFECTION.,"A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida(e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis)pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. Sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitolis used as the therapeutic agent.",KIMBERLY CLARK CO,SAYRE CURTIS;;HUANG LEI;;MARTIN STEPHANIE M;;YANG SHU-PING;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;JOHNSON ROBERT B,,https://lens.org/067-859-827-074-765,Patent Application,no,0,0,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/047;;A61K9/00;;A61P31/04;;A61P31/10,,0,0,,,,ACTIVE
97,EP,A1,EP 1809269 A1,198-675-566-992-536,2007-07-25,2007,EP 05818781 A,2005-11-09,US 2005/0040842 W;;US 98746304 A;;US 9120605 A;;US 19403905 A,2004-11-12,SUGARS AND/OR SUGAR ALCOHOLS FOR INHIBITING AND/OR TREATING VAGINAL INFECTION,,KIMBERLY CLARK CO,YANG SHU-PING;;HUANG LEI;;MARTIN STEPHANIE M;;VILLANUEVA JULIE;;GREENE SHARON;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/198-675-566-992-536,Patent Application,yes,0,0,9,11,0,A61K31/047;;A61K31/7004;;A61K31/7004;;A61K9/0034;;A61K9/0034;;A61K31/047;;A61K31/047;;A61P15/02;;A61P31/04;;A61P31/10,A61K31/047;;A61K9/00;;A61K31/7004;;A61P31/04;;A61P31/10,,1,0,,,See references of WO 2006053170A1,ACTIVE
98,US,A1,US 2008/0260838 A1,094-747-213-158-828,2008-10-23,2008,US 73595707 A,2007-04-16,US 73595707 A;;US 63287803 A;;US 74488206 P,2003-08-01,GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS,"A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,HOKENSON MARK J;;BRANDT DAVID;;KING MARK;;GREENE STEPHANIE;;FARIS MARY;;OBERG KEITH;;CHEATHAM WAYMAN WENDELL;;GELBER COHAVA;;LEONE-BAY ANDREA,MANNKIND CORPORATION (2007-05-03),https://lens.org/094-747-213-158-828,Patent Application,yes,100,106,1,276,3,A61K9/0075;;A61K9/1641;;A61K9/167;;A61K9/1676;;A61P3/04;;A61P35/00;;A61P3/10;;A61K9/167;;A61K9/1676;;A61K9/1641;;A61K9/0075,A61K9/14;;A61K38/16;;A61P3/04;;A61P3/10;;A61P35/00,424/489;;514/12,4,3,043-358-049-645-704;;089-727-620-861-79X;;007-188-896-148-675,9780839;;10.1002/(sici)1521-1878(199808)20:8<642::aid-bies7>3.0.co;2-k;;10.1021/ol901466r;;19655766;;10.1016/s0026-0495(99)90043-4;;10024091,"Ahren B. 'Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes' BioEssays 1998 v20 pages 642-651.;;WebMD (retrieved from http://www.webmd.com/pain-management/tc/pain-management-side-effects-of-pain-medicines on 9/21/12, 4 pages);;Raju et al ('Naseseazines A and B: a new dimeric diketopiperatizne framework from a marine-derived actinomycete, Streptomyces sp.' Organic letters v11(17) 2009 pages 3862-3865).;;Burcelin et al ('Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1' Metabolism v48 (2) February 1999 pages 252-258)",DISCONTINUED
99,CN,A,CN 104288756 A,188-778-688-769-171,2015-01-21,2015,CN 201410514033 A,2007-04-16,US 74488206 P,2006-04-14,Glucagon-like peptide 1 (GLP-1) pharmaceutical formulations,"The invention relates to glucagon-like peptide 1 (GLP-1) pharmaceutical formulations. Specifically, the invention discloses a composition which is table both in vivo and in vitro. The composition comprises glucagon-like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP). The composition can be used as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition can be used as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/188-778-688-769-171,Patent Application,no,2,3,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K38/26;;A61K9/14;;A61K31/496;;A61P1/00;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/28,,0,0,,,,DISCONTINUED
100,AU,A1,AU 2013/201640 A1,082-564-764-836-763,2013-04-11,2013,AU 2013/201640 A,2013-03-19,AU 2007/238000 A;;AU 2013/201640 A,2007-04-16,Glucagon-like peptide 1(GLP-1) pharmaceutical formulations,"GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS A composition is disclosed comprising glucagon- like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,LEONE-BAY ANDREA;;GELBER COHAVA;;BRANDT DAVID;;OBERG KEITH;;CHEATHAM WAYMAN WENDELL;;HOKENSON MARK J;;FARIS MARY;;GREENE STEPHANIE;;KING MARK,,https://lens.org/082-564-764-836-763,Patent Application,no,0,1,1,1,0,,A61K9/16;;A61K38/26,,0,0,,,,DISCONTINUED
101,JP,A,JP 2014043445 A,151-669-638-539-591,2014-03-13,2014,JP 2013191549 A,2013-09-17,US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS,"PROBLEM TO BE SOLVED: To provide pharmaceutical formulations for pulmonary delivery having utility as pharmaceutical formulations for treating diseases such as diabetes, cancers, and obesity.SOLUTION: Provided are dry powder compositions for pulmonary administration containing microparticles of glucagon-like peptide 1 (GLP-1) in combination with pharmaceutically acceptable salts of diketopiperazine (DKP) that are stable both in vitro and in vivo. The pharmaceutically acceptable salts of diketopiperazine have the formula of 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, where X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl, and preferably are 2,5-diketo-3,6-di(4-fumaryl-aminobutyl)piperazine disodium salts.",MANNKIND CORP,GREENE STEPHANIE;;DAVID BRANDT;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;ANDREA LEONE-BAY;;MARK J HOKENSON;;MARY FARIS,,https://lens.org/151-669-638-539-591,Patent Application,no,5,0,26,276,3,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K38/00;;A61K9/14;;A61K9/19;;A61K31/495;;A61P1/04;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P37/06;;C07K14/605,,0,0,,,,ACTIVE
102,WO,A2,WO 2007/121411 A2,172-049-734-882-415,2007-10-25,2007,US 2007/0066728 W,2007-04-16,US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS,"A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP;;GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/172-049-734-882-415,Patent Application,yes,0,86,26,276,3,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,,,0,0,,,,PENDING
103,KR,A,KR 20080111533 A,192-988-742-882-58X,2008-12-23,2008,KR 20087027774 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,GLUCAGON-LIKE PEPTIDE 1 (GLP-1)PHARMACEUTICAL FORMULATIONS,"A composition is disclosed comprising glucagon-like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery. ® KIPO & WIPO 2009",MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/192-988-742-882-58X,Patent Application,no,0,0,26,276,6,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,ACTIVE
104,CA,A1,CA 2646400 A1,125-230-246-587-590,2007-10-25,2007,CA 2646400 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS,,MANNKIND CORP,LEONE-BAY ANDREA;;FARIS MARY;;HOKENSON MARK J;;GREENE STEPHANIE;;CHEATHAM WAYMAN WENDELL;;KING MARK;;GELBER COHAVA;;BRANDT DAVID;;OBERG KEITH,,https://lens.org/125-230-246-587-590,Patent Application,no,0,0,26,276,3,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,PENDING
105,EP,A2,EP 2010155 A2,085-277-891-596-130,2009-01-07,2009,EP 07760728 A,2007-04-16,US 2007/0066728 W;;US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS,,MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,MANNKIND CORPORATION (2015-12-16),https://lens.org/085-277-891-596-130,Patent Application,yes,0,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,1,0,,,See references of WO 2007121411A3,DISCONTINUED
106,JP,A,JP 2016104736 A,106-499-786-071-846,2016-06-09,2016,JP 2015233125 A,2015-11-30,US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS,"PROBLEM TO BE SOLVED: To provide a glucagon-like peptide 1 (GLP-1) formulation which is useful for the treatment of diseases, such as diabetes mellitus, cancer, obesity, and the like, and has long term effectiveness and optimal absorbency when administered as a pharmaceutical.SOLUTION: The invention provides a dry powder composition containing glucagon-like peptide 1 (GLP-1) particles combined with a diketopiperazine (DKP) which is stable both in vitro and in vivo, wherein the composition has utility as a pharmaceutical formulation for treating diseases, such as diabetes, cancer, and obesity, and particularly the composition has utility as a pharmaceutical formulation for intrapulmonary delivery.SELECTED DRAWING: None",MANNKIND CORP,GREENE STEPHANIE;;DAVID BRANDT;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;ANDREA LEONE-BAY;;MARK J HOKENSON;;MARY FARIS,,https://lens.org/106-499-786-071-846,Patent Application,no,1,0,26,276,3,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K38/00;;A61K9/14;;A61K31/495;;A61P1/04;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00,,0,0,,,,PENDING
107,AU,A1,AU 2007/238000 A1,170-991-119-005-859,2007-10-25,2007,AU 2007/238000 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,Glucagon-like peptide 1(GLP-1) pharmaceutical formulations,,MANNKIND CORP,HOKENSON MARK J;;GELBER COHAVA;;GREENE STEPHANIE;;LEONE-BAY ANDREA;;OBERG KEITH;;FARIS MARY;;CHEATHAM WAYMAN WENDELL;;BRANDT DAVID;;KING MARK,,https://lens.org/170-991-119-005-859,Patent Application,no,0,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,INACTIVE
108,AU,B2,AU 2007/238000 B2,089-966-247-518-085,2013-01-17,2013,AU 2007/238000 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,Glucagon-like peptide 1(GLP-1) pharmaceutical formulations,"A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,KING MARK;;GREENE STEPHANIE;;CHEATHAM WAYMAN WENDELL;;LEONE-BAY ANDREA;;FARIS MARY;;GELBER COHAVA;;BRANDT DAVID;;OBERG KEITH;;HOKENSON MARK J,,https://lens.org/089-966-247-518-085,Granted Patent,no,4,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,INACTIVE
109,MX,A,MX 2008013216 A,151-348-743-735-888,2008-10-27,2008,MX 2008013216 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS.,"A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP,LEONE-BAY ANDREA;;CHEATHAM WAYMAN WENDELL;;GELBER COHAVA;;GREENE STEPHANIE;;BRANDT DAVID;;KING MARK;;OBERG KEITH;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/151-348-743-735-888,Patent Application,no,0,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,ACTIVE
110,KR,A,KR 20140072138 A,018-401-679-928-703,2014-06-12,2014,KR 20147011316 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,GLUCAGON-LIKE PEPTIDE 1 (GLP-1)PHARMACEUTICAL FORMULATIONS,,MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/018-401-679-928-703,Patent Application,no,0,1,26,276,6,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K38/26;;A61K9/14;;A61K9/16;;A61K31/496,,0,0,,,,ACTIVE
111,WO,A3,WO 2007/121411 A3,061-894-727-708-455,2007-12-13,2007,US 2007/0066728 W,2007-04-16,US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS,"A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery.",MANNKIND CORP;;GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/061-894-727-708-455,Search Report,yes,3,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,PENDING
112,BR,A2,BR PI0709964 A2,137-251-161-695-224,2011-08-02,2011,BR PI0709964 A,2007-04-16,US 74488206 P;;US 2007/0066728 W,2006-04-14,formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1),"FORMULAçOES FARMACêUTICAS CONTENDO PEPTIDEO GLUCAGON DO TIPO 1 (GLP-1) Uma composição é revelada compreendendo partículas de peptídeo glucagon do tipo 1 (GLP-1) em combinação com dicetopiperazina (DKP), sendo estável tanto in vitro como in vivo. A composição tem utilidade como uma formulação farmacêutica para tratar doenças como diabetes, cânceres e obesidade, mas na é limitada a tais doenças e condições. Em particular, a composição tem utilidade como uma formulação farmacêutica de liberação pulmonar.",MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J;;FARIS MARY,,https://lens.org/137-251-161-695-224,Patent Application,no,0,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K9/16;;A61K38/26,,0,0,,,,DISCONTINUED
113,US,A1,US 2007/0026074 A1,061-508-272-975-048,2007-02-01,2007,US 19406405 A,2005-07-29,US 19406405 A,2005-07-29,Vaginal treatment composition,"A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na + ) and calcium (Ca 2+ ) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.",KIMBERLY CLARK CO,MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON L;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,KIMBERLY-CLARK WORLDWIDE INC (2005-10-04),https://lens.org/061-508-272-975-048,Patent Application,yes,38,13,5,5,0,A61K9/0034;;A61K9/0034;;A61K31/192;;A61K31/192;;A61K31/70;;A61K31/70;;A61K47/36;;A61K47/36;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,A61K9/14;;A61K31/045;;A61K31/70,424/488;;514/23;;514/738,0,0,,,,INACTIVE
114,HK,A1,HK 1206241 A1,095-271-350-568-335,2016-01-08,2016,HK 15106772 A,2015-07-16,US 74488206 P,2006-04-14,GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS 1(GLP-1),,MANNKIND CORP,GREENE STEPHANIE;;BRANDT DAVID;;GELBER COHAVA;;KING MARK;;CHEATHAM WAYMAN WENDELL;;OBERG KEITH;;LEONE-BAY ANDREA;;HOKENSON MARK J J;;FARIS MARY,,https://lens.org/095-271-350-568-335,Patent Application,no,0,0,26,276,0,A61K9/0075;;A61K9/16;;A61K9/19;;A61K9/0019;;A61K9/0073;;A61K9/0075;;A61K9/08;;A61K9/143;;A61K9/145;;A61K9/1611;;A61K9/1682;;A61K31/496;;A61K38/26;;A61K38/26;;A61K45/06;;A61P1/00;;A61P1/04;;A61P1/18;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P37/06;;A61P43/00,A61K/;;A61P/,,0,0,,,,PENDING
115,WO,A2,WO 2007/018622 A2,022-477-414-091-86X,2007-02-15,2007,US 2006/0011918 W,2006-03-30,US 19406405 A,2005-07-29,VAGINAL TREATMENT COMPOSITION,"A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na¿+?) and calcium (Ca¿2+?) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.",KIMBERLY CLARK CO;;MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/022-477-414-091-86X,Patent Application,yes,0,4,5,5,0,A61K9/0034;;A61K9/0034;;A61K31/192;;A61K31/192;;A61K31/70;;A61K31/70;;A61K47/36;;A61K47/36;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,A61K47/36;;A61K9/06;;A61K31/192;;A61K31/70;;A61P31/04;;A61P31/10,,0,0,,,,PENDING
116,WO,A3,WO 2007/018622 A3,103-317-719-241-412,2007-05-18,2007,US 2006/0011918 W,2006-03-30,US 19406405 A,2005-07-29,VAGINAL TREATMENT COMPOSITION,"A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na + ) and calcium (Ca 2+ ) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.",KIMBERLY CLARK CO;;MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/103-317-719-241-412,Search Report,yes,8,0,5,5,0,A61K9/0034;;A61K9/0034;;A61K31/192;;A61K31/192;;A61K31/70;;A61K31/70;;A61K47/36;;A61K47/36;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,A61K47/36;;A61K9/06;;A61K31/192;;A61K31/70;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,,0,0,,,,PENDING
117,US,B2,US 7786176 B2,067-223-428-758-955,2010-08-31,2010,US 19406405 A,2005-07-29,US 19406405 A,2005-07-29,Vaginal treatment composition containing xylitol,"A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na + ) and calcium (Ca 2+ ) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1 minute, and in some embodiments, less than about 30 seconds. Among other things, such rapid gelation reduces the likelihood of leakage during use. In addition, because the gel may form intravaginally, it is more likely to retain its structure and shape over an extended period of time. In this manner, the gel may provide the prolonged release of a therapeutic agent that inhibits and/or treats vaginal infection. For instance, the gel may remain within the vagina for about 2 to about 48 hours to provide the desired effect.",KIMBERLY CLARK CO,MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,KIMBERLY-CLARK WORLDWIDE INC (2005-10-04),https://lens.org/067-223-428-758-955,Granted Patent,yes,100,10,5,5,0,A61K9/0034;;A61K9/0034;;A61K31/192;;A61K31/192;;A61K31/70;;A61K31/70;;A61K47/36;;A61K47/36;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,A61K31/045,514/738;;514/724;;514/576;;424/430,33,18,090-825-014-764-484;;001-752-011-651-916;;013-752-646-271-648;;021-629-738-742-44X;;033-121-239-113-719;;138-817-955-125-22X;;002-410-933-337-006;;024-354-819-231-798;;003-986-178-245-316;;165-790-925-933-068;;041-770-153-193-658;;043-037-454-656-434;;010-354-547-221-255;;057-294-029-719-313;;071-041-571-255-530;;010-267-697-393-428;;060-529-974-373-582;;020-732-870-765-699,12086731;;10.1016/s0378-5173(02)00232-6;;13176309;;pmc1011867;;10.1136/sti.61.6.391;;3910547;;3904590;;10361623;;10.1016/s0010-7824(99)00010-4;;10.1002/(sici)1521-3773(19980605)37:10<1328::aid-anie1328>3.3.co;2-0;;10.1002/(sici)1521-3773(19980605)37:10<1328::aid-anie1328>3.0.co;2-9;;29710912;;pmc372023;;10.1172/jci109382;;447831;;10.1093/infdis/145.3.337;;7061879;;6435273;;10.1002/(sici)1521-4133(19991)101:1<25::aid-lipi25>3.3.co;2-e;;10.1016/s1461-5347(00)00296-0;;11050460;;10.1099/00221287-143-2-331;;9043110;;11801377;;10.1016/s0378-8741(01)00363-4;;1656351;;1774052;;10.1136/sti.67.6.475;;pmc1194771;;10.1016/j.phytochem.2004.11.016;;15652581;;10.1007/bf02887573;;3121479;;10.1021/jf0101915;;11559138,"Chang et al, ""Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in phyisiological conditions"" International Journal of Pharmaceutics, 2002, vol. 241, pp. 155-163.;;Pformulate, ""Excipients: Gellan Gum."" Jan. 25, 2004 (retrieved from URL: http://www.pformulate.com/gellangum.htm on Jan. 22, 2010) (2 pages).;;Article-From a Doctor to a Doctor, J. T. Weeks, The Mississippi Doctor, vol. 32, No. 2, Jun. 1954-May 1955, pp. 56-57.;;Article-Adhesion of Gardnerelle vaginalis to vaginal epithelial cells:-variables affecting adhesion and inhibition by metronidazole, Peeters et al., Genitourin Med., vol. 61, 1985, pp. 391-395.;;Article-Specificity and Mechanism of In Vitro Adherence of Candida albicans, Reinhart, et al., Annals of Clinical and Laboratory Science, vol. 15, No. 5, 1985, pp. 406-413.;;Search Report and Written Opinion for PCT/US2005/040842, Apr. 6, 2006.;;PCT Search Report for Int'l Appl. No. PCT/US2006/01918 date of mailing Feb. 16, 2007.;;U.S. Appl. No. 10/987,463, filed Nov. 12, 2004, Yang et al., A Compound and Method for Prevention and/or Treatment of Vaginal Infections.;;U.S. Appl. No. 11/091,205, filed Mar. 28, 2005, Huang et al., A Method for Preventing and/or Treating Vaginal and Vulval Infections.;;U.S. Appl. No. 11/091,206, filed Mar. 28, 2005, Huang et al., A Method for Preventing and/or Treating Trichomonas Vaginitis.;;U.S. Appl. No. 11/094,496, filed Mar. 30, 2005, Huang et al., Method for Inhibiting and/or Treating Vaginal Infection.;;U.S. Appl. No. 11/194,039, filed Jul. 29, 2005, Yang et al., Therapeutic Agents for Inhibiting and/or Treating Vaginal Infection.;;Abstract of Japanese Patent No. JP2002226385, Aug. 14, 2002.;;Article-A Vaginal Fluid Simulant, Owen et al., Contraception, vol. 59, Feb. 1999, pp. 91-95.;;Article-Alkyl Polyglycosides. A New Surfactant Class Based on Renewable Raw Material, Knaut et al., Chimicaoggi, Sep. 1993, 6 pages.;;Article-Alkyl Polyglycosides-Properties and Applications of a new Class of Surfactants, Rybinski et al., Angew. Chem. Int. Ed., vol. 37, 1998, pp. 1328-1345.;;Article-Amine Content of Vaginal Fluid from Untreated and Treated Patients with Nonspecific Vaginitis, Chen et al., The Journal of Clinical Investigation., vol. 63, May 1979, pp. 828-835.;;Article-Biochemical Diagnosis of Vaginitis: Determination of Diamines in Vaginal Fluid, Chen et al., The Journal of Infectious Diseases, vol. 145, No. 3, Mar. 1982, pp. 337-345.;;Article-Effect of long-term, peroral administration of sugar alcohols on man, Kauko K. Mäkinen, Swed Dent J, vol. 8, 1984, pp. 113-124.;;Article-Sugar-based surfactants for consumer products and technical applications, Hill et al., Feu/Lipid, vol. 101, 1999, pp. 25-33.;;Article-The scope and potential of vaginal drug delivery, Vermani et al., Pharm. Sci. Tehnol. Today, Oct. 1, 2000, vol. 3, No. 10, pp. 359-364.;;Fact Sheet on Trichomonas Infection from CDC-Division of Parasitic Diseases, 5 pages, Sep. 2004, www.cdc.com.;;Information-Vaginal Infections from StopGettingSick.com, 2 pages, Aug. 2005, www.stopgettingsick.com.;;Product Information on Triton* BG-10 Surfactant from DOW Surfactants, 2 pages.;;Product Information on Triton* CG-110 Surfactant from DOW Surfactants, 2 pages.;;Article-Cloning and characterization of a gene (LIPI) which encodes a lipase from the pathogenic yeast Candida albicans, Fu et al., Microbiology, vol. 143, 1992, pp. 331-340.;;Article- In vitro antimicrobial activity of extracts and isolated constituents of Rubus ulmifolius, Panizzi et al., Journal of Ethnopharmacology, vol. 79, 2002, pp. 165-168.;;Article-Resolution of Resistant Vaginal Trichomoniasis Associated with the Use of Intravaginal Nonoxynol-9, Livengood, III et al., Obstetrics & Gynecology, vol. 78, No. 5, Part 2, Nov. 1991, 954-956.;;Article-The susceptibility of organisms associated with bacterial vaginosis to spermicidal compounds, in vitro, Jones et al., Genitourin. Med., vol. 67, 1991, pp. 475-477.;;Search Report and Written Opinion for PCT/US2006/003681.;;Article-Bioactive ellagitannins from Cunonia macrophylla, an endemic Cunoniaceae from New Caledonia, Fogliani et al., Phytochemistry, vol. 66, Elsevier Ltd., 2005, pp. 241-247.;;Article-Antimicrobial Properties of Aromatic Compounds of Plant Origin, Zemek et al., Folia Microbiology, vol. 32, No. 5, 1987, pp. 421-425.;;Article-Effect of Gallic Acid and Catechin on Lactobacillus Hilgardii 5w Growth and Metabolism of Organic Compounds, Alberto et al., Journal of Agriculture and Food Chemistry, vol. 49, 2001, pp. 4359-4363.",INACTIVE
118,EP,A2,EP 1909841 A2,196-703-798-427-037,2008-04-16,2008,EP 06749023 A,2006-03-30,US 2006/0011918 W;;US 19406405 A,2005-07-29,VAGINAL TREATMENT COMPOSITION,,KIMBERLY CLARK CO,MARTIN STEPHANIE M;;HUANG LEI;;YANG SHU-PING;;HUANG YANBIN;;VILLANUEVA JULIE;;GREENE SHARON LINDA;;AREHART KELLY;;SAYRE CURTIS;;JOHNSON ROBERT B,,https://lens.org/196-703-798-427-037,Patent Application,yes,0,0,5,5,0,A61K9/0034;;A61K9/0034;;A61K31/192;;A61K31/192;;A61K31/70;;A61K31/70;;A61K47/36;;A61K47/36;;A61P15/02;;A61P31/04;;A61P31/10;;A61P33/02,A61K47/36;;A61K9/06;;A61K31/192;;A61K31/70;;A61P31/04;;A61P31/10,,1,0,,,See references of WO 2007018622A3,DISCONTINUED
119,US,B1,US 10846776 B1,057-884-380-596-728,2020-11-24,2020,US 201815925424 A,2018-03-19,US 201815925424 A,2018-03-19,Account customized item list system,"Described herein is a system and techniques for implementing a single mechanism that, when activated, provides a list of items which is customized according to the user that activated the mechanism. In some embodiments, a list of item types may be received by the system. The system may identify a number of potential items for each of the item types in the list of item types. The potential items may be filtered based on configuration settings associated with the user in order to identify a most appropriate item for each item type in the list of item types. The user may then be provided with a list of items that includes the most appropriate item for each item type. In some embodiments, the user may be provided with the ability to complete a transaction for one or more item in the list of items.",AMAZON TECH INC,CHEANG GUILLERMO AUYON;;DEROUET STEPHANIE;;DHAR ANWASHA;;GIOVANELLI MICHAEL;;GREENE NOLAN;;HIATT JENNIFER ANNE;;O'CONNELL TIMOTHY;;TATARKIEWICZ XAVIER;;VOORHEIS SPENCER LYLE;;WANG YANG;;WELDON JOHN;;YAGLEY KRISTEN;;ZAHALAN MICHAEL,AMAZON TECHNOLOGIES INC (2018-04-03),https://lens.org/057-884-380-596-728,Granted Patent,yes,9,1,2,2,0,G06Q30/0631;;G06Q30/0613;;G06Q30/0635;;G06Q30/0641;;G06F16/955;;G06Q30/0635;;G06Q30/0641;;G06Q30/0631;;G06F16/955;;G06Q30/0613,G06Q30/06;;G06F16/955,,1,0,,,"Improving Contextual suggestions using Open Web domain knowledge Samar, Thaer; Bellogin, Alejandro; De Vries, Arjen. CEUR Workshop Proceedings 1421: 3-9. CEUR-WS. (Jan. 1, 2015).",ACTIVE
120,US,B1,US 11532026 B1,015-002-309-542-443,2022-12-20,2022,US 202017063391 A,2020-10-05,US 202017063391 A;;US 201815925424 A,2018-03-19,Account customized item list system,"Described herein is a system and techniques for implementing a single mechanism that, when activated, provides a list of items which is customized according to the user that activated the mechanism. In some embodiments, a list of item types may be received by the system. The system may identify a number of potential items for each of the item types in the list of item types. The potential items may be filtered based on configuration settings associated with the user in order to identify a most appropriate item for each item type in the list of item types. The user may then be provided with a list of items that includes the most appropriate item for each item type. In some embodiments, the user may be provided with the ability to complete a transaction for one or more item in the list of items.",AMAZON TECH INC,CHEANG GUILLERMO AUYON;;DEROUET STEPHANIE;;DHAR ANWASHA;;GIOVANELLI MICHAEL;;GREENE NOLAN;;HIATT JENNIFER ANNE;;O'CONNELL TIMOTHY;;TATARKIEWICZ XAVIER;;VOORHEIS SPENCER LYLE;;WANG YANG;;WELDON JOHN MICHAEL;;YAGLEY KRISTEN;;ZAHALAN MICHAEL,AMAZON TECHNOLOGIES INC (2018-04-03),https://lens.org/015-002-309-542-443,Granted Patent,yes,15,0,2,2,0,G06Q30/0631;;G06Q30/0613;;G06Q30/0635;;G06Q30/0641;;G06F16/955;;G06Q30/0635;;G06Q30/0641;;G06Q30/0631;;G06F16/955;;G06Q30/0613,G06Q30/06;;G06F16/955,,4,0,,,"Article, “LG Electronics Seeks Patent for Apparatus for Transmitting Broadcast Signals, Apparatus for Receiving Broadcast Signals, Method of Transmitting Broadcast Signals and Method of Receiving Broadcast Signals”, published Dec. 13, 2018 in Global IP News. Broadband and Wireless Network News [New Delhi].;;U.S. Appl. No. 15/925,424, “Non-Final Office Action”,—dated Apr. 14, 2020, 17 pages.;;U.S. Appl. No. 15/925,424, “Notice of Allowance”,—dated Jul. 22, 2020, 13 pages.;;Samar, et al., “Improving Contextual Suggestions Using Open Web Domain Knowledge”, CEUR Workshop Proceedings, vol. 1421, Jan. 1, 2015, 6 pages.",ACTIVE
121,US,A1,US 2012/0109701 A1,061-896-650-097-762,2012-05-03,2012,US 91721510 A,2010-11-01,US 91721510 A,2010-11-01,Fulfillment Workflow Optimization,"A system and method for an optimization of fulfillment workflow is disclosed. In accordance with one embodiment of the present disclosure. In accordance with embodiments of the present disclosure, a method may include receiving a request to be fulfilled from a client. The method may also include determining one or more item attributes associated with the request. The method may additionally include generating a batch of work units related to the request based at least in part on the one or more item attributes. The method may further include selecting an agent from a plurality of agents to process the batch. Moreover, the method may include transmitting the batch to the agent.",SEUGLING STEPHANIE FILOMENA;;MORGAN JANET MACKEY;;HUDGINS CHARLES CARY;;RITTER EDWARD C;;HUNTLEY CHRISTOPHER E;;FRICKE CHRISTINE M;;RILEY MARY K;;BADGLEY ANNE M;;GREENE TRINA MARIE;;PICKFORD JOHN DEWEL;;OLBERDING GARY L;;BISHOP RANDAL J;;MCGRAW JOHN F;;RIOS MARISOL;;EVATT KRISTI J;;ARCURE SCOTT C;;OXENDINE SUZETTE;;CORCORAN CATHLEEN;;BANK OF AMERICA,SEUGLING STEPHANIE FILOMENA;;MORGAN JANET MACKEY;;HUDGINS CHARLES CARY;;RITTER EDWARD C;;HUNTLEY CHRISTOPHER E;;FRICKE CHRISTINE M;;RILEY MARY K;;BADGLEY ANNE M;;GREENE TRINA MARIE;;PICKFORD JOHN DEWEL;;OLBERDING GARY L;;BISHOP RANDAL J;;MCGRAW JOHN F;;RIOS MARISOL;;EVATT KRISTI J;;ARCURE SCOTT C;;OXENDINE SUZETTE;;CORCORAN CATHLEEN,BANK OF AMERICA CORPORATION (2010-10-28),https://lens.org/061-896-650-097-762,Patent Application,yes,14,2,1,1,0,G06Q10/06;;G06Q10/06311;;G06Q10/063112;;G06Q10/06;;G06Q10/063112;;G06Q10/06311,G06Q90/00;;G06Q10/00,705/7.13;;705/7.14,0,0,,,,DISCONTINUED
